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 Abstract 
Background:  Functional Electrical Stimulation (FES) stimulates peripheral nerves via 
electrical current to evoke muscle contractions and when combined with lower extremity 
cycling (LE), creates patterned leg movements. Previous studies demonstrated FES 
cycling is safe and effective in the spinal cord injury and stroke populations with 
improvements seen in walking speed, muscle mass, and bone density.  Few studies have 
applied FES cycling to a neurodegenerative disorder, such as multiple sclerosis (MS).  The 
aim of this study is to assess the effect of an 8-week training program using FES cycling, 
compared to Cycling Only, in people with MS (PWMS).   
Methods: Using a sample of convenience, PWMS were recruited to participate and 
randomized to the FES Cycling group or the Cycling Only group.  Both groups received 
training three-times per week for 8- weeks using a LE ergometer.  Scores on the 6 Minute 
Walk Test (6MWT), Times 25-Foot Walk Test (T25FW), Five Times Sit-to-Stand (5XSST), 
and Timed Up and Go (TUG), and spatiotemporal measure of gait were collected at 
baseline, (before the 1st session), 4-weeks (before the 13th session), 8-weeks (after the 
24th training session), and at 4-week follow-up.  Scores on the MS Quality of Life-54 
(MSQOL), Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Walking Scale-12 
(MSWS-12), and Activities-specific Balance Confidence Scale (ABC) were collected at 
baseline, 8-weeks, and at 4-week follow-up.   
Results:  Fourteen participants (8 female, 6 male, mean age = 53.64  10.16 years; Patient 
Determined Disease Steps (PDDS) mean = 3.71  .091) completed the training.  Cycling 
power output significantly increased in both groups over time (FES Cycling, p = 0.03; 
Cycling only p = 0.004), but no differences were found between groups (p = 0.08).  The 
Cycling Only group demonstrated a slightly larger effect size for power output than the 
FES Group (d = 0.72 vs. 0.66).  Immediately after the intervention period, scores on the 
6MWT, 5XSST, and MFIS, and subscores of the MSQOL-54 improved significantly, but 
changes did not consistently favor one group over the other (p >0.05).  There were no 
significant differences between groups on any of the outcome measures.   
Conclusions:  FES Cycling or Cycling Only may be an effective intervention for improving 
walking endurance, sit-to-stand, and QOL in PWMS.  This unique pilot study compared 
FES cycling versus Cycling Only for PWMS using a customized progression protocol.  
Further research with larger sample sizes are needed to better understand the effects of 
FES Cycling on PWMS. 
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CHAPTER 1 
Background and Overview 
 Multiple Sclerosis (MS) is a chronic inflammatory disease in which the immune 
system attacks the central nervous system.1  There are 2.3 million cases of multiple 
sclerosis (MS) worldwide with approximately 1 million individuals living with MS in the 
United States.  It is the most common neurodegenerative disease found in developed 
countries, with a prevalence of 1 in 800.  The disease is two to three times more common 
in women than in men, and is commonly diagnosed between 20 and 50 years of age.2,3 
 During the disease process, the myelin sheaths that protect nerve fibers and 
facilitate nerve conduction velocity are damaged and, as a result, transmission of nerve 
impulses between the brain and spinal cord become impaired.2  Four clinical courses of 
MS have recently been redefined by a panel of experts as:  clinically isolated syndrome 
(CIS), relapsing-remitting multiple sclerosis (RRMS), secondary-progressive multiple 
sclerosis (SPMS), and primary-progressive multiple sclerosis (PPMS).4  Table 1-1 provides 
characteristics and descriptions of each clinical subtype.2  The most common form of the 
disease is RRMS, but by six to ten years after onset, a large percentage of individuals who 
were diagnosed with RRMS become classified as SPMS.3  This change occurs when 
individuals start to develop steady worsening of the disease with only minor recoveries 
or plateaus.3  
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Table 1-1 Classification of MS Clinical Courses4 
Clinical Subtypes % of MS cases Description 
Clinically Isolated 
Syndrome (CIS) 
Not available First clinical presentation (lasting > 
24 hours) of the disease that 
displays characteristics that could 
be MS 
Relapsing-remitting MS 
(RRMS) 
85-90% Acute attacks followed by complete 
or incomplete recovery 
Secondary progressive MS 
(SPMS) 
Not available Steady worsening of individuals 
with RRMS. Individuals experience 
minor recoveries or plateaus 
Primary-progressive MS 
(PPMS) 
10% Slow but progressive neurologic 
decline from onset with no relapses 
or remissions 
 
 MS is a complex disease due to the wide range of clinical courses and 
heterogeneity of symptoms.  MS can affect an individual’s function at every level of the 
International Classification of Functioning, Disability and Health (ICF) Model, including 
body function and structure, activities, and participation (Figure 1-1).5  Changes in body 
structure and function that commonly occur in people with MS (PWMS) include muscle 
weakness or paralysis, spasticity, fatigue, incoordination, intention tremor, paresthesias, 
dizziness, ataxia, visual disturbances, impairment of bowel and bladder functions, 
cognitive dysfunction, sexual dysfunction, pain, spasms, speech and swallowing 
disturbances, and emotional changes.6  When changes in body structure and function 
persist, it often leads to changes in activities such as transfers, ambulation, and stair 
negotiation.  In turn, these limitations can affect an individual’s ability to participate in 
her or his life roles in the home, work, and community.  
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Figure 1-1 International Classification of Function, Disability and Health (ICF) 
Model 
 
 
 
 
 The role of exercise can have a significant impact on quality of life (QOL), activity, 
and participation in persons living with MS.7,8  A 5-year longitudinal study that tracked 
the effect of exercise on functional limitations and quality of life revealed that those who 
exercised more frequently experienced less functional limitations and a higher QOL 
compared to those who exercised less frequently.5  In addition, those who demonstrate 
higher levels of cardiorespiratory fitness, have been shown to have improved 
cerebrovascular function, improved cognitive task performance, and improved 
recruitment in certain areas of the cerebral cortex.9  
 Due to the heterogeneity of the disease, rehabilitation professionals utilize a 
variety of approaches and interventions to treat the changes in body structure and 
function, activity limitations, and participation associated with MS.  Approaches such as 
resistance training,10,11 aerobic training,12 aquatic therapy, 13 yoga,14 cycling,15,16 and body 
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weight supported treadmill training (BWSTT)17,18 have all demonstrated promising 
results in targeting a variety of impairments and limitations.  In a time where healthcare 
dollars are being stretched and cost containment is on the forefront, therapists need to be 
time efficient while prescribing the most effective interventions.  Interventions that target 
multiple body structures, while addressing activity limitations, participation, and QOL, 
may promote efficiency and effectiveness.  The use of an intervention that combines 
resistance and aerobic training, such as cycling, while providing a repetitive motion may 
be an effective tool for enhancing function in PWMS. 
 Functional Electrical Stimulation (FES) is a rehabilitation tool that stimulates 
intact peripheral motor nerves via electrical current evoking muscle contractions for the 
purpose of assisting functional movement.19  It has been utilized in patients with paralysis 
or weakness due to upper motor neuron lesions.20  The use of FES in rehabilitation dates 
back to the early 1960’s with the use of a heel switch that triggered short bursts of 
electrical stimulation to the peroneal nerve resulting in ankle dorsiflexion.21  It is now 
used to supplement or replace lost function due to neurological dysfunction and can be 
applied to assist individuals with activities such as reaching, grasping, walking, and 
cycling.22 
 FES, combined with lower extremity (LE) cycling, creates a patterned movement of 
the legs and assists individuals with impaired voluntary control of their muscles in 
completing the cycling task.  It has been utilized in a wide variety of patient populations 
including, but not limited to, spinal cord injury (SCI), stroke, traumatic brain injury (TBI), 
Parkinson’s disease (PD), Cerebral Palsy (CP), and MS.  Studies on the effectiveness of FES 
LE cycling conducted in the stroke and SCI populations have demonstrated improvements 
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in gait velocity23, balance,24 LE muscle strength,25 LE muscle mass, 26 aerobic capacity,24,27 
LE bone density,28,29 and LE range of motion,30 as well as a short-term reduction of muscle 
spasms.22  For PWMS, several studies have documented the use of electrical stimulation 
for single muscle groups,33–38 but few studies have applied it to multiple muscles using a 
FES cycling training paradigm. 
 PWMS receive traditional rehabilitation, which includes physical therapy,  during 
the course of their disease, but there is a lack of consensus regarding optimal 
interventions and exercise dosage.39  FES cycling is utilized clinically for PWMS and 
according to a company that specializes in FES technology and training, approximately 3-
5% of their FES users are PWMS, which translates to approximately 2,000 people (e-mail 
communication with Scott Simcox, Restorative Therapies, January 12, 2018); however, 
there is a limited amount of research  regarding dosage and effectiveness of FES cycling in 
PWMS. 
 Previous studies regarding FES cycling for PWMS have been conducted on 
individuals with greater disability levels than those proposed in this study, and few 
measured the impact of this rehabilitation tool on quality of life.36–38,40–42  Several studies 
had methodological weaknesses including a lack of a sufficient number of subjects, detail 
regarding dosage choices, a comparison or control group, and/or a customized 
progression protocol.  These studies will be discussed in detail in a review of the 
literature in Chapter 2.  The purpose of this study was to determine the benefits of FES 
cycling versus cycling without FES on walking performance and quality of life in PWMS.   
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Statement of the Problem 
 Previous studies have demonstrated FES cycling is a safe, feasible, and effective 
exercise intervention for non-progressive neurological disorders,23,36,43,44 but only a few 
studies have applied this intervention to a neurodegenerative disorder, such as MS.  These 
individuals have similar impairments and activity limitations compared to individuals 
with non-progressive disorders such as SCI and stroke, yet there is lack of evidence to 
support the use of FES cycling for PWMS. 
 The purpose of this study was to assess the immediate and short-term effects of an 
8-week LE cycling program on walking performance and QOL for PWMS.  The goal of this 
study was to examine if FES cycling is more effective than cycling alone.  The groups were 
compared during training, after training, and one-month post-training to determine if 
there were changes in walking endurance, spatiotemporal gait characteristics, ability to 
transition from sit to stand, and quality of life. 
Relevance and Significance of the Study 
 
 The concept of neuroplasticity after brain damage is well accepted in neuroscience.  
This current study used the theoretical framework proposed by Kleim and Jones45 
regarding principles of experience-dependent neural plasticity as they apply to PWMS.  
Kleim and Jones discuss ten principles of neuroplasticity, and several are relevant to the 
work in this study.45  Principles outlined in their paper related to the current investigation 
include: “use it or lose it,” “use it and improve it,” “repetition matters,” and “intensity 
matters.”45  “Use it or lose it” speaks to the idea of loss of specific brain functions and 
functional degradation if specific inputs are not provided to the body and “use it and 
improve it” refers to the idea that training specific functions can lead to improvement in 
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that function.45  Kleim and Jones discuss that repetition at high intensities are necessary 
to induce plasticity.45 
 The evidence regarding the relationship between task-specific exercise and 
positive neuroplastic changes in the central nervous system46,47 is mounting.  Specificity 
of training would dictate that in order to improve walking, one would need to train 
walking, but this type of activity is often not safe at high intensities for PWMS because of 
the challenges it poses to one’s balance and postural control.  Finding a rehabilitation 
intervention that individuals of varying disability level can benefit from is crucial to the 
process. 
 It has been hypothesized that cycling has its own set of underlying neural 
mechanisms, which are repetitive in nature, and similar to the concept of central pattern 
generators for walking and upper extremity coordination.48  This could imply that cycling 
may have some carryover that would help to improve walking performance.  This study 
measured walking outcomes (including endurance, gait speed, and spatiotemporal 
walking parameters), further exploring this hypothesis.  Cycling has been shown to have 
positive effects on quality of life, walking distance, walking speed, and fatigue, and can be 
safely applied at moderate intensities in PWMS.12,15,49   
 In PWMS, physical exercise has beneficial effects on aerobic capacity, upper and 
lower extremity strength, balance, fatigue, and depression.15,50,51  Based on the available 
research, Dalgas, Ingemann-Hansen, and Stenager52 suggest that both resistance and 
endurance exercises are safe and beneficial for PWMS that have an Expanded Disability 
Severity Scale (EDSS) score of less than 7.  EDSS scores from 0 to 7 encompass a large 
range of disability and include those individuals with a normal neurological exam 
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(EDSS=0) to those who require constant bilateral assistive devices to walk about 20 
meters without resting (EDSS= 6.5).53  Dalgas et al52 report that programs should be 
designed by professionals and tailored to the individual’s capabilities, and lower 
extremity exercises should have high priority.  In addition, studies support that low to 
moderate intensity endurance exercises are well tolerated by PWMS without any adverse 
long-term side effects.50,54 
 Cycling on a typical exercise bike is an effective way for PWMS to exercise.15,55  The 
results of a pilot study on PWMS (EDSS 4.0 - 6.0) showed bi-weekly cycling for 30 minutes 
for 12 weeks produced significant improvement in the 6 Minute Walk Test (6MWT) and 
improved outcomes on the Guys Neurological Disability Index.49  In a larger randomized 
controlled study, progressive cycling, combined with balance exercise, was found to be 
effective for PWMS compared to those performing home-based LE balance and 
strengthening exercises.15  Individuals who performed a bi-weekly program of 
progressive cycling and balance for 8 weeks, demonstrated a significant change in a timed 
10 meter walking test (10MWT), total duration of exercise, tolerated maximum workload, 
Timed Up and Go (TUG), Dynamic Gait Index (DGI), Functional Reach (FR), Fatigue 
Severity Scale (FSS), Falls Efficacy Scale, and Beck Depression Inventory (BDI).15  
Although the findings of these studies were positive, researchers failed to measure 
retention of gains after the training period was completed. 
 FES cycling may be an effective way for PWMS to safely exercise while having a 
positive effect on gait speed, aerobic capacity, function and quality of life (QOL).  In 
addition, the use of this technology may motivate an individual to engage in physical 
activity because the cycle provides real-time visual feedback.  Once a patient is familiar 
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with FES cycling, they can perform it as part of a wellness program in the clinical setting 
or in the privacy of their home.  The cycle being used in this study allows the therapist to 
monitor progress and change parameters remotely.15  In a study examining the perceived 
barriers to exercise, physical exertion and limited access to exercise locations were listed 
as the greatest barriers to exercise in PWMS.56  Since cycling is performed in a seated 
position, it is safe for individuals with balance deficits due to their inability to perform 
activities safely in a standing position.  Over time, this treatment paradigm could 
potentially save money and time not only for PWMS, but also the healthcare system.  FES 
cycling could be utilized in the home environment and may be fully or partially covered 
by medical insurance.  In the past 10 years, FES home-based cycling has been successfully 
utilized in patient populations such as SCI36,57 and CP.58 
Research Questions and Hypotheses 
Research Question 1 
Is there a difference in aerobic capacity as measured by the 6 Minute Walk Test (6MWT) 
between FES Cycling and Cycling Only training in PWMS? 
Research Question 2 
Is there a difference in gait speed as measured by the Times 25-foot Walk Test (T25FW) 
between FES Cycling and Cycling Only in PWMS?  
Research Question 3 
Is there a difference in functional lower extremity strength as measured by the 5 Times 
Sit-to-Stand (5XSST) between FES Cycling and Cycling Only in PWMS?  
Research Question 4 
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 Is there a difference in functional mobility as measured by the Timed up and Go (TUG) 
between FES Cycling and Cycling Only in PWMS?  
Research Question 5 
Is there a difference in spatiotemporal components of gait between FES Cycling and 
Cycling Only in PWMS?   
Research Question 6 
Is there a difference on quality of life and self-reported walking and balance measures 
between FES Cycling and Cycling Only in PWMS?   
 
Summary 
 
 MS is a disabling neurodegenerative disorder that can result in severe disability 
affecting every facet of an individual’s life, creating a financial burden on the individual, 
family, health care system, and society.59  It is important for clinicians and people living 
with MS to have a variety of safe and effective tools to treat individuals with this long-
term, progressive disease.  Due to the lack of research on the use of FES cycling in PWMS, 
this study compares the effectiveness of FES cycling to cycling alone, using a variety of 
objective and subjective measures that span the ICF model and are easily applied in 
contemporary clinical practice. 
Definition of Terms 
 
1. Functional Electrical Stimulation (FES)- when a functional component, such as cycling, 
walking or reaching, is added to electrical stimulation. 
2. FES cycling- a therapeutic intervention that activates LE muscles in a sequential 
pattern to produce a cycling motion. 
3. Fatigue- a perceived lack of physical and/or mental energy that may interfere with 
 11 
usual and desired activities.60 
4. Amplitude (mA)- is the current rate of electricity flow.  
5. Pulse width (μsec)- is the application of current over brief periods of time. 
 
6. Frequency (Hz)- the number of waves that pass a given point per second. 
 
7. Ramp- time it takes for current to go from zero to maximum amplitude. 
 
8. Training Period- time period from baseline to post-training. 
 
9. Retention Period – time period from post-training to one-month post training. 
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 CHAPTER 2 
 Introduction  
  MS is a chronic progressive neurological disease that destroys the myelin 
that insulates axons in the central nervous system, which affects the transmission of 
electrical impulses along the axon, slowing nerve conduction.2  A variety of 
pharmacological treatments are available to slow the progression of the disease and to 
treat MS-related symptoms.61,62  In addition, there are a wide variety of rehabilitation 
techniques, exercise regimens, and treatment modalities that physical therapists 
prescribe to help manage MS symptoms and assist individuals in maintaining a physically 
active lifestyle throughout the disease process. 
  Over the past 20 years, FES cycling has been utilized in a variety of 
neurological populations, but research studies have been limited to mostly non-
progressive disorders.  There is a paucity of FES cycling literature in the MS population, 
but the available studies have established that this device is safe to use in PWMS.  
Currently, there are no randomized comparative studies examining the effectiveness of 
FES cycling for PWMS.  In addition, there is a lack of literature regarding dosage including: 
duration, frequency, treatment progression, and electrical stimulation parameters for FES 
cycling for PWMS.  This study is unique in that it utilized a customized interval training 
treatment progression, based on baseline submaximal exercise testing and a standardized 
progression protocol, over an 8-week period for a total of 24 sessions.   
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Impact of MS 
 Common activity limitations among PWMS are gait and balance disturbances, 
including falls.63  People with MS report a fall incidence of greater than 50% and this 
increases as individual’s age and the disease progress.63,64  When a large group of PWMS 
were surveyed, the activities with which they reported frequent falls included: transfers, 
ambulation, standing activities, stairs/curbs, and exercise/physical activity.63   
 When comparing 2 groups of PWMS, fallers vs. non-fallers, measures that 
distinguished between these two groups include the 6MWT, TUG, and sway velocity.64  
When comparing PWMS who had minimal disability in gait to matched healthy controls, 
those with MS demonstrated significant differences in several spatiotemporal gait 
parameters including: gait velocity, step length, cadence, base of support, step time, and 
double support time.65,66  Those with MS also demonstrated greater intra-individual 
variability with regard to step time and single support time when compared to healthy 
individuals.65  Individuals with mild to moderate (EDSS 2.5 – 6) disability demonstrated 
impairments in gait speed and spent a greater amount of time in the double-support 
phase of gait compared to healthy individuals.67  These studies support the use of 
spatiotemporal gait parameters to detect subtle, yet important changes in gait and to 
measure the effect of physical therapy interventions on gait performance.  
 MS-related fatigue is reported in approximately 65% of PWMS.68  The MS council60 
published a consensus definition of MS-related fatigue as a “subjective lack of physical or 
mental energy that is perceived by the individual or caregiver to interfere with usual and 
desired activities.”  Fatigue can be related to the disease or due to secondary factors 
including depression, pain, sleep disturbances, medications, and deconditioning.69  In a 
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study of individuals with MS (mean EDSS 4.07 ± 2.28) detailing the effect of depression, 
fatigue, and disability on quality of life, the authors found that fatigue was strongly 
associated with a low score on the physical and mental health composite on the MSQOL-
54 (r= -.66, P<.0001; r= -.69, P<.001, respectively).70  In addition, a step-wise regression 
model showed that fatigue is a significant predictor (67%) of quality of life.70 
 
Exercise and MS 
 Exercising and living an active lifestyle are beneficial to PWMS.7,71  Individuals 
with greater disability in ambulation tend to achieve less than the recommended daily 
activity levels when compared to those individuals without ambulation limitations.72  
Individuals who exercise often report a decrease in the perception of fatigue.73  
Improvements in fatigue outcome measures have been reported in a variety of exercise 
types, including high-intensity resistive exercises,74,75 yoga,14 and endurance/aerobic 
exercises.54  In addition, physically active PWMS monitored by accelerometers reported 
lower levels of disability, depression, fatigue, and pain.76  
 In an animal model training study in which an autoimmune encephalopathy 
similar to the disease process in MS was induced, researchers demonstrated that 
endurance type exercise may serve to slow the disease progression and reduce the length 
of exacerbations.77  Other experts have suggested that exercise may serve to protect,78 
regenerate, and adapt neuronal processes that can reduce long-term disability.46  Proteins 
such as nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) may 
have an impact on progressive diseases such as MS and may play a significant role in the 
neural regenerative process.  In a study by Gold et al78 investigators reported statistically 
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significant increases in NGF and BDNF serum concentration levels, in PWMS (EDSS mean 
of 2.3 ± 0.2), after only one, 30-minute session of cycling.  However, due to the short 
training duration, no conclusions could be made regarding the effect of exercise on neural 
plasticity from this study.  In a more recent randomized control trial in PWMS, 
researchers compared an exercise group to a sedentary group and found significant 
changes in BDNF after 24 sessions of endurance and resistance training.79  In contrast, 
despite the authors’ hypotheses that serum concentrations levels of NGF and BDNF would 
be elevated after a training protocol using a traditional bicycle, no changes in BDNF or 
NGF were found in PWMS after an 8-week, two times per week, 30 minute intervention.80  
Interpretation of this study should be approached with caution since the exercise protocol 
may not have been intense or long enough in duration to induce long-term changes in 
neurotrophic factors.  Findings did support significant changes in quality of life, physical 
fitness or coordination.80 
 It is a challenge for PWMS to pursue an active lifestyle and exercise prescription is not 
well utilized in this population.
81
  A variety of interventions have been used that target 
resistance training, endurance training, or combined training.  Aerobic training can include 
treadmill training, arm and/or leg ergometry, aquatic therapy, and yoga.  Individuals who 
participated in aerobic training programs demonstrated improvements in physical fitness, 
activities of daily living (ADL), mood, and fatigue.
50
  When further examining aerobic training 
studies, the duration and frequency of training sessions vary considerably.  Training sessions 
ranged from 1-5 days/week
14,49,71
 for periods of  2 - 26 weeks.
14,82
  A sample of studies that 
utilized cycling as part of the training intervention also present with a wide range of 
frequencies and durations, ranging from 2 times per week for 8-weeks,
50
 2 times per week for 
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12-weeks,
49
 5 times per week for 3-4 weeks,
71
 3 times per week for 24-weeks,
83
 3 times per 
week for 15-weeks,
50
 and 4-5 times per week for 16-weeks.
84
  Frequency and durations as little 
as 2 times/week for 8-weeks have shown improvements in quality of life and lower blood 
lactate levels, indicating training effects.
80 
 When further examining the resistance training studies, the range of duration and 
frequency of training sessions varies considerably.  Training sessions ranged from 2-7 
days/week85,86 for periods of  8-10 weeks.87,88  Improvements in muscle strength and 
functional capacity in individuals with RRMS (EDSS between 3.0 and 5.5) have been 
reported after a 12 week, bi-weekly, lower extremity strengthening program that 
included a five minute warm-up on a stationary bicycle and five lower extremity 
exercises.10  Functional capacity testing included a variety of measures, such as a chair 
stand test, stair-climbing test, 10MWT and 6MWT, and significant improvements 
occurred in all measures and continued improvements were documented at post-testing 
follow-up at 24 weeks.10 
 
Cycling and MS 
 Cycling is a safe and effective method of exercise for PWMS.15,49  A small pilot study 
by Kileff and Ashburn49 assessed the effects 30 minutes of cycling during a 2 times per 
week, 12 week cycling program.  This study included people with moderate disability 
(EDSS 4.0 – 6.0) and outcomes were favorable with subjects demonstrating an 
improvement in their 6MWT and Guys Neurological Disability Scale scores.49  
Improvements were not observed in the 10MWT and Functional Reach (FR) test, which is 
not surprising since gait speed and balance training were not the focus of the training.49  
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In a randomized controlled study by Cakt et al 15 progressive cycling, combined with 
balance exercises, were found to be more effective for individuals with RRMS and SPMS 
compared to a group performing home-based balance and strengthening exercises.  
 Collet et al16 performed a cycling study that examined outcomes using three 
different protocols.  Subjects in all groups participated in 20 minutes of cycling, two-times 
per week.  Subjects were randomized into one of three groups: continuous cycling (at 
45% peak power), intermittent cycling (30 seconds cycling/ 30 seconds rest at 90% peak 
workload), or combined cycling (10 minutes intermittent at 90% peak workload and 10 
minutes continuous at 45% peak workload).  Outcomes were measured at the halfway 
point at 6 weeks, at the end after 12 weeks, and follow-up at 24 weeks.16  Investigators 
found significant differences in 2 minute walk test (2MWT) after 6 weeks of cycling (6.96 
± 2.56m, 95% CI: 1.81 – 12.10, Effect size = 0.25, p < 0.01) and no significant increase in 
this outcome from 6 to 12 weeks.16  When all participants were combined for analysis, a 
repeated measures analysis of variance (repeated measure ANOVA) revealed significant 
and positive changes in both the 2MWT and TUG, and leg power (p <0.01, p< 0.05, p<0.05 
respectively) at the 6 week mark.  Interestingly, no further improvements in the 2MTW 
and TUG were seen at 12 weeks, but leg power continued to demonstrate significant 
improvements (p<0.01).16  At 24 weeks (12 weeks after the training period) significant 
decreases were seen in the 2MTW, TUG, and leg power indicating detraining.16  Based on 
the between groups analysis, participant attendance, and adverse events, the authors 
recommended that low-intensity continuous cycling may be the safest approach for 
PWMS, noting that further study with larger samples and different dosages needs to be 
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performed.16  Based on Collett et al’s16 study it appears that changes in endurance occur 
earlier in training than changes in strength. 
 Functional Electrical Stimulation  
  Neuromuscular electrical stimulation (NMES) provides stimulation at 
frequencies ranging from 20-50 Hz and assists skeletal muscles in producing a tetanic 
muscle contraction by stimulating intact peripheral motor nerves.19,89  It has been applied 
to patients with paralysis or weakness due to upper motor neuron lesions and is 
commonly utilized in patients with stroke, SCI, CP, and MS.20–22,33,34,58 
  Several studies have documented the use of electrical stimulation for single 
muscle groups in PWMS with variable success.33–35  Chang et al33 found that PWMS 
reported reduced perceived fatigue as measured by Modified Fatigue Impact Scale (MFIS) 
scores after surface FES treatment was applied to the quadriceps muscles.   Subjects were 
in a seated position and were instructed to avoid actively engaging in the movement or 
task.  In PWMS who presented with foot drop, Barrett et al34 compared passive FES 
applied to the peroneal muscle to a home exercise program (HEP) that included LE 
strengthening and stretching, seated balance activities, and standing balance activities.  
The exercise group demonstrated a greater improvement in walking speed and distance 
compared to the FES group.34  This study supports the use of FES as an adjunct to active 
therapy for use in PWMS. 
 A randomized control study in PWMS by Broekmans et al35 compared resistance 
training, with and without electrical stimulation to the quadriceps, and found no 
significant difference between muscle strength gains between groups after 20 weeks of 
resistance training that consisted of unilateral leg press, leg extension, and leg curls.  In 
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addition, there were no gains in functional mobility as measured by the TUG, Timed 25-
Foot Walk (T25FW), 2MWT, Functional Reach, and Rivermead Mobility Index.35  The 
quadriceps were the only muscle groups stimulated in this study and were only 
stimulated during the exercises.  The selected outcome measures may not have been the 
appropriate choices to capture a change in function since improvement on these 
measures are unlikely to be due to changes in muscle strength of a single muscle group. 
 When functional movement is paired with electrical stimulation, it is referred to as 
functional electrical stimulation (FES).21  FES has evolved over 50 years from the simple 
heel switch and is now routinely used to supplement or replace lost functional mobility 
due to neurological impairment during a variety of activities.22  In the 1980s, the 
combination of cycling using FES was introduced90 and is now most known for being used 
by individuals with SCI.  However, research studies support the safety and efficacy in 
other neurological populations including CVA,23,43 CP,57 and MS.36 
 FES cycling using an ergometer combines the technology of electrical stimulation 
and cycling.  This device contains software that delivers stimulation during cycling and is 
designed to stimulate multiple muscle groups at the appropriate time in the cycling 
pattern to produce a smooth cyclical motion.  The selection of stimulation parameters, 
cycling speed, and resistance can be customized to each patient’s tolerance and fitness 
level.  In addition, the ergometer allows clinicians and researchers to measure specific 
outcomes during cycling, including the amount of work (power output), distance traveled, 
and asymmetry during cycling.   
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FES Cycling in Neurological Populations  
 FES cycling has been studied in individuals with SCI more than any other 
neurological diagnosis.  Exercise adherence rates for home use of FES cycling in lower 
extremities for people with SCI ranges from 62%91 to 82%92,93 in published case reports.  
These studies ranged in length from 6-weeks to 1-year.  Studies show benefits in multiple 
body systems including, cardiovascular, integumentary, and musculoskeletal, but little 
evidence in the SCI literature exists that directly links the use of FES cycling to clinically 
meaningful functional change in this population due to the level of disability.94–96  Frotzler 
et al29 and Chen et al28 studied the use of high-volume FES cycling for improving bone 
density and found significant increases in trabecular and total bone mineral density in the 
distal femur when the gluteals, quadriceps, and hamstrings were stimulated.  In addition, 
improvements in muscle mass,26 muscle strength,93 and muscle fiber composition toward 
more fatigue resistant fibers were found.93 
 A wide range of cycling time (30 – 60 minutes), frequency (2-3 times per week), 
and duration (12 – 24 weeks) has been reported in the SCI literature depending on the 
goal of the study.26,91,92,96,97  Stimulation parameters regarding frequency, pulse width, 
and amplitude also vary greatly depending on SCI classification, spasticity, and level of 
sensation.26,91,92,96,97 
 FES cycling has also been studied in individuals recovering from acute, sub-acute 
and chronic stroke.23–25,27,31,43  These studies examined a variety of outcomes including: 
spasticity,98 aerobic capacity,24,27 maximal power output,23,27 balance,27 maximal isometric 
voluntary contractions (MVC),25 gait velocity,23,24,43 sit to stand transfers,23,25 and upright 
motor and trunk control.25,43 
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 Four studies examined the effects of cycling with and without FES.27,31,43,99  Janssen 
et al27 evaluated the effects of FES cycling versus active cycling without muscle provoked 
electrical stimulation in a group of 12 people with chronic stroke who trained two times 
per week for 6-weeks with a goal of cycling for a total time of 25 to 30 minutes.  
Stimulation parameters were set at a frequency of 60Hz, a pulse width of 450s and 
amplitude to tolerance.  Outcome measures were used to measure aerobic capacity, 
maximal power output, functional performance, and lower limb muscle strength.27  
Significant improvement occurred in both groups on all measures except for muscle 
strength, but no differences were found between the two training groups.27  Researchers 
need to continue to take a closer look at FES cycling compared to cycling alone to 
determine optimal dosage and which of these interventions may be most beneficial in the 
stroke population.  In addition, stimulation parameters need to be customized to 
maximize muscle activation during stimulation.   
Yeh et al31 focused on the effect of FES assisted cycling on spasticity in individuals 
with sub-acute stroke.  Subjects performed 2 sessions of cycling for 20 minutes each, one 
with FES assistance, the second without.  Cycling sessions were separated by at least one 
day.31  Findings supported that FES cycling had a greater effect on reducing hypertonia 
than cycling without FES when measured immediately after the training session.  FES 
parameters were set at a frequency of 20Hz and a pulse width of 300s, with amplitudes 
ranging from 0 – 100mA.31  Investigators did not perform any follow-up to evaluate 
potential long-term effects. 
A larger randomized control study by Ambrosini et al43 involved subjects with 
chronic hemiparetic stroke.  Thirty-five individuals were randomized into either an FES 
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cycling group or a placebo FES cycling group.43  The placebo group performed passive 
cycling with electrodes applied, but did not receive any stimulation.  This was a 4-week, 
20 session training study in which each session lasted up to 25 minutes.  FES parameters 
were set at a frequency of 20Hz and a pulse width of 300s with the amplitude set to 
tolerance.43  Muscles stimulated included the quadriceps, hamstrings, gluteals, and 
anterior tibialis.  The FES cycling group demonstrated significant improvement on the 
Motricity Index, Trunk Control Test, Upright Motor Control Test, gait speed, and mean 
work of the paretic leg after training.43  The placebo group did not demonstrate any 
significant improvements in outcomes after training.43  These findings are significantly 
different than those from Janssen et al,27 but the patient population and study design 
were not equivalent, making comparisons difficult.  Differences in outcomes of these 
studies may be attributed to: patient acuity, intensity of the training protocol, duration of 
training, stimulation settings, and outcome measure selection.  One primary difference 
was that in the Janssen et al27 study, subjects performed active cycling, whereas the 
subjects in the Ambrosini et al43 study cycled passively, with sham stimulation. 
Bauer et al99 extended the work of Ambrosini  et al43 and Janssen et al27 and 
evaluated the effects of active cycling with and without FES on balance and gait in a group 
of 40 individuals with severe hemiparesis due to stroke.  Individuals cycled 20 minutes, 3 
times per week for 4 weeks at a self-selected speed above 20 rpm.99  While in the study, 
subjects also received other interventions during their scheduled physical, occupational, 
and speech therapy sessions.99  Individuals in the FES group received stimulation to only 
the paretic limb with a frequency of 25Hz, a pulse width of 250s, and amplitude set to 
tolerance.99  Significant differences for the FES group were found during the intervention 
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phase (pre to post-intervention) for the balance portion of the Performance-Oriented 
Mobility Assessment (POMA) and on the individual’s Functional Ambulation Classification 
(FAC) with both measures revealing moderate to high effect sizes.99  The authors also 
measured the effects of the intervention on muscle tone in the quadriceps and hamstrings 
using the Modified Ashworth Scale (MAS) and found there were no statistically significant 
differences in either intervention group.99  The study methodology was similar to 
Janssen’s study27 in which individuals were actively cycling and the frequency of 
stimulation was relatively low; greater results may have been seen with higher 
frequencies and cycling speeds. 
Alon, Conroy, and Donner23 demonstrated improvements in people pedaling 
power, the TUG, and gait velocity in people with chronic stroke using a 3 times per week, 
8-week, 30 minute FES cycling training paradigm using a frequency of 50Hz, a pulse width 
of 250s, and amplitude set to tolerance.  Subjects in their study cycled at or close to 60 
rpm while resistance was gradually increased.23  Their training was safe and well 
tolerated by a variety of post-stroke disability levels. 
The post-stroke population has several similarities to the MS population in that 
they both demonstrate volitional movement, partially preserved sensation or 
hypersensitivity, and asymmetrical movement patterns due to spasticity, weakness or 
motor control.  Based on these similarities, FES cycling may lead to similar benefits in 
PWMS. 
Multiple studies report that PWMS benefit in a variety of ways from resistance and 
aerobic training.83,85,100  Exercise equipment that can offer a safe, moderate intensity 
workout is readily available in the traditional gym environment, but this often is not the 
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best option for PWMS due to gait or balance difficulties, or the need for assistance.  FES 
cycling can be performed in the home environment with some initial patient education 
and set-up by a professional.  This offers PWMS an exercise option if they do not have the 
time or ability to travel outside their home, have limited therapy through their insurance, 
or have financial constraints preventing attendance to wellness programs. 
There is a small number of case reports and pilot studies that have examined the 
efficacy and effectiveness of FES cycling for PWMS.36,37,40,101  The available FES cycling 
studies are summarized in Table 2.1.  A review of the literature yields no randomized 
clinical trials or quasi-experimental studies comparing FES cycling to other interventions 
in PWMS. 
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Table 2-1 Summary of FES Cycling Studies for PWMS 
 
 
 
 
 
Study  Sample 
Size 
Disability Study 
Design 
Main 
Outcome 
Measures 
Protocol/ 
Dosage 
FES 
Parameters 
Muscles 
Stimulated 
Results 
 
Krause, 
Szecsi and 
Straube37 
1 Non-
ambulatory
SPMS, EDSS 
= 7.5 
Case 
Study 
MAS and 
Pendulum 
Test 
2 sessions, 
30 min. with 
3-5 min. 
breaks,  
Only reported 
amp - 90mA 
Quads, 
hamstrings, 
gluteals 
Reduction in 
spasticity 
immediately post-
training. 
Szecsi et 
al40 
12 (4 
drop-
outs) 
EDSS 4.0 – 
8.0 
Single-
group, 
cross-
over 
design  
Cycling 
cadence 
and torque 
recordings, 
MAS, MMT, 
10MWT 
3 times per 
week for 2 
weeks, 6 
sessions 
total, 12-18 
total min. of 
pedaling (6 
min. of 
stimulated 
pedaling)  
PW = 300μsec,  
Freq = 20Hz, 
Maximal amp = 
127mA 
Quads, 
hamstrings 
Power and 
smoothness improved 
during stimulated 
pedaling within 
session.  No 
significant change 
over 2 weeks.  Short-
term reduction in 
spasticity.  No change 
in MMT or 10MWT. 
Ratchford 
et al36  
5 PPMS or 
SPMS, EDSS 
6.0 – 6.5 
inclusive 
Single-
group, 
pilot 
study 
2MWT, 
T25FW, 
TUG, leg 
strength, 
MSFC 
3 times per 
week, 1-
hour 
sessions, for 
6 months 
(home-
based) 
PW = 250μsec, 
Freq = 33 to 
45Hz 
Quads, 
hamstrings, 
gluteals 
Improvements in 
strength of stimulated 
muscles.  
Improvements in 
walking endurance 
gait speed, and quality 
of life. 
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Abbreviations: EDSS = Expanded Disability Status Scale, ISNCSCI = International Standards for Neurological Classification of Spinal Cord Injury, MS = 
Multiple Sclerosis, MFIS= Modified Fatigue Impact Scale, MSQLI = Multiple Sclerosis Quality of Life Inventory, MMT = Manual Muscle Test, MAS = 
Modified Ashworth Scale, MSFC = Multiple Sclerosis Functional Composite, SF-36 =Short-Form 36, Freq = frequency, PW = pulse width, amp = amplitude, 
min. = minute, 2MWT = 2 Minute Walk Test, T25FW = Timed 25-Foot Walk  
Study  Sample 
Size 
Disability Study 
Design 
Main 
Outcome 
Measures 
Protocol/ 
Dosage 
FES 
Parameters 
Muscles 
Stimulated 
Results 
 
Fornusek 
and 
Hoang41 
7 EDSS 6.5 -
8.5, SPMS 
Single-
group 
design 
Thigh girth, 
transfer 
ability and 
cardio-
respiratory 
response 
2-3 times per 
week, 10 
weeks, 18 
sessions, 
progressed to 
40 min 
sessions, 
passive 
pedaling at 
cadence of 10 
rev-min 
Initial settings: 
amp = 30mA, 
increased as 
tolerated, PW 
= 300μsec, 
Freq = 35Hz 
Quads, 
hamstrings, 
gluteals 
Significant 
increases in thigh 
circumference, 
improvement in 
perceived transfer 
ability, small 
increases in 
cardiorespiratory 
metabolism. 
Hammond 
et al102 
40 EDSS 2.5 -
7.5, RRMS, 
SPMS, PPM,  
Retro-
spective 
cohort 
study 
EDSS, 
ISNCSCI 
4.4 hours of 
therapy per 
month 15-
month 
period. 
Protocol not 
reported. 
Parameters 
not reported 
Not 
reported 
ISNCSCI motor 
scores significantly 
improved when 
compared to non-
FES users. Stable 
neurologic function 
over 15 months. 
Backus et 
al38  
14 Household 
ambulation 
of < 70 feet, 
Moderate to 
Severe MS 
Single-
group 
design 
MFIS, 
MSQLI, 
MMT, MAS 
3 times week 
for 4 weeks, 
30 min. 
sessions, 12 
sessions, 
target speed 
35 -50 rpm 
PW = 200μsec, 
Freq = 50Hz 
Quads, 
hamstrings, 
gluteals 
Significant decrease 
in physical and 
psychosocial 
subscales of MFIS. 
Improved cycling 
times. 
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Krause, Szecsi, and Straube37 report a single case study of a non-ambulatory, 46 
year-old man with secondary progressive MS with an EDSS score of 7.5.  The investigators 
bilaterally stimulated three muscle groups during cycling: the gluteals, quadriceps, and 
hamstrings.  This individual tolerated 30 minutes of stimulated cycling with short (3-5 
minute breaks).  He tolerated stimulation amplitudes up to 90mA, but authors did not 
report the frequency or pulse width.  This individual experienced a reduction in spasticity 
after each of the two training sessions as measured by the MAS and the pendulum test.37  
The authors did not measure spasticity reduction hours or days later, therefore no 
conclusions can be made regarding the long-term effectiveness.  In addition, there were 
no outcomes or subjective descriptions reported that related this reduction of spasticity 
to gait, functional, or quality of life. 
Szecsi et al40 examined the effect of FES cycling on biomechanical and functional 
outcomes.  Eight PWMS completed the FES cycling training 3 times per week for 2 weeks 
for a total of 6 sessions, while also receiving conventional therapy.  Training sessions 
were 12-18 minutes in length and contained stimulation and non-stimulation phases.  
Although no adverse reactions were reported, four subjects dropped out; reasons 
provided were: change of schedule, change of medications, failure to comply, and 
difficulty with transfers due to a high degree of disability.  The quadricep and hamstring 
muscle groups were stimulated in bilateral lower extremities.40  They utilized a fixed 
frequency of 20Hz, a maximal amplitude of 127mA, and a fixed pulse width of 300μsec.40  
These settings may not be optimal to elicit strong contractions in all PWMS.103  Symmetry 
of pedaling and power output was examined at various stimulation and non-stimulation 
intervals during the 12 -18 minutes of cycling.40  Subjects were able to achieve greater 
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cycling power and symmetry of pedaling with FES than without FES.40  Functional 
outcomes were measured both before and after training and included the 10MWT, MAS 
and Manual Muscle Testing (MMT).40  There were no significant changes in these 
measures except for a short-term reduction in spasticity before and after each training 
session.40  Subjective feedback from participants revealed reports of increased functional 
abilities (e.g. transfers, stairs, activities of daily living) and quality of gait, such as 
improved leg lifting.40  It is unknown if greater functional improvements would have been 
revealed if the training period was longer and more intense.  The training period in this 
study was significantly below the exercise recommendations for PWMS.  In addition, a 
frequency of 20Hz is on the low end of what is recommended for FES cycling.  A study by 
Eser et al103 demonstrated that, in people with motor and sensory incomplete SCI, when 
pulse width and amplitude were held at a constant, higher frequencies (50 and 60 Hz) 
elicit larger power outputs. 
In a pilot study by Ratchford et al36 the research team examined the relationship 
between FES cycling and changes in walking performance, LE strength, and QOL.  Four 
individuals (EDSS 6.0 to 6.5 inclusive) with primary or secondary progressive MS 
completed the study.  Individuals performed FES cycling in the home environment using 
an FES cycle for 6 months.  They were instructed to cycle 3 times per week for one-hour 
sessions.  In addition to looking at impairments and functional measures at baseline, 3 
months, and after the 6-month period, researchers also examined the relationship 
between FES cycling and changes in cytokines and growth factors in cerebral spinal fluid 
(CSF).36  Participants were trained to use the FES cycle in their home and started with the 
same initial settings: a symmetric biphasic waveform, phase duration 250μsec 
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randomized ± 25%, and a frequency 33 to 45Hz.36  Electrical stimulation was applied to 
the quadriceps, hamstrings, and gluteal muscles.36  There were no serious adverse 
advents, but one participant reported an increase in spasticity, which was treated by an 
increase in their spasticity medication.36  Another participant with a history of irritable 
bowel syndrome reported increased bowel incontinence, which was remedied by 
adjustments in this individual’s bowel program.36  
The outcomes of the Ratchford et al study were favorable, but due to small sample 
size, statistical analysis was not performed.36  The mean number of sessions per week was 
3.8 (range 3.1 -5.1), demonstrating that these individuals were able to tolerate training 
during the suggested time period.36  The average power output and cycling mileage from 
the first two weeks compared to the last two weeks improved from 3.2 watts to 4.6 watts 
and from 9.9 miles to 10.6 miles.36  The improvements in the main neurologic measures, 
the 2MWT, T25FW, and the TUG, were 13%, 36%, and 22%, respectively.36  Investigators 
also observed improvements in self-selected walking speed, double support time, and 
step length coefficient of variation, as measured on the instrumented GAITRite 
walkway.36  Results showed a decrease in pro-inflammatory cytokines and an increase in 
nerve-related growth factors in the PWMS who performed FES cycling when compared to 
healthy controls.36  These preliminary findings suggest that FES cycling may reduce 
inflammation and promote neuronal repair, along with improvements in clinical outcome 
measures.36 
In a retrospective study, Hammond et al102 reported on 40 individuals who 
participated in a long-term FES cycling program for 15 months.  The sample of subjects 
had EDSS scores ranging from 2.5 – 7.5 and were distributed across the three main types 
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of MS (RRMS, SPMS, PPMS).102  The main outcome measures were the EDSS and the 
International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI).  
The ISNCSCI is an evaluation tool that examines sensory and motor function as well as 
anal and perianal function, but has yet to be validated in the MS population.102  Details 
regarding duration, intensity, stimulation parameters, and muscles stimulated were not 
published.  EDSS and ISNCSCI scores remained stable over the 15 month periods and in 
those with PPMS and RRMS and there was a slight decrease in EDSS score, noting 
improvement in disability, although the changes were not statistically significant.102  
Based on this study, long-term FES cycling use may help to stabilize or prevent disease 
progression in PWMS. 
Fornusek and Hoang41 investigated the feasibility and stimulation tolerance in 
seven individuals ranging from an EDSS 6.5 - 8.5.  The focus of their study was to 
individualize stimulation and cycling progression over 18 sessions (2-3 times per 
week).41  Individuals were instructed not to actively cycle and to allow the ergometer to 
passively move their legs at 10 rev-min.  Objective outcome measures included pre- and 
post- thigh circumference and metabolic exercise testing (heart rate, oxygen uptake, and 
ventilation) using open circuit spirometry.41  Individuals were also interviewed regarding 
therapeutic benefits and detriments of the intervention.  They were asked to rate the 
change in their ability to transfer on a 15 point scale where -7 indicated a “great deal 
worse,” 0 indicated “no change,” and +7 indicated “a very great deal better.”41  
Participants showed significant changes in thigh circumference (p >.001) and although 
improvements in metabolic testing were present, statistical analysis was not performed 
due to the small sample size.41  All participants reported a positive change in transfer 
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ability (median 4, interquartile range 2-5).41  This study provided evidence that 
individuals with advanced MS with intact sensation tolerate NMES when it is 
appropriately applied and gradually increased.41  Since individuals were not actively 
cycling, improvements can solely be attributed to the NMES. This study did not explore if 
the addition of active cycling would impact further improvements in outcomes. 
Backus et al38 completed an FES cycling study to evaluate the safety, cycling 
performance, fatigue, spasticity, pain, and quality of life on PWMS with severe weakness.  
Fourteen participants cycled 3 times per week for 4-weeks for a total of 12 sessions with 
no adverse events.38  The pulse width was set at 200μsec and frequency at 50Hz.  
Amplitude was based on the amount of stimulation needed to achieve a target cycling 
speed between 35 and 50 rpm.  Sessions included a 2-minute passive warm-up followed 
by 30 minutes of active cycling, which was either voluntary or assisted with electrical 
stimulation, and a 2-minute passive cool-down.38  Once a participant was able to pedal for 
30 minutes while maintaining a cycling speed of 35 to 50 rpm for three consecutive 
sessions, resistance was then increased by 0.14Nm increments.38  Investigators 
performed statistical analysis on the twelve participants who had a positive change in 
power output and a t-test revealed a significant improvement from pretest to posttest (p 
= 0.01) and a large effect size (Cohen’s d = 1.06).38  Data was then analyzed as two sub-
groups, those who could not cycle for the entire 30 minutes and those could complete 30 
minutes of cycling.  Seven of the fourteen individuals could not cycle the entire 30 
minutes, but all demonstrated significant increases in active cycling time (p = 0.04) and 
medium-large effect size (Cohen’s d = 0.77).  This group did not show a significant change 
in power output from pre- to post-training (p = 0.07).  The other sub-group (those who 
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could complete 30 minutes of cycling) (n = 7) demonstrated a significant change in 
resistance (p < 0.01), but not power (p =0.06), from pre-to-post training, but effect sizes 
for resistance and power were both large in magnitude (Cohen’s d = 2.53 and 5.25, 
respectively).  Muscle strength, spasticity and pain scale outcomes were not significant, 
however, there was a significant decrease in two subscales on the MFIS (physical, p = .02, 
Cohen’s d = .43 and psychosocial, p < .01, Cohen’s d = 0.74) and the SF-36 social subscale 
(p < .01, Cohen’s d = 0.90).  There appears to be a strong effect of QOL social subscales, 
which may be due to the socialization that participants experienced as part of the study.   
The results of the FES cycling MS studies described above only stimulated 
proximal muscle groups,36–38,40,41,101,102 omitting  muscle groups such as anterior tibialis 
or gastrocnemius musculature, both of which are integral for efficient gait.  The anterior 
tibialis is the primary muscle utilized for clearing the foot during heel strike and swing, 
and the gastrocnemius plays an integral role in the propulsion of gait during swing phase; 
both of these muscle groups can be effected in PWMS.104 
The present study compared FES cycling to Cycling Only in PWMS.  Based on a 
review of the literature, the dosage of FES cycling and Cycling Only groups was selected to 
be 3 times per week, for 8-weeks for a maximum of 45 minutes per training session.  Since 
weakness often occurs in multiple muscle groups, stimulation was applied to both LEs 
and five muscle groups, including the gluteals, quadriceps, hamstrings, anterior tibialis, 
and gastrocnemius.  An individualized interval-training progression protocol was 
employed and is described in detail in the methodology.  
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Electrical Stimulation Parameters 
 Activation of motor units during voluntary contractions are recruited from small 
(Type I, slow twitch, very fatigue resistant), to intermediate (Type IIa, fast-twitch, fatigue 
resistant), to large (Type IIb, fast twitch, fatigable) motor units, as demands for force are 
increased (Henneman’s size principle).19  When using NMES, it was originally thought that 
recruitment of motor units occurred from the largest to smallest motor units as 
stimulation intensity increased, but this has been disproven by several studies.19,105  It is 
currently accepted that when using NMES, muscles are activated non-physiologically, in a 
random, non-selective manner,105 which can lead to decreased efficiency of muscle 
contractions and neuromuscular fatigue.89  It has been suggested that this decreased 
efficiency may be due to non-physiologic motor recruitment89 and/or poorly timed 
biomechanical factors.106  These challenges also apply to FES cycling, but strategies can be 
employed to offset the high degree of fatigue that can occur with FES.89  Hunt et al106 
suggests that the timing of muscle activation needs to be optimized, as well as 
investigating alternative stimulation strategies such as varying the stimulation patterns 
and frequency settings.  In addition, it has been suggested that customization of 
stimulation parameters can reduce fatigue and improve power output.89 
In FES cycling, efficiency and power output have been found to be lower when 
compared to volitional cycling.107  In a study comparing volitional and electrically 
stimulated cycling in a group of able-bodied subjects, the mean metabolic efficiency of 
volitional cycling versus FES cycling was 29.8% and 16.4% respectively.106  FES cycling 
efficiency in people with impaired sensory and vasomotor pathways has also been found 
to be slightly lower than FES efficiency when compared to anesthetized able-bodied 
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individuals.108 
This current study was limited to the waveform and muscle activation patterns 
that are pre-set by the RT300 cycle (RT300, Restorative Therapies, Inc., Baltimore, MD).  
The RT300 cycle delivers electrical stimulation to peripheral nerves of selected muscles 
in coordination with crank rotation, and alterations cannot be made in the timing of 
muscle activation within the cycling motion.109  The selection of stimulation parameters 
influences FES cycling performance and should be set by trained clinicians with 
knowledge of FES and MS.  Electrical stimulation may induce discomfort in individuals 
with intact or partial sensory and motor paresis, so it is crucial that clinicians adjust 
stimulation parameters accordingly.  The RT300 Sage Stimulation Controller allows the 
clinician to alter the stimulation parameters throughout a treatment session depending 
on the patient response, comfort, and treatment goals.109 
PWMS present with some challenges due to issues with skin hypersensitivity, 
spasticity, and fatigue, but adjustments to stimulation parameters can be made to 
minimize these challenges.89  In this current, study the selection of the starting 
stimulation levels were based on the primary investigators (PI) clinical experience, 
coursework completed on FES cycling, clinical electrophysiology principles, and 
recommendations from Restorative Therapies, Inc. based on their current database on 
PWMS who use their cycle for training.  Based on a database review by Restorative 
Therapies Inc., a frequency of 43.5 Hz was suggested as the optimal frequency and to be 
held at a constant (oral communication with T. Ann McElroy, January 30, 2014).  Muscle 
stimulation frequencies typically range from 20-50Hz,89 and higher frequencies tend to be 
more comfortable due to the smoothing effect of the pulses. 
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A strong muscle contraction is obtained by adjusting the amplitude and pulse 
width.19  The starting pulse width was 250μsec and amplitude was adjusted in a 
systematic manner to optimize participant comfort and maximize agonist cross-sectional 
contraction without stimulating the antagonist muscle or causing a noxious reaction.  
Robinson and Snyder-Mackler19 note that small increases in stimulation can cause a large 
increase in the force of the muscle contraction and therefore stimulation should be slowly 
adjusted.  In this study, the amplitude was adjusted for each muscle group individually, 
while recognizing that it may take several minutes and/or sessions to increase participant 
tolerance to stimulation. 
Summary   
 Based on a review of the FES cycling literature in neurological populations, FES 
cycling may be an effective tool for PWMS to exercise while improving function and 
quality of life.  The published studies in PWMS have not been large enough to draw any 
definitive conclusions regarding the efficacy of this exercise intervention compared to 
cycling alone.  This is an area that needs to be explored since cycling is performed in a 
seated position, is safe for individuals who exhibit balance deficits that limit their ability 
to perform activities in standing position, and can be performed in the home 
environment.  
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 CHAPTER 3 
 Introduction 
 This chapter outlines the research design and methodology used in this 
intervention study.  The specific procedures, protocols, data safety monitoring, resources, 
and scheduling procedures are presented.  The inclusion and exclusion criteria are 
defined.   In addition, the reliability and validity of the selected outcome measures and 
instrumentation are reported.  
 
Research Design and Methods 
 This study is a prospective comparison group design with repeated measures.  The 
study was conducted at Stony Brook University’s (SBU) Rehabilitation Research and 
Movement Performance (RRAMP) laboratory in Stony Brook, NY.  An FES ergometer 
(RT300, Restorative Therapies, Inc., Baltimore, MD) and a BTS G-Walk® system, along 
with BTS G-Studio software (BTG Bioengineering, viale Forlanini 40, 20024 Garbagnate 
Milanese MI, Italy and 147 Prince Street, Suite 11, Brooklyn, NY), were utilized in this 
study.  Institutional Review Board (IRB) approval for this research was obtained first 
from Stony Brook University (IRBNetID: 534378-15) on May 29, 2015, and Nova 
Southeastern University issued an authorization agreement (IRB Registration #: 
00000054) on October 2, 2015.  Continuing IRB review through Stony Brook University 
was obtained annually and the project remained active through March 2, 2018. 
  
 
 
 37 
 
Recruitment Procedures 
PWMS were recruited from various sources including: physician practices, 
physical therapy practices, support groups, web postings, email, fitness centers, and 
personal communication.  Stony Brook University Medical Center (SBUMC) is a 
designated MS Comprehensive Care Center and is accredited by the National Multiple 
Sclerosis Society.  See appendix A for a copy of the recruitment flyer and physician letter.  
 
Description of Human Participants 
Participants were screened over the phone for eligibility based on 
inclusion/exclusion criteria (Table 3-1) and Patient Determined Disease Steps (PDDS) 
criteria (appendix B).   Once the met initial eligibility requirements, they participated in 
an in-person assessment session for further screening. 
During the in-person screening session, potential participants were screened for 
cognitive deficits using the Montreal Cognitive Assessment (MoCA) (appendix C).110  
Potential participants completed a demographic and medical questionnaire (appendix D) 
to determine if they met the remaining inclusion and exclusion criteria.  Once they met 
the full eligibility criteria, a physical assessment (appendix E) was completed including 
joint range of motion, the degree of spasticity, sensory function, motor function, and 
functional mobility. 
  
 38 
 
Table 3-1 Inclusion and Exclusion Criteria 
Inclusion Criteria 
Medical Diagnosis of MS 
At least 18 years of age, inclusive 
Patient-determined Disease Steps (PDDS) score between 3.0 and 6.0 inclusive 
Ability to attend training sessions 3 times per week for an 8-10 week period 
Passing a submaximal exercise tolerance test 
Adequate hip range of motion (at least 110 degrees) 
Adequate knee range of motion (10-90 degrees) 
Exclusion Criteria 
Cognitive deficits (score < 22/30 on the Montreal Cognitive Assessment) that would 
interfere with their ability to sign consent and understand study procedures  
History or presence of other neurological pathologies that interfere with movement 
Received physical therapy within the 4 weeks prior to the study 
History of an acute exacerbation within the 4 weeks prior to the study 
Immunosuppressive or steroid therapy within the past 4 weeks prior to the study 
Significant spasticity (Modified Ashworth Score ≥ 3 at the quadriceps and hamstring 
muscles) that interferes with the cycling motion 
History of congestive heart failure 
Coronary artery disease 
Uncontrolled hypertension 
History of epilepsy or history of seizures 
Cardiac demand pacemaker or implanted defibrillator 
Unhealed fractures in the lower extremities 
Pressure sores or open wounds on the LEs 
Pregnant or trying to conceive 
Eligible participants were consented (appendix F: Research Consent Form) in 
accordance with the Declaration of Helsinki and then randomly assigned to either the FES 
Cycling group or the Cycling Only group using blocked randomization in order to ensure 
equal numbers in each group.  Group assignment was performed by placing four slips of 
paper in a box.  Two slips said “FES” and the other two said “Cycling.”  The investigator 
had participants select a slip of paper from the box after the consent process.  Once all 4 
slips were selected, they were returned to the box for the next four subjects.  A detailed 
procedure manual for the study is available in appendix G. 
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Classification of Disability in MS 
 The EDSS is the most common tool used by neurologists and researchers to classify 
disease stages in PWMS.  The scale ranges from 0 to 10 in .5 unit increments; the higher 
an individual is on the scale, the greater the level of disability.53  Those who score from 
level 1.0 to 4.5 represent individuals with a high degree of ambulatory ability with fewer 
limitations.  Individuals who score from 5.0 to 9.5 represent individuals with a greater 
loss of ambulatory ability.111   The categories range from, (0) = normal neurologic exam; to 
(5) = ambulatory without aid or rest for 200 meters and disability severe enough to impair 
full daily activities; to (10) = death due to MS.53  While EDSS is the gold standard for 
classifying disease stages in PWMS, its ability to measure changes in disability is limited 
and its responsiveness in measuring change after a therapeutic interventions are 
poor.50,112,113  In addition, the EDSS must be administered by a trained neurologist, 
making it difficult for accurate data to be readily available for research.  
Patient-reported outcomes of disability in MS have been used as inclusion criteria 
in clinical trials as a replacement for the EDSS.114,115  It has been suggested that such 
measures can be more cost effective, practical, and convenient than the EDDS.116  The 
Patient Determined Disease Steps (PDDS) was developed from the Disability Steps (DS), 
which was designed to determine disability mainly based on ambulation and motor 
functioning.117,118  The DS was then converted into a scale for patient use by the North 
American Research Committee on MS (NARCOMS) and the PDDS is considered a self-
report surrogate of the EDSS.119  The PDDS was used as part of the inclusion criteria for 
participant selection for the current study.  The PDDS is a nine-level ordinal scale ranging 
between 0 (normal) and 8 (bedridden).   Learmonth et al116   found a strong correlation 
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between the EDSS and PDDS in a sample of 96 individuals with MS (p = 0.78, 95% CI = 
0.691- 0.850, p = 0.0001).  Based on a regression equation of EDSS scores on PDDS scores, 
the research group was able to determine that a score of 0 (normal) on the PPDS equates 
to 2.9 on the EDSS scale.  The scales do not exactly correspond to each other, but a 
relationship exists when using the following equation, EDSS score = 2.9 + .63(PDDS).116  
The PDDS and EDSS were also strongly correlated with ambulatory measures such as the 
6 Minute Walk (6MWT), Timed 25-Foot Walk (T25FW), Timed Up and Go (TUG), and the 
12 item Multiple Sclerosis Walking Scale (MSWS-12), and no significant differences 
between the correlations for each measure were found.116  Based on these findings and its 
clinical utility, the PDDS has adequate criterion and construct validity.116  
 In this study, individuals who rated themselves between 3 (Gait Disability) and 6 
(Bilateral Support) on the PDDS were eligible to be included in this study.  These criteria 
were chosen based on the research questions related to walking ability. 
Cognitive Screening 
 Since PWMS can present with cognitive impairments, a  screening was performed 
to assess each participant’s capacity to provide informed consent, understand basic 
instructions, and provide feedback during training sessions.  There is no universally 
accepted screening measure to determine capacity to give informed consent in research 
studies, but there is a consensus that screening should be related to the risks presented 
by the research.120  Although this study presents minimal risk to participants, it was 
important for participants to have an understanding of the equipment, training, and 
protocol being utilized. 
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In order to screen for cognitive deficits, the Montreal Cognitive Assessment 
(MoCA) was used (permission to use MoCA received from Dr. Ziad Nasredine, via email 
communication, October 20, 2014).  The MoCA was developed to assist physicians in 
screening for mild cognitive impairment (MCI)121 and is feasible to use in clinical trials.122  
The MoCA is a 30-point test that can be administered in 10 minutes and contains tasks 
that assess orientation, short-term memory, visual-spatial ability, attention, 
concentration, working memory and language.110,121 
The MoCA is reported to have greater sensitivity and specificity than the widely 
utilized Mini-Mental State Examination (MMSE) in detecting MCI and a score of 26 was 
determined to be the cut-off for detecting differences between MCI and Alzheimer’s 
Disease.121  In PWMS (EDSS = 2.6, SD = 1.87), the MoCA has been compared to another 
commonly used cognitive measure, the Multiple Sclerosis Neuropyschological 
Questionnaire (MSNQ), which has two versions, the MSNQ-P and MSNQ-I.  The MSNQ-P is 
filled out by the patient and the MSNQ-I is filled out by an informant, such as a family 
member or close friend.123  A significant moderate correlation between the MSNQ-I and 
the MoCA (r = -0.390, p = 0.012) was found, but no significant relationship between the 
MSNQ-P and the MoCA was found (r = -.300, p = 0.06).  The MoCA also demonstrated good 
construct validity when compared to a combination of cognitive tests that evaluated three 
cognitive domains: executive/speed of information processing, learning, and delayed 
recall (r = 0.37, p = 0.03; r = 0.69, p < 0.001; r = 0.636, p< 0.001).123 
The range on the MoCA for those with mild cognitive deficits ranges from 19 – 25.2 
with a SD = 3.1.110  In this study a cut-off score of 22 or less was used as exclusion criteria.  
A score of 22 was chosen since it is one standard deviation (SD) above the lower end of 
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the range of mild cognitive deficits.  The PI wanted to ensure that the people participating 
in this study understood the procedures and protocol.  
Baseline Activity Measure 
Godin Leisure-Time Exercise Questionnaire (GLTEQ) 
 The GLTEQ is a short, self-administered questionnaire that asks a person to report 
the frequency of strenuous, moderate, and mild activity during a typical week.124  The 
frequencies are multiplied by metabolic equivalents and then added together to give a 
total leisure time score.  The GLTEQ was administered at the beginning of the study to 
gather baseline information regarding physical activity levels.  The GLTEQ is a valid 
measure of physical activity in healthy individuals when compared to maximum oxygen 
uptake testing (VO2 Max).124 The GLTEQ form is available in appendix H. 
Outcome Measures 
 Outcome measures were selected based on the International Classification of 
Functioning, Disability, and Health (ICF) model, recommendations from the APTA 
Neurology Section’s Multiple Sclerosis Outcome Measures Taskforce,125 clinical expertise, 
and research goals of the current study (Table 3-2).  Members of the taskforce developed 
specific recommendations for practice environments (entry-level education, research, 
acute care, inpatient and outpatient) and also rated each outcome on a 4-point ordinal 
scale (4= highly recommended, the outcome measure has excellent psychometric 
properties and clinical utility; 3= recommended, the outcome measure has good 
psychometric properties and good clinical utility; 2= unable to recommend at this time, 
there is insufficient information to support a recommendation of this outcome measure; 
1= not recommended, the outcome measure has poor psychometric properties and/or 
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poor clinical utility).  All measures that were recommended for research were considered 
if they were rated a 3 or 4.126  
The chosen battery of outcome measures for this study were: 6 Minute Walk Test 
(6MWT), Timed 25-Foot Walk (T25W), Timed Up and Go (TUG), 5 Times Sit-to-Stand 
(5XSST), 12 Item Multiple Sclerosis Walking Scale (MSWS-12), Modified Fatigue Impact 
Scale (MFIS), Multiple Sclerosis Quality of Life Inventory (MSQOL-54), and Activities-
specific Balance Confidence (ABC) Scale.  Objective outcome measure procedures for the 
6MWT, T25FW, TUG, and 5XSST can be viewed in appendix G.  Self-report outcome 
measures are available in appendix I-L. 
Selected outcome measures were collected at the following intervals:  
 baseline - within one-week prior to the first training session;  
 mid-point of training - before 13th training session; 
 post-training - between 1-3 days after the 24th training session, and  
 follow-up - one-month after the last training session. 
Physical tests were administered in the following order for each participant: 
6MWT, T25W, TUG, and 5XSST.  Participants were provided at least a five-minute rest 
period between all physical tests.  Safety precautions during testing included: a quiet area 
free of distractions, gait belt, guarding, and assistance as needed.  In order to measure 
both temporal and spatiotemporal gait parameters, the BTS G-Walk (Table 3-3; Figure 3-
1) was utilized to collect gait data during the 6MWT, TUG, and T25FW.   The G-Studio 
software automatically generated spatiotemporal parameters after each trial.  
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Reliability and Validity of Selected Measures 
 
Clinical Measures 
For all physical measures, a participant’s regular footwear was worn during data 
collected and participants were instructed to wear the same footwear for each testing 
session.  Each participant wore a gait belt and the investigator was nearby, but behind the 
participant so that their speed was not influenced by the investigator.  If an assistive 
device was utilized by a participant in their daily life, they were instructed to use it during 
all physical measures except the 5XSST.  Each participant received scripted instructions 
each time they completed these tests. 
6 Minute Walk (6MWT)  
 The 6MWT measures a person’s self-paced walking distance over a 6 minute 
period and is a valid and reliable measure of walking performance in PWMS.127–129  The 
6MWT was found to have excellent test-retest reliability (ICC = 0.96, 95% CI 0.87- 0.99) 
over a one-week interval in PWMS (EDSS 2.0 – 6.5).130  Pilutti et al114 also found there to 
be a significant difference between the 6MWT performance in PWMS with mild vs. 
moderate to severe disability (mild= 530.7m, range 292.6 - 782.1m, moderate to severe= 
349.8m, range 51.5 – 605.3m, p <0.0001).  It was also found that PWMS (EDSS 2.0 - 6.4, 
median 4.0) classified as fallers demonstrated a significant difference in the their 6MWT 
distance compared to a group of non-fallers (fallers = 1288 feet, non-fallers = 1533 feet, t 
= 2.2, p = 0.02).64 
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Table 3-2 Outcome measures 
Outcome Measure Collection of Data 
12 Item Multiple Sclerosis Walking Scale (MSWS-12)A  Baseline 
 Post-training 
 1 month after training 
Modified Fatigue Impact Scale (MFIS)B, A, P  Baseline 
 Post-training 
 1 month after training 
Multiple Sclerosis Quality of Life Inventory (MSQOL-
54)A, P 
 Baseline 
 Post-training 
 1 month after training 
Activities-specific Balance Confidence (ABC) ScaleP  Baseline 
 Post-training 
 1 month after training 
6 Minute Walk (6MWT)A  Baseline 
 Mid-point  
 Post-training 
 1 month after training 
Timed 25-Foot Walk (T25FW)A  Baseline 
 Mid-point  
 Post-training 
 1 month after training 
Timed Up and Go (TUG)A  Baseline 
 Mid-point  
 Post-training 
 1 month after training 
Five Times Sit-to-Stand (5XSST)A  Baseline 
 Mid-point 
 Post-training 
 1 month after training 
Spatiotemporal OutcomesA 
6MWT and Timed 25-Foot Walk (T25FW)A 
Stride length, Step Symmetry & Double-limb Support A 
 
Temporal Outcomes 
TUG A 
Sit to Stand and Stand to Sit Phase Duration 
Mid-turning and End-turning Phase Duration 
 Baseline 
 Mid-point  
 Post-training 
 1 month after training 
 
 
ICF Model Domain:  B, Body Structures & Function; A, Activity; P, Participation 
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Table 3-3 BTS G-Walk Technical Specifications 
Dimensions  70 X 40 X 18 mm 
Weight 37 grams 
Sensors typologies Triaxial accelerometer 16 bit/axes with 
multiple sensitivity (±2, ±4, ±8, ±16 g) 
Triaxial magnetometer, 13 bit (±1200 uT) 
Triaxial gyroscope, 16 bit/axes, with multiple 
sensitivity (±250, ±500, ±1000, ±2000 °/s) 
Battery Rechargeable via USB 8 hours of autonomy 
Frequency  Accelerometer: from 4 to 1000 Hz 
Gyroscope: from 4 to 8000 Hz 
Magnetometer: up to 100 H 
Working Real-time/batch 
 
Figure 3-1 BTS G-Walk Sensor and Ergonomic Belt 
 
 
 
Cadence and stride length also explain differences in 6MWT performance in people 
with mild, moderate, and severe MS when controlling for age (F{2,299} = 38.17, p<0.001, 
partial –η2= 0.20; F{2,299} = 44.30, p< 0.001, partial – η 2 = 0.23, respectively), but there 
was no significant difference in cadence between a control group and people with mild MS 
(p = 0.06).114  Using a regression analysis, these researchers also demonstrated that 
cadence and stride length explained the difference in the 6MWT between PWMS and 
controls.114 
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In this study, the testing area was a rectangular walkway (40ft x 12ft), clear of 
obstructions and foot traffic.  The 6MWT instructions were standardized and adapted 
from Goldman, Marrie, and Cohen.129  Participants were instructed to walk as far and as 
fast as possible for 6 minutes while being mindful of their exertion.  All participants 
completed the 6MWT without requiring seated rest periods.  One participant needed to 
take brief standing pauses during the test.  When participants completed the 6 minutes, 
the spot where they were instructed to stop was marked and distance was recorded in 
feet and then converted to meters.  Participants wore the BTS G-Walk during the 6MWT 
to collect spatiotemporal data since these parameters may further explain improvements 
in performance in PWMS.  
Timed 25-Foot Walk (T25FW) 
 Walking speed is a commonly used measure in clinical practice and has been cited 
in the literature as the “sixth vital sign.”131  Gait speed was measured using the T25FW 
and participants were instructed to walk at a “fast but safe speed” consistent with a 
protocol suggested by Gijbels et al132 and Bethoux and Bennett.133  This measure was 
chosen due to its clinical utility, ease of administration and common use as part of the 
MSFC.134 
The minimally important clinical difference (MICD) has also been established for 
the T25W and will allow for post-test comparisons regarding gait speed.135–137  For 
individuals with greater disability, a ≥ 20% change in the T25FW correlates with clinically 
meaningful change when compared to other measures such as the MSWS-12135 and 
EDSS.148  The T25FW has a floor effect and is less sensitive in detecting clinical change in 
those with mild disability.133 
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Goldman et al136 examined changes in the T25FW in relation to changes in life 
roles.  A T25FW of 6.0 to 7.99 seconds is related to a change in occupation, 
unemployment, walking with a device, and/or the need for some help with instrumental 
activities of daily living (IADL).  Walking speeds greater than or equal to 8 seconds are 
related to the need to use a walker and inability to perform IADLs.136  The T25FW failed to 
detect differences in gait speed in individuals who are classified as fallers vs. non-fallers 
(p = 0.06).114  This may be due to several factors, including the contribution of fatigue to 
falls in PWMS.  This provides justification as to why the 6MWT may be a better measure 
to detect fall risk in PWMS.114 
In this study, individuals walked a straight 25-foot distance with an added distance 
of 10 feet at the beginning and end to allow for acceleration and deceleration. Two trials 
were collected and averaged.  Participants were instructed to walk as quickly and  as 
safely as  possible. 
Timed Up and Go (TUG)  
 The TUG is a simple and widely used performance-based measure that  is 
significantly related to fall risk in healthy older adults and it is commonly used in research 
and clinical settings.140  The TUG measures the time it takes in seconds to stand up, walk 3 
meters, turn around and walk back to a chair and sit down.  Higher times reflect a greater 
risk of falls.  The TUG is validated for use in PWMS127,128 and demonstrates good test-
retest reliability (EDSS ≤ 4.0, ICC = 0.84, CI = 0.66- .93; EDSS > 4.0, r = 0.88, CI = 0.76 - 
0.95).141  In PWMS with an EDSS between 4.0 and 6.0, researchers have established a 
strong correlation between the TUG and the Functional Ambulatory Profile (FAP) (r= -
0.88, p< 0.05), gait velocity (r= -0.90, p <0.05), double support time (r = 0.81, p<0.05), 
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single-support time (r= -0.86, p< 0.05), and base of support (r = 0.48, p< 0.05).65  In 
addition, PWMS (EDSS 2.0 -6.5, median 4.0) classified as fallers demonstrated higher TUG 
times compared to a group of non-fallers and scores were significantly different between 
these two groups (t = - 1.7, p = 0.04).64  On average, TUG scores for fallers were 9.7 
seconds and for non-fallers 7.8 seconds.64 
In this study, a standard height chair (seat to floor height = 18 ½ inches) was 
placed at the beginning of the 3-meter (approx. 10 feet) walkway and the participant 
turned around a cone (Figure 3-2).  Data on phase duration for sit to stand, stand to sit, 
mid-turning, and end-turning were collected using the BTS G-Walk. 
 
Figure 3-2 Timed up and Go 
 
 
Five Times Sit-to-Stand (5XSST) 
The 5XSST is a timed test that measures how long it takes for an individual to 
repeatedly transition from sitting to standing.  Evidence supports that sit-to-stand tests 
are appropriate and time-efficient tests to use in the clinical setting to assess LE 
strength.142,143  A strong relationship between a 10 times sit-to-stand test and knee 
extensor and flexor strength was found in 139 healthy individuals ages 20-62.142  
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Currently, there is no data available that demonstrates the reliability or validity of the 
5XSST in PWMS.  The 5XSST has been found to be a valid and reliable measure of fall risk 
in people with PD144 and the older adult population.145,146  
In this study, the same chair utilized for the TUG measurements was also used for 
the 5XSST.  Participants received scripted instructions to stand up and sit down as quickly 
as possible 5 times, keeping their arms folded across their chest.  If the participant used 
arm rests to safely sit and stand, they were permitted to do so, and when the test was 
repeated at the various time points, participants were tested in the same manner.  One 
trial of the 5XSST was performed and the timer was started when the participant’s 
buttocks left the seat and stopped when the participant stood the 5th time. 
BTS G-Walk 
The BTS G-Walk wireless inertial sensor was secured on the elastic belt in a 
pouch and placed on the L5 vertebrae to collect gait data during the 6MWT, T25FW, and 
TUG.  Evidence supports that body-worn motion sensors provide additional information 
about gait and balance that standard timed walking tests do not detect.147 The BTS G-
Walk has been validated by BTS  Bioengineering by comparing key gait parameters 
(stance phase, swing phase, double support phase, and gait cycle duration) to the BTS 
GAITLAB (standard motion analysis) in 30 healthy adults, 25-50 years old and found the 
BTS G-Walk to be accurate with a deviation of 2.28%.148 
Self-Report Measures 
 For all self-report measures, participants were oriented to the measure and given 
the opportunity to ask questions.  Participants completed the measures at home and 
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brought them in the next training session.  The measures were reviewed to ensure they 
were filled out in their entirety.   
12 Item Multiple Sclerosis Walking Scale (MSWS-12)  
 The MSWS-12 is a 12-item self-report questionnaire149 that takes approximately 
10 minutes to complete and reflects a persons’ perception of the impact that MS has on 
walking ability during the past 2 weeks.  Each of the items scored ranges from 1 to 5, in 
which higher scores indicate a greater impact of MS on their walking.  The scores were  
summed and then transformed to a 0 -100 scale by subtracting 12 from the total, dividing 
by 48, and then multiplying by 100. 
 The MSWS-12 has strong psychometric properties, including good internal 
consistency (Cronbach’s alpha = 0.97) and test-retest reliability (ICC = 0.94).150  
Concurrent validity has been demonstrated by comparing the MSWS-12 to other 
commonly used self-reported measures and physical mobility measures.  Using Cohen’s 
interpretation of correlation (0.10 = small, 0.30 = medium, 0.50 = large),151 the MSWS-12 
demonstrates a medium to large correlation with EDSS scores (EDSS 1.0 - 4.5, r = 0.71, 
EDSS 5.0 – 8.0, r = 0.33, EDSS 1.0 – 8.0, r = 0.80, p = 0.0001), large inverse correlations to 
movement measured by an accelerometer over a 7- day period (EDSS 1.0 - 4.5, r = -0.51, 
EDSS 5.0  - 8.0, r = -0.48, EDSS 1.0 – 8.0, r = -0.64, p = 0.0001), and large correlations with 
the physical impact subscale of the Multiple Sclerosis Impact Scale (MSIS) (EDSS 1.0 - 4.5, 
r = 0.74, EDSS 5.0 – 8.0, r = 0.75, EDSS 1.0 – 8.0 , r = 0.77, p = 0.0001).150,152  In addition, in 
individuals with RRMS (EDSS not reported), the MSWS-12 was highly correlated with the 
oxygen costs of “comfortable walking” during a 6MWT (r = 0.64, p = 0.001).153  In a study 
measuring self-reported health status at admission and discharge, the MSWS-12 
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demonstrated strong responsiveness (effect size = 0.89) to receiving inpatient 
rehabilitation in a sample of 43 PWMS (mean EDSS = 7.2).154  Responsiveness, minimal 
clinically important difference (MCID), or minimal detectable change (MDC) of the MSWS-
12 to exercise training trials have yet to be established at the time of this review. 
 
Modified Fatigue Impact Scale (MFIS) 
 The MFIS (a modification of the Fatigue Impact Scale (FIS) that was introduced in 
1994),155 is a component of the Multiple Sclerosis Quality of Life Inventory (MSQLI).  The 
original FIS was constructed based on interviews with people living with MS and how 
fatigue impacted their lives.155  The MFIS is a 21 item self-report questionnaire that takes 
5-10 minutes to complete.  It uses a 5-point likert scale to rate the patient’s perception of 
how MS-related fatigue affects an individual’s life on an everyday basis.  It contains three 
subscales that include: cognitive, physical, and psychosocial dimensions.  Scores on the 
subscales can be analyzed individually or as a summed score to give an overall fatigue 
score.  Higher scores indicate a greater impact of fatigue. 
Researchers demonstrated that the psychometric properties of the MFIS include 
low floor and ceiling effects, (1.1% and 0.7%, respectively)156 and good internal 
consistency (Cronbach’s alpha = 0.96).116  In a study conducted in four European 
countries, the MFIS demonstrated good test-retest reliability (ICC range = 0.84 - 0.93, 
99% CI),117 which is similar to the test-retest reliability demonstrated in other studies.158  
The MFIS also demonstrates good construct validity when compared to the Fatigue 
Severity Scale (r = 0.47).156 
 53 
 
In a study by Rampello et al12 the MFIS scores did not significantly change after 
either aerobic training or standard neurological rehabilitation in a sample of 19 subjects 
with mild to moderate disability.  A 12-week supported treadmill training study also 
failed to demonstrate any significant changes in the MFIS,159 so it appears the MFIS may 
lack the ability to measure responsiveness158 to change in fatigue over time.  Although 
other fatigue scales exist that demonstrate similar properties,156 the MFIS was chosen 
because it represents a broader range of fatigue than other scales and takes into account 
the previous 4 weeks of fatigue, versus other scales, such as the Fatigue Severity Scale 
(FSS), which only asks individuals to evaluate their fatigue from the previous week.  Since 
fatigue can vary greatly in PWMS, capturing a 4-week overview may be a more accurate 
representation of fatigue. 
Multiple Sclerosis Quality of Life Inventory (MSQOL-54) 
 The MSQOL-54 is a multidimensional self-report quality of life questionnaire that 
takes 15-30 minutes to complete (permission to use MSQOL-54 received from Barbara 
Vickry, MD, MPD, via email communication, March 21, 2014).160  This questionnaire 
measures health-related quality of life using both generic and disease-specific measures 
and was constructed by experts in the field.160  This measure was chosen since it is more 
comprehensive than other MS disease-specific quality of life scales and is recommended 
for use amongst a group of multidisciplinary international experts.161 
 Researchers created this inventory by combining disease-specific questions that 
include impairments such as fatigue and cognition with a generic health-related quality of 
life scale (short-form 36-health questionnaire).  There is no overall score for the MSQOL-
54 since it contains 12 subscales, two summary scores, and two single-item measures.  
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The subscales are: physical function, role limitations-physical, role limitations-emotional, 
pain, emotional well-being, energy, health perceptions, social function, cognitive function, 
health distress, overall quality of life, and sexual function.  The summary scores are the 
physical health composite summary and the mental health composite summary. The 
single item measures are satisfaction with sexual function and change in health.  
 The psychometric properties of the MSQOL-54 subscales show good internal 
consistency (Cronbach’s alpha = 0.75 -  0.96) and good test-retest reliability with ICCs 
ranging from 0.69 to 0.96.160  In addition, the MSQOL-54 demonstrates moderate 
responsiveness on both the physical and mental summary scales (standard 
responsiveness mean for physical scale = 0.71 and mental scale = 0.57).162  In an aerobic 
training study by Rampello et al12 the researchers found significant changes in three of 
the MSQOL-54 scale scores (emotional well-being, energy, and health distress). 
Activities-specific Balance Confidence (ABC) Scale 
The ABC measures an individual’s perceived level of balance confidence when 
performing 16 activities of daily living.  Each item is rated on a scale of 0% to 100% (“no 
confidence” to “complete confidence”) and then a mean score is calculated.163  This scale 
was originally designed to be used in community-dwelling elders,163 but has been 
subsequently used in neurological populations. 
The ABC has been utilized and studied in PWMS, and significant differences in 
scoring balance confidence have been found when PWMS were compared to age-matched 
controls.147  In PWMS, the ABC was found to have good clinical utility since it can be used 
as a predictor of falls.127  When comparing fallers vs. non-fallers, the ABC demonstrated 
significant differences in scores with a score > 40 classifying an individual as a faller with 
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a sensitivity of 65% and specificity of 77%.127  Dibble et al164 found significant differences 
between fallers and non-fallers on the ABC, Dynamic Gait Index (DGI), and Berg Balance 
Scale (BBS) (p <0.05 for all tests).  When compared to other commonly used clinical 
balance measures, such as the BBS, DGI, and TUG, the ABC demonstrated good validity (r 
= - 0.32, r = -0.39, r = 0.35, p< 0.0001 for all tests).127  In PWMS, the ABC has also been 
found to have excellent test-retest reliability (ICC = 0.92, CI = 0.80 - 0.97) and no ceiling 
effect in PWMS.165 
Submaximal Exercise Tolerance Testing 
 The assessment for exercise tolerance was designed in coordination with the 
American College of Sports Medicine (ACSM) guidelines.166,167  ACSM recommends that 
before beginning an exercise regimen, professionals employ two or more techniques to 
measure relative intensity.166  ACSM suggests using submaximal testing166 as a practical 
approach to testing since most physical therapists do not have the necessary equipment 
for metabolic testing.  Heart rate (HR), blood pressure (BP), and rating of perceived 
exertion (RPE) can be used to measure to measure relative intensity during a graded 
exercise test.166  In this study, a submaximal clinical exercise tolerance test (SXTT) was 
performed on the LE ergometer used in the intervention since recommendations support 
that it is best to do exercise testing on the equipment used for training.168   
This study followed the ACSM recommendations for performing exercise testing 
for persons with MS.169  These recommendations include: 
 testing in the morning, if this is the optimal time for the participant 
 beginning with a warm-up of unloaded pedaling 
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 using a fan for cooling as needed 
 using a continuous or discontinuous protocol of 3 to 5 minute stages with an 
increase of work rate of approximately 12 to 25 Watts (W) per stage 
 monitoring heart rate and blood pressure 
 using the RPE scale to estimate stress level (Appendix J)166  
In this study, the SXTT was conducted on the RT300 LE ergometer which was the 
same equipment being utilized during training (Figure 3-3; Table 3-4) (RT300, 
Restorative Therapies Inc., Baltimore, Maryland, USA).  Participants were asked to cycle at 
a target speed of at least 45 rpm, or the maximal speed they were are able to sustain, 
while the investigator systematically increased resistance.  The participant began with an 
interval of unloaded cycling followed by an increase in resistance every 3 minutes.  
Resistance was increased 3 Newton-meters (Nm) per stage, which is approximately 14 
Watts per stage.16,169  The SXTT was discontinued when the participant reached self-
reported fatigue, if their vital signs fell outside a safe range, or if they could not maintain 
45 rpm speed.  Maximal workload was defined as the last interval a participant can cycle 
at least one-minute.  HR, pulse oxygen (SPO2) and BP were measured at baseline, and then 
recorded during the last minute of each testing intervals.167  In addition, the RPE scale 
was introduced to participants and scores were reported recorded during the last 15 
seconds of each interval (see appendix N). 
During the SXTT, ACSM’s guidelines for discontinuing testing were followed and 
included:16,167 
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 self-reported fatigue- participant expressed they can no longer pedal due to 
fatigue 
 reaching 70% heart rate reserve, which is 85% of age-predicted HRmax, (HR max 
= 220 – age x .85) 
 failing to conform to exercise protocol, which for this study was defined as 
falling 10 rpm below the target rpm speed of 45 for greater than 10 seconds. 
 hypotensive responses-  systolic BP drops ≥ 10 mmHg from baseline167 
 hypertensive responses-  systolic BP increases to > 250 mmHg  and/or a 
diastolic BP increase of  > 115mmHg167 
 symptom exacerbation,168,169 including headache, change in vision, numbness, 
sudden paralysis, dizziness, and vertigo 
 chest pain, shortness of breath, wheezing,  and leg cramps167 
Figure 3-3 RT300 LE Ergometer (Restorative Therapies, Reprinted with 
permission) 
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Table 3-4 RT 300 and Sage Controller Technical Specifications 
Length 31.5” or 80 cm 
Width 19.3” or 49 cm 
Height 36.2” – 40.6” or 92 – 103 cm 
Length of leg pedal 4.3” or 11 cm 
Speed Range 20 – 55 rev/min (+/- 2 rev/min) 
Torque range 1 – 22Nm (+/-  1Nm) 
Controller Display/Interface Touch-sensitive LCD 
Communications Wireless or Ethernet 
Operating System Windows Mobile 
 
 
Training Protocols 
Participants trained for 45 minutes, three times- per-week, for approximately 8-
weeks using the RT300.  Basic demographic information (age, weight, and diagnosis) was 
entered into Restorative Therapies Internet (RTI) Data Link and a random ID number was 
generated along with a four-digit pin number.  The participant number was used as the 
participant ID number on all paperwork associated with the study.  
Participants were positioned in the training chair (Figure 3-4; Table 3-5) and their 
LE’s were placed on the bike pedals and secured using strapping according to the 
manufacture’s recommendations.  The bike and chair were positioned to maintain 
approximately 5-15 degrees of knee flexion when in the fully extended position of cycling.  
The height of the ergometer was adjusted so that the rear of the participant’s thigh did 
not press into the seat cushion during cycling.  In order to optimize positioning and 
cycling angles, when necessary, adjustments to seat height and depth were made utilizing 
cushions.  Each participant’s set-up was documented and used every training session.  
 
Figure 3-4 TUG, 5XSST and Training Chair 
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Table 3-5 Chair Specifications 
Manufacturer OFM™ Anti-Bacterial Vinyl Padded 
Guest/Reception Chair With Arms 
Model 811588014224 
Arm Type Fixed 
Seat Dimensions 19 1/2” X 19 1/4” 
Seat to Floor Height 18 ½ inches 
Weight Capacity Up to 250 pounds 
 
FES Cycling Protocol 
In the FES Cycling group, the stimulated muscles were standardized and included 
the gluteals, hamstrings, quadriceps, anterior tibialis, and gastrocnemius.  At the 
beginning of every session, the skin was cleaned with alcohol and dried prior to electrode 
placement.  Each participant had their own set of electrodes that were labeled with their 
participant number and stored at the research lab.  Electrodes were placed according to 
the guidelines outlined and participant morphology (Table 3-6; Figure 3-5).  Before and 
after each training session, skin was inspected for erythema, breakdown and/or irritation.  
Expiration dates on the electrodes were checked prior to usage.  The manufacturer of the 
electrodes recommends that each electrode be used for a maximum of 10-15 sessions.  If 
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an electrode no longer adhered appropriately to the skin, it was discarded, and a new 
electrode was utilized.  In order to track usage, each participant’s package of electrodes 
was labeled with the date of each session.  Further detail regarding electrode placement 
and set-up can be reviewed in appendix G. 
After all objective outcome measures were obtained, initial stimulation settings 
were set during the baseline testing session prior to the training period.  Standardized 
instructions were read to each participant prior to set-up and can be reviewed in 
appendix G. 
Table 3-6 Electrode sizing and placement 
Muscle Electrode 
Size 
Location of placement 
Quadriceps 3” X 4” One electrode was placed a hand width above the knee 
centered on the belly of the quad and the second electrode 
was placed at least a hand width above the first electrode. 
For participants with a longer thigh length, it was placed 
higher on the quadriceps belly. 
Hamstrings 3” X 4” Electrodes were placed in line with the quadriceps 
electrodes, but on the back of the thigh and were centered in 
the middle of the hamstrings.   
Gluteals 2” X 3.5” One electrode was placed vertically with the top of the 
electrode parallel to the top gluteal cleft and the second 
electrode two-finger widths lateral to the first electrode.   
Anterior 
Tibialis 
2” X 3.5” One electrode was placed proximally on the muscle belly and 
the second electrode was placed distally about 2/3 way 
down the shin. 
Gastrocnemius 2” X 3.5 One electrode was placed horizontally across the calf, just 
below the knee and the second electrode was placed just 
distal to the gastrocnemius belly. 
*The electrode sizes above were used as  guidelines and individual adjustments were made based 
participant morphology.  
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Figure 3-5 LE Electrode Placement Guidelines (Restorative Therapies, Reprinted 
with permission) 
 
 
Stimulation frequency for all participants was set at 43.5Hz for all muscle groups 
and was not changed throughout the study.  During this baseline session, participants 
cycled against their starting resistance obtained on the SXXT (60% of the maximal 
resistance achieved during the SXTT168).  All muscle groups were stimulated with a 
starting pulse width of 250μsec.  Amplitude ramped up at 1% per second and the 
participant was instructed to tell the investigator to hold the stimulation when they felt 
any of their muscles reach a point where the stimulation was uncomfortable.  The 
investigator then adjusted each muscle group individually to its maximal tolerable 
stimulation while the participant continued to cycle.  Adjustments in amplitude were 
increased in increments of 1mA until a participant achieved a strong muscle contraction 
or reached his or her tolerance to stimulation.  If a participant’s tolerance to stimulation 
was reached before a detectable contraction was palpated, pulse width was decreased by 
10μsec increments and then amplitude was increased by 1mA increments until a strong, 
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but tolerable muscle contraction was achieved.  The maximum level of stimulation was set 
at the value that has been determined to create the strongest tolerable motor response.  If 
a participant was still unable to achieve a strong muscle contraction due to discomfort, 
the highest stimulation parameters they reached were utilized.  Parameters were then 
adjusted during training sessions as participants accommodated to the stimulation.  All 
initial settings were automatically saved in the RTI Data Link database.  
The participant’s stimulation levels from baseline session were used as starting 
parameters for the first training session.  If, during training sessions, the participant was 
able to tolerate more stimulation in any individual muscle group, amplitude was 
increased in 1mA increments.  Participants started each session using the stimulation 
parameters from their previous session.   
Participants experienced a 2-minute warm-up period in which the ergometer’s 
motor provided passive in which the motor moved the participants’ legs.  This allowed for 
the participant to work out any spasms or stiffness they were experiencing.  The 
ergometer then transitioned into “active mode” in which the electrical stimulation slowly 
ramped up to allow the individual to accommodate to the stimulation.  During this period, 
the participant received stimulation while also using their own muscle power against a 
set resistance while working to maintain a set target speed of at least 45 rpm.   
Participants were encouraged to cycle for at least 45 minutes using an interval 
training protocol (5 minutes of active cycling with stimulation, followed by 1 minute of 
passive cycling without stimulation).  This 5:1 ratio was repeated 7 times during each 
session.  At the end of the session, participants received a 1-minute cool-down of passive 
cycling with no stimulation.  
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When using FES cycling with other patient populations (e.g. complete SCI) who 
need stimulation and/or motor support, the ergometer can be set to assist with cycling 
when they fall below a set control speed.  Since all individuals in this study had volitional 
control to cycle at or above the control speed of 45 rpm, stimulation 
minimums/maximums were set to the same level to ensure stimulation remained on 
during the 5-minute stimulation period no matter how fast the participant cycled.  
Although the ergometer can provide ‘motor support,’ no participants in this study 
required assistance from the motor to maintain the minimum control speed of 45 rpm.  
If at any time during training a participant reported fatigue and needed to 
discontinue cycling, stimulation was discontinued, and the participant was permitted to 
finish the rest of their session in passive mode with the motor fully assisting their 
movement (Figure 3-6) or restart cycling after a rest period of less than 5-minutes.  Only 
one participant needed to stop one training session due to fatigue. 
All participants were able to cycle the full 45 minutes during their first training 
session using the 5:1 protocol.  Resistance was increased after a minimum of 3 sessions, 
by 5% increments, using a standardized progression protocol.  The decision to increase 
resistance was based on stability of performance (i.e. PRE report, mileage) and 
investigator expertise.  After an increase occurred, the investigator monitored mileage 
each session.   Increases in resistance occurred only when the participant was able to 
cycle approximately the same mileage as their previous session or if the participant 
expressed they can tolerate an increase in resistance.  Workload was  progressively 
increased during the 24 session training period to a maximum of 80% of the starting 
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workload.168  Standardized instructions were read to the participant prior to first training 
session and can be viewed in appendix G. 
Figure 3-6 Therapy Session Progression  
 
 
Cycling Only Protocol 
Participants in this training group were positioned on the RT300 in the same 
manner as those in the FES training group, but they did not receive electrical stimulation 
nor wear stimulation pads; the RT300 was used as an ergometer only.  Adjustments in 
resistance were made using the progression protocol described for the FES Cycling group.  
Standardized instructions were read to each participant prior to set-up and can be 
reviewed in appendix G. 
 
 
Warm up  Phase 
Ergometer's motor 
moved legs 
Active Phase 
 Electrical Stimulation evoked 
coordinated muscle contracts 
and person cycled using 
voluntuary muslce power against 
motor resistance 
Cool Down Phase 
Ergometer's motor 
moved legs while still 
moving through range 
of motion 
Passive Phase 
If fatigued was percieved, 
stimulation ceases and 
session continued with 
motor assisting movement 
for the remainder of the 
session 
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RT300 Features 
Participants in both groups received real-time visual feedback from the screen on 
the ergometer (Figure 3-7) and summative feedback after their training session.  They 
received information regarding distance traveled, right to left cycling symmetry, power 
output, heart rate, and SPO2 and were told not to focus on any one particular outcome. 
The RT300 has several features that were utilized during this study.  One feature 
was the “control speed offset.”  If a participant’s cycling speed fell below the target speed 
by a pre-set revolution per minute (rpm), the ergometer’s motor was set to take over for 
the remainder of the session and assist the participant.  The control speed offset was set 
at -10 rpm for all participants.  The target speed for all participants was 45 rpm and if a 
participant’s speed fell below 35 rpm the ergometer’s motor took over and the cycle 
would finish the session in passive mode.  This feature was not utilized by any of the 
participants.  
The SAGE stimulator also monitored electrode adherence, so if an electrode fell off 
during cycling, the ergometer paused and ceased stimulation.  An error message was then 
displayed on the screen indicating which electrode(s) needed to be checked.  Once the 
electrode was secured, the session continued.  This occurred infrequently and did not 
impact training sessions. 
All participants were continuously monitored by a wireless HR and pulse oximeter 
with individually set parameters.  Each participant's maximum heart rate was set at 85% 
of their age-adjusted max HR (220-age x .85).  If a participant’s HR went above maximum, 
the ergometer paused, and the participant was given a short rest until their HR returned 
to their target heart rate range.  The minimum heart rate was set at 5 bpm below the 
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participant’s resting baseline to allow for normal HR variability that can occur from day-
to-day.  The minimum SPO2 was set at 88% for all participants and there no instances 
when this parameter fell below 88% during a session. 
Each participant's target HR was also calculated (65% of their age-adjusted max 
HR) and they were encouraged to keep their HR within a target HR range (65% to 85% of 
their age-adjusted max HR).   
 
Figure 3-7 RT300 Training Screen (Restorative Therapies. Reprinted with 
permission) 
 
 
 
Scheduling of Training Sessions 
Schedules were developed to assure the proper timing for training and testing 
sessions.  At least one day of rest was scheduled between training sessions.  Participants 
committed to completing 3 sessions within a 7-day period.  Make-up sessions were 
scheduled as needed on weekends, but the training period was not permitted to extend 
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beyond a 10-week period.  All participants completed their training within the 8 -10 week 
period.  The PI was responsible for scheduling the research space and equipment 
necessary throughout the study. 
Data Safety Monitoring and Participant Confidentiality 
 
Paper records for this study are stored in a file cabinet in a locked closet in the 
research lab and will be maintained for 5 years after completion of the study.  Participant 
numbers were assigned to each participant from RTI Data Link and were used on all 
forms associated with the participant.  Personal information, including participant 
number, phone numbers, and email addresses were available only to the PI for the 
purpose of scheduling on a password protected laptop. 
The cycling parameters for each participant were stored under the individual’s 
participant identification number.  Data from each training session was automatically 
saved in each participant’s electronic file in RTI Data Link.  The RTI Data Link and RT300 
are password protected and HIPAA compliant and all participant information was de-
identified. 
Data Analysis 
Data was entered into spreadsheets by the PI and an undergraduate research 
assistant and were checked for errors. 
Descriptive statistics were performed to determine the measures of central 
tendency.  Ordinal baseline demographic data were compared across treatment groups to 
assess the adequacy of randomization using the Mann-Whitney U for ordinal data (PPDS, 
GLTQ, MoCA, MSWS-12, MSQOL, ABC, MFIS) and independent t-tests for continuous data 
(age, years since diagnosis, 6MWT, T25FW, TUG, 5XSST).   
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 Descriptive, parametric, and non-parametric statistics were performed using the 
statistical software program SigmaPlot®, V 12.5, San Jose, CA.  To analyze the cycling 
outcomes for mileage and power output within each group, parametric methods were 
utilized since the data was continuous, therefore a paired t-test and independent t-test 
were used accordingly.  Between groups comparisons were made using a Two-Way 
Analysis of Variance (ANOVA).  
 To analyze the effect of the interventions, a Repeated Measure Analysis of Variance 
(repeated measure ANOVA) was chosen because since the is no nonparametric test for 
two-group designs with more than two repeated measures.  Between and within group 
comparisons for each time period and standard error were calculated using a linear 
mixed-effect model in SAS V9.4 (the SAS Institute, Cary, NC).  There were some data 
points missing at random due to instrumentation errors with the BTS G-Walk and the 
mixed-effect model provides flexibility to handle these issues.170  Missing data included 
BTS G-Walk, data at: baseline for the TUG for one FES group participant (FES01), mid-
point 6MWT data for two Cycling Only participants (Cycling 01 and 02), and post-training 
TUG data for one Cycling Only participant (Cycling 04).  Cnaan, Laird and Slasor170 state, 
“If the missingness is unrelated to outcome, then the maximum likelihood estimates are 
valid and fully efficient.”  In addition, the mixed model is a flexible approach and handles 
uneven spacing of repeated measures and can be generalized to non-normal outcomes.  
These model uses both fixed effects (treatment levels) and random effects (subjects) to 
calculate between and within group differences.171  
Effect size (Cohen’s d) was also calculated for cycling and clinical outcome 
measures (6MWT, T25FW, TUG, 5XSST) to examine the magnitude of differences in 
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outcomes within groups during the training period.  A greater effect size indicates a larger 
difference between groups.  An effect size of 0.2 to 0.5 was considered small, an effect size 
of 0.5 to 0.8 was considered medium, and an effect size above 0.8 was considered large.151 
This sample size for this study was determined based on intention to complete a 
clinical pilot study to investigate methodology, clinical outcomes, and tolerance to cycling 
in PWMS.  Data and information collected from this research will be used to conduct a 
power analysis for a larger scale study.  
Resources 
The PI performed all data collection at the Rehabilitation Research and Movement 
Performance (RRAMP) laboratory at Stony Brook University (SBU), in Stony Brook, NY.  
This research laboratory was equipped with an RT300 ergometer and a BTS G-Walk® 
system along with BTS G-Studio software.  The PI purchased an armchair, water for 
participants, and office supplies.  Restorative Therapies, Inc. provided the electrodes. 
The PI was present during all training sessions and performed all outcome 
measure testing.  Since the PI served at the clinician supervising the intervention and data 
collection, there was no blinding in this study.  
The PI was awarded two grants, the New York Physical Therapy Association 
(NYPTA) Arthur J. Nelson Research Designated Fund ($5,000) and Lee Silverman Voice 
Training (LVST) Global Small Student Grant Funding ($1,500).  The NYPTA grant 
supported subject honorariums and conference travel, and the LSVT grant provided 
support for a laptop purchase and statistical consulting from a biostatistician. 
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Chapter 4 
Introduction 
 
 This chapter is a narrative of the results of this study along with tables and figures 
that highlight differences between and within the FES and Cycling Only groups on clinical 
and self-report measures.  Supplemental tables can be found in the appendix and are 
referenced in the body of the discussion. 
 
Results  
 
Of the 36 PWMS screened for eligibility, 15 met the inclusion criteria and were 
enrolled in the study.  Eight subjects were randomly assigned to the FES Cycling group 
and seven to the Cycling Only group.  All participants met the inclusion/exclusion criteria. 
One participant in the FES cycling group withdrew after the second session due to 
developing neck pain and did not continue in the study.  Fourteen participants (7 FES 
Cycling Group, 7 Cycling Only Group) completed training and were included in the 
analysis.  The flow diagram of enrollment in the study based on the Consolidated 
Standards of Reporting Trials (CONSORT) is reported in Figure 4-1. 
 
Participant Characteristics  
Baseline demographics for the overall sample, FES group, and Cycling Only group 
are presented in Table 4-1.  Mann-Whitney U and Independent t tests demonstrated that 
the baseline characteristics between groups were similar for disease severity, activity 
levels, cognition, length of time since MS diagnosis (p >0.05).  However, there was a 
significant difference in age between groups with the FES Cycling group being an average 
of 12 years older than the Cycling Only group (t12 = 2.17, p = 0.018).  The FES Cycling 
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group also had a higher rate of assistive device use for mobility.   
 
Figure 4-1 CONSORT flow diagram of enrollment 
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Table 4-1 Baseline Demographics, Characteristics, Selected Clinical and Self-Report 
Measures  
 Overall  FES Cycling Cycling Only  P Value 
Total, n 14 7 7  
Age, years 
Mean(SD) 
Median 
   Range 
 
53.64(10.16)  
54.5 
30-68 
 
59.71(7.54) 
58 
48-68 
 
47.51(8.97) 
49 
30-57 
 
t12 = 2.17,  
p = 0.018a 
Gender, n 
Male 
Female 
 
6 (43%) 
8 (57%) 
 
4 (57%) 
3 (43%) 
 
2 (13%) 
5 (72 %) 
 
 
PDDS 
   Mean(SD) 
Median 
   Range 
 
3.71(0.91) 
3.5 
3-6 
 
3.71(0.76) 
4 
3-5 
 
3.71(1.11) 
3 
3-6 
 
U = 22, 
p = 0.81b 
GLTQ 
Mean(SD) 
Median 
   Range 
 
21.57(28.65) 
8 
0-88 
 
29.86(33.18) 
24 
0-88 
 
13.29(22.75) 
6 
0-64 
 
U = 17.5, 
p = 0.38b 
 
MoCA 
   Mean(SD) 
Median 
   Range 
 
26.43(2.13) 
26.5 
22-29 
 
27.0(1.41) 
27 
25-29 
 
25.86(2.67) 
26 
22-29 
 
U = 18.5, 
p = 0.46b 
Years since dx 
   Mean(SD) 
Median 
   Range 
 
13.14(12.08) 
10 
3-46 
 
14.0(14.61) 
10 
3-46 
 
12.29(10.05) 
10 
4-\34 
 
t12 = -0.256  
p = 0.80a 
Assistive 
Device Use 
(yes/no) 
 
4/10 (28.6%) 
 
3/4 (75%) 
 
1/6 (16.7%) 
 
Abbreviations: SD = standard deviation, FES = Functional Electrical Stimulation, PPDS = Patient Determined 
Disease Steps, GLTQ = Godin Leisure-Time Questionnaire, MoCA = Montreal Cognitive Assessment, 
dx=diagnosis 
a = as determined by independent sample t-tests 
b =as determined by Mann-Whitney U tests 
 
Baseline outcomes for clinical and self-report outcome measures for the overall 
sample, FES group, and Cycling Only group are presented in Table 4-2.  There was no 
significant difference between groups on all clinical and self-report measure (p > 0.05).  
The 5XSST approached statistical significance with the Cycling Only group demonstrating 
better performance (i.e. shorter times) than the FES group (t12 = 2.069, p = 0.061).  
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Table 4-2 Baseline Group Comparison of Clinical and Self-Report Measures  
 Overall  FES Cycling Cycling Only  P Value 
Total, n 14 7 7  
6MWT (m) 
Mean(SD) 
Median 
    Range 
 
362.32(118.32) 
352.04 
143.86-553.21 
 
357.18(141.21) 
366.7 
143.87-553.21 
 
367.46(101.65) 
337.4 
202.39-508.71 
 
t12 = 0.16,  
p = 0.88 a 
T25FW (m/s) 
Mean(SD) 
Median 
    Range 
 
1.37(0.43) 
1.421 
0.624-2.05 
 
1.33(0.53) 
1.39 
0.62-2.05 
 
1.40(0.34) 
1.48 
0.75-1.71 
 
t12 = 0.30,  
p = 0.77 a 
TUG (s) 
Mean(SD) 
Median 
    Range 
 
11.39(5.18) 
9.615 
5.97-24.26 
 
13.05(6.25) 
10.73 
5.97-24.26 
 
9.73(3.52) 
9.2 
6.89-17.38 
 
t12 = 1.22, 
p = 0.25 a 
5XSST (s) 
Mean(SD) 
Median 
    Range 
 
15.12(4.07) 
15.04 
9.57-21.71 
 
17.14(4.52) 
18.6 
10-21.71 
 
13.11(2.45) 
14.7 
9.57-15.21 
 
t12 = 2.07, 
p = 0.06 a 
MSWS-12 
    Mean(SD) 
Median 
    Range 
 
40.78(11.40) 
44 
24-57 
 
38.71(10.84) 
33 
25-54 
 
42.86(12.42) 
48 
24-57 
 
U = 20.5,  
p = 0.62 b 
ABC 
    Mean(SD) 
Median 
    Range 
 
58.29(24.31) 
58.44 
18.75-85 
 
64.42(24.42) 
77.5 
28.75-85 
 
52.64(24.57) 
57.5 
18.75-84.38 
 
U = 16.5,  
p = 0.32 b 
MFIS 
    Mean(SD) 
Median 
    Range 
 
44.57(15.44) 
42.5 
16-74 
 
42.00(12.49) 
38 
28-59 
 
47.14(18.58) 
52 
16-74 
 
U = 20.5,  
p = 0.62 b 
 
MSQOL-54 
Overall 
    Mean ± SD 
Median 
    Range 
 
59.40 ± 17.08 
60.84 
23.3-81.67 
 
61.10 ± 16.83 
63.33 
36.67-81.67 
 
47.57 ± 8.98 
58.33 
23.33-78.33 
 
U = 20.5,  
p= 0.620 b 
Abbreviations: SD = standard deviation, FES = Functional Electrical Stimulation, 6MWT = 6 Minute Walk 
Test, T25FW = Timed 25-Foot Walk, TUG = Timed Up and Go, 5XSST = 5 times sit to stand, MSWS-12 = 12- 
item Multiple Sclerosis Walking Scale, ABC = Activities-specific Balance Confidence Scale, MFIS = Modified 
Fatigue Impact Scale, MSQOL-54 = Multiple Sclerosis Quality of Life Inventory 
a = as determined by independent sample t-tests 
b =as determined by Mann-Whitney U tests 
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Cycling Outcomes 
  
 Data for each of the 24 training sessions were collected in the RT300 SAGE 
controller.  During data analysis, each participant’s first cycling session was excluded to 
allow for adjustment to the equipment and procedures.  In order to compare starting 
cycling performance to final cycling performance, the average of three sessions was 
calculated for the purpose of data analysis (starting performance = sessions 2-4; final 
cycling performance = sessions 22-24).   This was done to account for variability in fatigue 
from session-to-session that may impact performance.    
 Starting cycling mileage and starting cycling power output for the FES and Cycling 
Only groups were compared using an independent t-test and no significant difference was 
found between groups at the start of the training period (t12 = 0.88, p = 0.40; t12 = -0.51, p 
= 0.62).  Final cycling mileage and final cycling power output for the FES and Cycling Only 
groups were compared using an independent t-test and no significant difference was 
found between groups at the end of the training period (t12 = 0.57, p = 0.58; t12 = -0.54, p= 
0.60).  FES and Cycling Only outcomes for mileage and power output are presented in 
Table 4-3 and 4-4.   
 Using a paired t-test, no significant difference was found between starting and final 
cycling mileage for either the FES and Cycling Only group (t6 = -1.14, p = 0.30; t6 = 1.47, p 
= 0.19).  A small effect size was found for mileage for both the FES group and Cycling Only 
group (d = 0.30; d = 0.24).  However, there was a significant difference found for change in 
cycling power output for both the FES group and Cycling Only group (t6 = -2.88, p = 0.03, p 
< 0.05; t6 = -4.46, p = 0.004).  A medium effect size for cycling power output was found for 
the FES group and Cycling Only group (d = 0.66; d = 0.72).  Using a two-way ANOVA, no 
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significant difference was found between groups for mileage and cycling power output 
(F12 = 0.80, p = 0.38; F12 = 3.28, p = 0.08).  Increases in cycling mileage and cycling power 
output across the training sessions are displayed in Figure 4-2 and 4.3.   
Table 4-3 Cycling outcomes for mileage within and between groups  
Mileage FES Cycling  
 
Cycling Only  
 
Pc 
Btw time 
intervals 
Pd 
Btw Starting and 
Final intervals 
 Mean(SD) 
95% CI 
  
Starting  8.83(1.63) 9.76(2.28) t12 = 0.88,  
p = 0.40 
 
Final 9.66(1.70) 10.36(2.72) t12 = 0.57,  
p = 0.58 
 
Change 0.83 0.6  F12 = 0.80,  
p = 0.38d 
Pa 
Within group 
diff. btw start 
and final 
t6 = -1.14,  
p = 0.30a 
t6 = -1.47,  
p = 0.19 a 
  
Effect Sizeb 
(Cohen’s d) 
0.30 0.24   
Abbreviations: SD = Standard Deviation, FES = Functional Electrical Stimulation, Btw = between 
a = p-value is comparison between starting and final time periods within group using paired t-test  
b = Effect Size calculated using the starting and final cycling averages 
c = p-value is comparison between groups at time periods using an independent t-test 
d = p-value is the overall difference between starting and final time periods using a two-way ANOVA 
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Table 4-4 Cycling outcomes for cycling power output within and between groups  
Power 
Output 
(Watts) 
FES Cycling  
 
Cycling Only  
 
Pc 
Btw time 
intervals 
Pd 
Btw Starting and Final 
intervals 
 Mean(SD) 
95% CI 
  
Starting  37.77(18.60) 33.32(13.83) t12 = -.51,  
p = 0.62 
 
Final 52.12(24.30) 45.71(19.94) t12 = -0.54,  
p = 0.60 
 
Change 14.35 12.39  F12 = 3.28,  
p = 0.08 d 
Pa 
Within group 
diff. btw start 
and final 
t6 = -2.88,  
p = 0.03* 
t6 = -4.46,  
p = 0.004* 
  
Effect Sizeb 
(Cohen’s d) 
0.66 0.72   
Abbreviations: SD= Standard Deviation, FES = Functional Electrical Stimulation, Btw = between 
a = p-value is comparison between starting and final time periods within group using paired t-test  
b = Effect Size calculated using the starting and final cycling averages 
c = p-value is comparison between groups at time periods using an independent t-test 
d = p-value is the overall difference between starting and final time periods using a two-way ANOVA 
  
 
Figure 4-2 Average Cycling Mileage by Group (FES and Cycling Only) Across 
Training Sessions 
Abbreviations: FES = Functional Electrical Stimulation 
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Figure 4-3 Average Cycling Power Output by Group (FES and Cycling Only) Across 
Training Sessions 
 
Abbreviations: FES = Functional Electrical Stimulation 
 
Outcomes Measures: Clinical and Self-Report Measures 
Research Question 1 
Is there a difference in aerobic capacity as measured by the 6 Minute Walk Test (6MWT) 
between FES Cycling and Cycling Only training in PWMS? 
Results for the 6MWT for the intervention groups as a function of walking distance 
in meters are presented in Table 4-5.  There was a main effect for time (F (1,12) = 3.90, p 
= 0.02), but no main effect between groups (F (1,12) = 0.04, p = 0.84).  In addition, there 
was no interaction of group x time (F (1,12) = 0.08, p = 0.97).  The effect sizes for the FES 
and Cycling Only groups were small (d = 0.19; d = 0.30). 
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Table 4-5 6MWT Outcomes at Baseline, Mid-point, Post-intervention, and One-
month Follow-up based on the mixed-effect model 
6MWT (m) FES Cycling  
 
Cycling Only 
 
Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group 
by time 
 Mean(SE) 
95% CI 
   
Baseline 357.18(54.34)
246.98-467.38 
367.46(54.34) 
257.26-477.66 
  0.89 
Mid-point 376.54(54.34)
266.33-486.74 
395.85(54.3) 
285.65-506.05 
  0.80 
Post-
intervention 
385.09(54.34)
274.89-495.3 
405.49(54.34) 
295.29-515.70 
  0.79 
Follow-up 393.37(54.34)
283.16-503.57 
406.82(54.34) 
296.62-517.02 
  0.86 
Change over 
Training 
Perioda 
27.91 38.03 F = 0.04, 
p = 0.84 
F = 3.90, 
p = 0.02* 
 
Training 
Effect Sizee 
(Cohen’s d) 
0.19 0.30    
Abbreviations: 6MWT = 6 Minute Walk Test, m = meters, FES = Functional Electrical Stimulation,  
Btw = between, SE = Standard Error, CI = Confidence Interval 
a = Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
e = Effect Size calculated using the baseline and post-intervention means 
 
Within group findings for the 6MWT for the FES and Cycling Only groups are 
presented in Table 4-6 and Figure 4-4.  The FES and Cycling Only group had a significant 
increase in walking distance from baseline to post-intervention (p = 0.04; p = 0.03).  The 
Cycling Only group also showed a significant increase from baseline to follow-up (p = 
0.03).  
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Table 4-6 Within group differences for 6MWT based on the mixed-effect model 
6MWT  
 FES Cycling Cycling Only 
Baseline - Mid-point NS NS 
Baseline - Post-intervention 0.04 0.03 
Baseline - Follow-up NS 0.03 
Mid-point - Post-intervention NS NS 
Mid-point - Follow-up NS NS 
Post-intervention - Follow-up NS NS 
Abbreviations: FES = Functional Electrical Stimulation, 6MWT = 6 Minute Walk Test 
 
Figure 4-4 6MWT change by group (FES and Cycling Only) over time (Baseline, Mid-
point, Post-intervention, Follow-up) (mean  SE) 
 
Abbreviations: 6MWT = 6 Minute Walk Test, FES = Functional Electrical Stimulation, SE = Standard Error 
* denotes significance from baseline to follow-up 
+ denotes significance from baseline to post-intervention 
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 Results for the T25FW for the intervention groups as a function of gait speed in 
meters are presented in Table 4-7.  There was no main effect for group or time (F (1,12) 
=1.09, p = 0.37; F (1,12) = 0.35, p = 0.85, respectively).  Training effect size within each 
group was small (d = 0.11; d = 0.12). 
Table 4-7 T25FW Outcomes at Baseline, Mid-point, Post-intervention, and One-
month Follow-up based on the mixed-effect model 
T25FW 
(m/s) 
FES Cycling  Cycling Only Pb 
Overall Btw 
Group 
Pc 
Overall 
Btw Time 
Pd  
Btw Group by 
time 
 Mean(SE) 
95% CI 
   
Baseline 1.33(0.18) 
0.97-1.70 
1.40(0.18) 
1.04-1.76 
  0.78 
Mid-point 1.34(0.18) 
0.98-1.70 
1.42(0.18) 
1.05-1.78 
  0.75 
Post-
intervention 
1.39(0.18) 
1.03-1.75 
1.45(0.18) 
1.09-1.8 
  0.82 
Follow-up 1.44(0.18) 
1.08-1.80 
1.42(0.18) 
1.06-1.78 
  0.93 
Change over 
Training 
Perioda 
0.06 0.05 F = 1.09, 
p = 0.37 
F = 0.3, 
p = 0.85 
 
Effect Sizee 
(Cohen’s d) 
0.11 0.12    
Abbreviations: T25FW = Timed 25-Foot Walk, m/s= meters per second, FES = Functional Electrical 
Stimulation, Btw = between, SE = Standard Error, CI = Confidence Interval 
a =Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
e = Effect Size calculated using the baseline and post-intervention means 
 
Within group findings for the T25FW for the FES Cycling and Cycling Only groups 
are presented in Table 4-8 and Figure 4-5.  There was no significant change in gait speed 
for either group, during any time period. 
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Table 4-8 Within group differences for T25FW based on the mixed-effect model 
T25FW  
 FES Cycling Cycling Only 
Baseline - Mid-point NS NS 
Baseline - Post-intervention NS NS 
Baseline - Follow-up NS NS 
Mid-point - Post-intervention NS NS 
Mid-point - Follow-up NS NS 
Post-intervention - Follow-up NS NS 
Abbreviations: FES = Functional Electrical Stimulation, T25FW = Timed 25-Foot Walk 
Figure 4-5 T25FW change by group (FES and Cycling Only) over time (Baseline, Mid-
point, Post-intervention, Follow-up) (mean  SE) 
Abbreviations: T25FW = Time 25-Foot walk, FES = Functional Electrical Stimulation, SE = Standard Error 
 
Research Question 3 
Is there a difference in functional lower extremity strength as measured by the 5 Times Sit-
to-Stand (5XSST) between FES Cycling and Cycling Only in PWMS?  
Results for the 5XSST for the intervention groups as a function of time in seconds 
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but no main effect for group (F (1,12) = 2.10, p = 0.17).  In addition, there was a significant 
interaction of group X time (F (1,12) = 4.29, p = 0.011) (Figure 4.6).  A medium training 
effect size for the 5XSST was found for the FES group and Cycling Only groups (d = 0.675; 
d = 0.534).  
Table 4-9 5XSST Outcomes at Baseline, Mid-point, Post-intervention, and One-
month Follow-up based on the mixed-effect model 
5XSST 
(sec) 
FES Cycling  Cycling 
Only 
Pb 
Overall Btw 
Group 
Pc 
Overall Btw 
Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95% CI 
   
Baseline 17.14(1.28) 
14.54-19.73 
13.11(1.28) 
10.52-15.71 
  0.03* 
Mid-point 14.89(1.28) 
12.30-17.48 
12.53(1.28) 
9.94-15.13 
  0.20 
Post-
intervention 
14.33(1.28) 
11.73-16.92 
11.70(1.28) 
9.11-14.30 
  0.16 
Follow-up 13.52(1.28) 
10.92-16.11 
12.44(1.28) 
9.85-15.03 
  0.56 
Change over 
Training 
Perioda 
-2.81 -1.41 F = 2.10,  
p = 0.17 
F = 11.82, 
p <0.001* 
 
Training 
Effect Sizee 
(Cohen’s d) 
0.68 0.53    
Abbreviations: 5XSST = 5 times sit to stand, sec = seconds, FES = Functional Electrical Stimulation,  
Btw = between, SE = Standard Error, CI = Confidence Interval 
a =Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
e = Effect Size calculated using the baseline and post-intervention means 
 
Table 4-10 Within group differences for 5XSST based on the mixed-effect model 
5XSST  
 FES Cycling Cycling Only 
Baseline - Mid-point 0.0005 NS 
Baseline - Post-intervention <0.0001 0.02 
Baseline - Follow-up <0.0001 NS 
Mid-point - Post-intervention NS NS 
Mid-point - Follow-up 0.02 NS 
Post-intervention - Follow-up NS NS 
Abbreviations: FES = Functional Electrical Stimulation, 5XSST = 5 times sit to 
stand 
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Within group findings for the 5XSST for the FES Cycling and Cycling Only groups 
are presented in Table 4-10 and Figure 4-6.  Using the mixed-effects model, there was a 
significant difference between groups (p = 0.03) at baseline, with the Cycling Only group 
demonstrating better performance (i.e., lower scores demonstrating faster speed).  In 
both FES and Cycling Only groups there was a significant decrease in 5XSST time between 
baseline and post-intervention (p < 0.0001 and p = 0.021, respectively).  The FES group 
also showed significant changes from the baseline to mid-point, from the baseline to 
follow-up, and from the mid-point to follow-up time periods (p = 0.0005, p <0.0001, p = 
0.024, respectively). 
Figure 4-6 5XSST change by group (FES and Cycling Only) over time (Baseline, Mid-
point, Post-intervention and Follow-up) (mean  SE),  
 
Abbreviations: 5XSST = 5 Times Sit to Stand, FES = Functional Electrical Stimulation, SE = Standard Error 
# denotes significance from baseline to mid-point 
+ denotes significance from baseline post-intervention 
* denotes significance from baseline to follow-up 
= denotes significance from mid-point to follow-up 
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Research Question 4 
Is there a difference in functional mobility as measured by the Timed up and Go (TUG) 
between FES Cycling and Cycling Only in PWMS?  
Results for the TUG for the intervention groups as a function of time in seconds are 
presented in Table 4-11.  There was no main effect for time or group (F (1,12) = 1.89, p = 
0.16; F (1,12) = 0.47, p = 0.51, respectively).  There was a significant interaction of group x 
time (F (1,12) = 4.00, p = 0.02).  The effect sizes for the FES and Cycling Only groups were 
small (d = 0.30; d = 0.03).   
Table 4-11 TUG Outcomes at Baseline, Mid-point, Post-intervention, and One-month 
Follow-up based on the mixed-effect model 
TUG (sec) FES Cycling  Cycling 
Only 
Pb 
Overall Btw 
Group  
Pc 
Overall Btw 
Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95% CI 
   
Baseline 13.05(1.89) 
9.22-16.88 
9.73(1.89) 
5.90-13.56 
  0.22 
Mid-point 11.54(1.89) 
7.71-15.37 
9.53(1.89) 
5.70-13.36 
  0.46 
Post-
intervention 
11.29(1.89) 
7.45-15.12 
10.38(1.89) 
6.55-14.21 
  0.74 
Follow-up 11.15(1.89) 
7.32-14.98 
10.17(1.89) 
6.34-14.00 
  0.72 
Change over 
Training 
Perioda 
-1.76 0.65 F = 0.47, 
p = 0.51 
F = 1.89, 
p = 0.16 
 
Training 
Effect Sizee 
(Cohen’s d) 
0.30 0.15    
Abbreviations: TUG = Timed Up and Go, sec = seconds, FES = Functional Electrical Stimulation, Btw = 
between, SE = Standard Error, CI = Confidence Interval 
a =Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
e = Effect Size calculated using the baseline and post-intervention means 
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Within group findings for the TUG for the FES Cycling and Cycling Only groups are 
presented in Table 4-12 and Figure 4-7.  Only the FES group demonstrated significant 
improvements from baseline to mid-point, post-intervention, and follow-up, but changes 
were not great enough to demonstrate a significant group effect (p=.01, p = 0.004, p =.002, 
respectively).   
Table 4-12 Within group differences for TUG based on the mixed-effect model 
TUG  
 FES Cycling Cycling Only 
Baseline - Mid-point 0.01 NS 
Baseline - Post-intervention 0.004 NS 
Baseline - Follow-up 0.002 NS 
Mid-point - Post-intervention NS NS 
Mid-point - Follow-up NS NS 
Post-intervention - Follow-up NS NS 
Abbreviations: FES = Functional Electrical Stimulation, TUG = Timed Up and Go 
 
Figure 4-7 TUG change by group (FES and Cycling Only) over time (Baseline, Mid-
point, Post-intervention, Follow-up) (mean  SE) 
 
Abbreviations: TUG = Times Up and Go, FES = Functional Electrical Stimulation, SE = Standard Error 
# denotes significance from baseline to mid-point 
+ denotes significance from baseline post-intervention 
* denotes significance from baseline to follow-up 
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BTS G-Walk® results for the TUG for the intervention groups are presented in 
Table 4-13.  There was no main effect between groups for all parameters. There was a 
main effect for time for TUG End-turning phase duration (F (1,12) = 4.78, p<0.007).  All 
other comparisons and interactions were not significant. 
Within group difference at each of the time periods and are available in appendix O 
and described below.  The Cycling Only group demonstrated a significant difference in the 
TUG Sit to Stand Phase Duration at baseline to post-intervention, mid-point to post-
intervention, and post-intervention to follow-up periods demonstrating a greater 
improvement in performance (p= 0.05, 0.01, and 0.001, respectively).  The Cycling Only 
group also demonstrated a significant difference in the TUG Stand to Sit Phase Duration at 
the mid-point to post-intervention demonstrating a greater improvement in performance 
(p = 0.04).  The FES group demonstrated a significant difference in the TUG Mid-Turning 
Phase Duration at baseline to post-intervention and baseline to follow up (0.02 and 
0.001), and the Cycling Only group demonstrated a significant difference from  baseline to 
mid-point.  No significant differences in End-Turning were seen at any time period for 
either group. 
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Table 4-13 TUG Spatiotemporal outcomes from the BTS G-Walk® at Baseline, Mid-
point, Post-intervention, and One-month follow-up based on the mixed-effect model 
TUG- Sit to 
Stand Phase 
Duration (s) 
FES 
Cycling  
Cycling Only Pb 
Overall Btw 
Group  
Pc 
Overall 
Btw Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 1.12(0.13) 
0.85-0.13 
1.30(0.13) 
1.04-1.56 
  0.34 
Mid-point 1.36(0.13) 
1.10-1.61 
1.12(0.13) 
0.87-1.38 
  0.20 
Post-
intervention 
1.16(0.13) 
0.90-1.41 
1.51(0.13) 
1.24-1.79 
  0.06 
Follow-up 1.16(0.13) 
0.91-1.42 
1.00(0.13) 
0.74-1.26 
F = 0.10,  
P = 0.76 
F = 2.12, 
p = 0.11 
0.36 
Change over 
Training 
Perioda 
0.04 0.21 .   
TUG- Mid-
Turning 
Phase 
Duration (s)  
FES 
Cycling  
Cycling Only Pb 
Overall Btw 
Group  
Pc 
Overall 
Btw Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 3.86(0.61) 
2.63-5.10 
2.91(0.57) 
1.75-4.07 
  0.26 
Mid-point 4.41(0.57) 
3.26-5.57 
4.02(0.57) 
2.86-5.17 
  0.63 
Post-
intervention 
4.25(0.57) 
3.09-5.40 
2.47(0.61) 
1.23-3.71 
  0.04* 
Follow-up 3.20(0.57) 
2.04-4.35 
3.22(0.57) 
2.06-4.37 
F = 1.81,  
p = 0.20 
F = 1.73, 
p = 0.18 
0.98 
Change over 
Training 
Perioda 
0.39 -0.44    
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TUG- End-
turning Phase 
Duration (s)  
FES 
Cycling  
Cycling Only Pb 
Overall Btw 
Group  
Pc 
Overall 
Btw Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 2.93(0.62) 
1.66-4.21 
2.00(0.61) 
0.76-3.23 
  0.29 
Mid-point 2.01(0.61) 
0.77-3.25 
1.07(0.61) 
-0.17-2.31 
  0.28 
Post-
intervention 
1.77(0.61) 
0.53-3.01 
1.43(0.62) 
0.15-2.70 
  0.70 
Follow-up 1.29(0.61) 
0.06-2.53 
1.29(0.61) 
0.05-2.53 
F =0.51,  
p = 0.49 
F = 4.78, 
p<.007* 
1.00 
Change over 
Training 
Perioda 
-1.16 -0.57    
TUG- Stand to 
Sit Phase 
Duration (s) 
FES 
Cycling  
Cycling Only Pb 
Overall Btw 
Group  
Pc 
Overall 
Btw Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 1.82(0.23) 
1.35-2.29 
1.80(0.22) 
1.36-2.24 
  0.95 
Mid-point 1.86(0.22) 
1.41-2.30 
1.70(0.22) 
1.26-2.14 
  0.61 
Post-
intervention 
1.91(0.22) 
1.47-2.36 
1.53(0.23) 
1.05-2.00 
  0.23 
Follow-up 2.29(0.22) 
1.84-2.73 
1.54(0.22) 
1.10-1.99 
F = 2.0,  
p = 0.18 
F = 0.32,  
p = 0.81 
0.02* 
Change over 
Training 
Perioda 
0.09 -0.27    
Abbreviations: TUG = Timed Up and Go, s = seconds, FES = Functional Electrical Stimulation, Btw = between, 
SE = Standard Error 
a =Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
e = Effect Size calculated using the baseline and post-intervention means 
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Spatiotemporal Outcomes 
Research Question 5 
Is there a difference on spatiotemporal components of gait between FES Cycling and Cycling 
Only in PWMS?   
Results for spatiotemporal parameters for the 6MWT and T25FW for the 
intervention groups are presented in Table 4-14 and 4-15.  There was no main effect 
between groups for all parameters except for the 6MWT where there was a main effect 
for time for Left and Right Stride Length (F (1,12) = 3.56, p = 0.02; F (1,12) = 3.43, p = 
0.03).  Within group differences on spatiotemporal gait parameters based on the mixed-
effect model are presented in appendix P and Q.  There were limited amounts of within 
group differences that were found to be significant.  The only significant finding was for 
the 6MWT, where the Cycling Only group demonstrated significant changes in right stride 
length and left stride length over time from baseline to mid-point, baseline to post-
intervention, and baseline to follow-up. 
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Table 4-14 6MWT Spatiotemporal outcomes from BTS G-Walk® at Baseline, Mid-
point, Post-intervention, and One-month Follow-up based on the mixed-effect 
model 
 
6MWT- Stride 
Length-Left 
(m) 
FES Cycling  Cycling 
Only 
Pb 
Overall Btw 
Group  
Pc 
Overall Btw 
Time 
Pd  
Btw 
Group by 
time 
 Mean(SE) 
95%CI 
   
Baseline 1.53(0.10) 
1.32-1.74 
1.44(0.10) 
1.23-1.65  
  0.56 
Mid-point 1.55(0. 10) 
1.34-1.76 
1.54(0.10) 
1.33-1.76 
  0.96 
Post-
intervention 
1.56(0.24) 
1.35-1.77 
1.56(0.10) 
1.35-1.77 
  0.99 
Follow-up 1.55(0.10) 
1.34-1.76 
1.59(0.10) 
1.38-1.80 
F = 3.56, 
p = 0.92 
F = 3.56, 
p = 0.02* 
0.79 
Change over 
Training 
Perioda 
-0.01 0.12    
6MWT- Stride 
Length-Right 
(m) 
FES Cycling  Cycling 
Only 
Pb 
Overall Btw 
Group  
Pc 
Overall Btw 
Time 
Pd  
Btw 
Group by 
time 
 Mean(SE) 
95%CI 
   
Baseline 1.53(0.10) 
1.32-1.74 
1.44(0.10) 
1.23-1.65 
  0.54 
Mid-point 1.55(0.10) 
1.34-1.76 
1.54(0.10) 
1.33-1.76 
  0.97 
Post-
intervention 
1.57(0.10) 
1.36-1.78 
1.56(0.10) 
1.35-1.77 
  0.95 
Follow-up 1.54(0.10) 
1.34-1.75 
1.59(0.10) 
1.38-1.80 
F = 0.01. 
p = 0.92 
F = 3.43, 
p = 0.03* 
0.77 
Change over 
Training 
Perioda 
0.00 0.12    
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6MWT- Step 
Symmetrye 
FES Cycling  Cycling 
Only 
Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 1.00(0.03) 
0.94-1.05 
1.03(0.03) 
0.98-1.09 
  0.35 
Mid-point 1.03(0.03) 
0.98-1.08 
0.99(0.03) 
0.92-1.05 
  0.30 
Post-
intervention 
0.98(0.03) 
0.92-1.04 
1.00(0.03) 
0.95-1.07 
  0.49 
Follow-up 1.01(0.03) 
0.96-1.07 
1.01(0.03) 
0.95-1.07 
F = 0.05, 
p = 0.84 
F = 0.06, 
p = 0.98 
0.91 
Change over 
Training 
Perioda 
-.0.02 -0.03    
6MWT- 
Double-
Support- Left 
(% cycle) 
FES Cycling  Cycling 
Only 
Pb 
Overall Btw 
Group  
Pc 
Overall Btw 
Time 
Pd  
Btw 
Group by 
time 
 Mean(SE) 
95%CI 
   
Baseline 14.15(1.46) 
11.19-17.12 
11.86(1.46) 
8.89-14.82 
  0.274 
Mid-point 14.70(1.46) 
11.73-17.67 
11.65(1.46) 
8.45-14.86 
  0.165 
Post-
intervention 
13.71(1.46) 
10.74-16.67 
14.25(1.46) 
11.28-
17.21 
  0.796 
Follow-up 12.18(1.46) 
9.22-15.15 
13.96(1.46) 
10.99-
16.92 
F = 0.183, 
p = 0.68 
F = 0.580, 
p = 0.632 
0.396 
Change over 
Training 
Perioda 
-0.44 2.39    
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6MWT- 
Double-
Support- Right 
(% cycle) 
FES Cycling  Cycling 
Only 
Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 14.94(1.76) 
11.37-18.52 
12.02(1.76) 
8.45-15.60 
  0.250 
Mid-point 15.16(1.76) 
11.58-18.74 
11.96(1.93) 
8.03-15.89 
  0.229 
Post-
intervention 
14.08(1.76) 
10.50-17.66 
14.66(1.76) 
11.08-18.24 
F = 0.171, 
p = 0.686 
F = 0.611, 
p = 0.613 
0.819 
Follow-up 11.88(1.76) 
8.30-15.46 
13.85(1.76) 
10.27-17.43 
  0.435 
Change over 
Training 
Perioda 
-0.86 2.64    
Abbreviations: FES = Functional Electrical Stimulation, 6MWT = 6 Minute Walk Test, m=meters,  
SE= Standard Error 
a = Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
e = step symmetry calculated by taking the absolute value of the left step length/right step length
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Table 4-15 T25FW Spatiotemporal outcomes at Baseline, Mid-point, Post-
intervention, and One-month Follow-up based on the mixed-effect model 
T25FW – 
Stride Length- 
Left (m) 
FES Cycling  Cycling Only Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw 
Time 
Pd  
Btw 
Group by 
time 
 Mean(SE) 
95%CI 
   
Baseline 1.59(0.10) 
1.38-1.80 
1.64(0.10) 
1.43-1.85 
  0.76 
Mid-point 1.58(0.10) 
1.37-1.80 
1.62(0.10) 
1.41-1.83 
  0.78 
Post-
intervention 
1.55(0.10) 
1.34-1.76 
1.64(0.10) 
1.42-1.85 
  0.55 
Follow-up 1.52(0.10) 
1.31-1.73 
1.68(0.10) 
1.47-1.90 
F = 0.35, 
p = 0.57 
F = 0.23, 
p = 0.88 
0.28 
Change over 
Training 
Perioda 
-0.04 0.00    
T25FW - 
Stride Length- 
Right (m) 
FES Cycling  Cycling Only Pb 
Overall Btw 
Group  
Pc 
Overall 
Btw Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 1.59(0.10) 
1.38-1.80 
1.63(0.10) 
1.42-1.84 
  0.80 
Mid-point 1.57(0.10) 
1.36-1.78 
1.62 (0.10) 
1.41-1.83 
  0.74 
Post-
intervention 
1.54(0.10) 
1.33-1.75 
1.64(0.10) 
1.43-1.85 
  0.50 
Follow-up 1.52(0.10) 
1.31-1.73 
1.69(0.10) 
1.48-1.90 
F = 0.37, 
p = 0.55 
F = 0.32, 
p = 0.81 
0.28 
Change over 
Training 
Perioda 
-0.05 0.01    
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T25FW- Step 
Symmetrye 
(m) 
FES Cycling  Cycling Only Pb 
Overall 
Btw 
Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group by 
time 
 Mean(SE) 
95%CI 
   
Baseline 1.02(0.04) 
0.95-1.09 
1.01(0.04) 
0.94-1.08 
  0.92 
Mid-point 1.02(0.04) 
0.95-1.09 
0.99(0.04) 
0.91-1.06 
  0.52 
Post-
intervention 
0.94(0.04) 
0.87-1.01 
1.00(0.04) 
0.94-1.08 
  0.17 
Follow-up 1.05(0.04) 
0.98-1.12 
1.02(0.04) 
0.95-1.09 
F = 1.92, 
p = 0.19 
F = 1.37, 
p = 0.27 
0.65 
Change over 
Training 
Perioda 
-0.08 0.01    
T25FW - 
Double-
Support- Left 
FES Cycling  Cycling Only Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group by 
time 
 Mean(SE) 
95%CI 
   
Baseline 13.63(1.52) 
10.55-16.7 
13.01(1.52) 
9.93-16.08 
  0.77 
Mid-point 13.53(1.52) 
10.45-16.61 
13.43(1.52) 
10.36-16.51 
  0.97 
Post-
intervention 
15.39(1.52) 
12.31-18.47 
12.60(1.52) 
9.53-15.68 
  0.20 
Follow-up 12.80(1.52) 
9.73-15.88 
12.03(1.52) 
8.95-15.11 
F = 0.34, 
p= 0.57 
F = 1.08, 
p = 0.37 
0.72 
Change over 
Training 
Perioda 
1.76 -0.41    
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T25FW - 
Double-
Support- Right 
FES Cycling  Cycling Only Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 12.50(1.62) 
9.21-15.79 
12.06(1.62) 
8.76-15.35 
  0.85 
Mid-point 13.31(1.62) 
10.02-16.60 
13.99(1.62) 
10.69-17.28 
  0.77 
Post-
intervention 
14.97(1.62) 
11.67-18.26 
13.65(1.62) 
10.36-16.95 
  0.57 
Follow-up 12.62(1.62) 
9.33-15.91 
13.97(1.62) 
10.68-17.27 
F = 0.001, 
p = 0.97 
F = 1.49, 
p = 0.23 
0.56 
Change over 
Training 
Perioda 
2.47 1.59    
Abbreviations: FES = Functional Electrical Stimulation, T25FW = Timed 25-Foot Walk, m/s= meters per 
second, SE = Standard Error 
a =Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
e = step symmetry calculated by taking the absolute value of the left step length/right step length 
 
Self-Report Measures 
Research Question 6 
Is there a difference on quality of life and self-reported walking and balance measures 
between FES Cycling and Cycling Only in PWMS?   
 
MSQOL-54 
 
Results for the MSQOL-54 for the invention groups are presented in Table 4-16.  
There was no significant difference between groups at any specific time period.  There 
was a main effect for time for the MSQOL-54 Mental Composite and MSQOL-54 Overall 
QOL subscale (F (1,12) = 4.17, p = 0.03; F (1,12) = 5.60, p = 0.01, respectively).   
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Within group differences for MSQOL-54 are presented in appendix R.  Significant 
changes in the MSQOL-54 Physical Composite for the FES group were present from 
baseline to post-intervention (p = 0.01) and for Overall Quality of Life from baseline to 
post-intervention and baseline to follow-up (p = 0.005; p = 0.004, respectively).  A within 
groups difference was also present for the Cycling Only group for the Mental composite 
from baseline to post-intervention (p = 0.05).  
Table 4-16 MSQOL-54 Outcomes at Baseline, Mid-point, Post-intervention, and One-
month Follow-up based on the mixed-effect model 
MSQOL-54 
Physical 
Composite 
FES Cycling  Cycling 
Only 
Pb 
Overall 
Btw Group  
Pc 
Overall Btw 
Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 50.58(6.66) 
36.84-64.32 
50.87(6.66) 
37.13-64.61 
  0.98 
Post-
intervention 
61.27(6.66) 
47.53-75.01 
53.70(6.66) 
39.96-67.43 
  0.43 
Follow-up 
 
57.65(6.66) 
43.91-71.39 
51.19(6.66) 
37.45-64.93 
F = 0.27,  
p = 0.06 
F = 2.95,  
p = 0.07 
0.50 
Change over 
Training 
Perioda 
10.49 2.83    
MSQOL-54 
Mental 
Composite 
FES Cycling  Cycling Only Pb 
Overall Btw 
Group  
Pc 
Overall Btw 
Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 67.95(8.54) 
50.32-85.58 
55.73(8.54) 
38.10-73.36 
  0.32 
Post-
intervention 
77.06(8.54) 
59.43-94.69 
66.36(8.54) 
48.73-83.99 
  0.39 
Follow-up 
 
78.20(8.54) 
60.57-95.83 
62.53(8.54) 
44.90-80.16 
F = 1.30,  
p = 0.28 
F = 4.17,  
p = 0.03* 
0.21 
Change over 
Training 
Perioda 
9.11 10.63    
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MSQOL-54 
Overall QOL 
FES Cycling  Cycling 
Only 
Pb 
Overall 
Btw Group  
Pc 
Overall Btw 
Time 
Pd  
Btw Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 61.19(6.28)  
48.24-74.15 
57.62(6.28) 
44.66-70.57 
  0.69 
Post-
intervention 
70.95(6.28) 
58.00-83.91 
60.95(6.28) 
48.00-73.91 
  0.27 
Follow-up 71.43(6.28) 
58.47-84.39 
60.48(6.28) 
47.52-73.43 
F = 0.93,  
p = 0.35 
F = 5.60,  
p = 0.01* 
0.23 
Change over 
Training 
Perioda 
9.04 3.33    
Abbreviations: MSQOL-54 = Multiple Sclerosis Quality of Life Inventory, FES = Functional Electrical 
Stimulation, Btw = between, SE = Standard Error 
a =Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
 
MFIS 
Results for the MFIS for the invention groups are presented in Table 4-17.  There 
was no main effect for group on the MFIS Total, but there was a main effect for time (F 
(1,12) = 4.08, p = 0.03).  There were within group differences group at various time 
periods for both the FES group and Cycling Only group .  From baseline to post-
intervention, the Cycling Only group experienced significant changes in the MFIS 
Cognitive subscore (p = 0.04), the FES group experienced changes in the MFIS Physical 
subscore (p =0.01), and the FES group experienced significant changes in the MFIS total 
score (p 0.03).  There were no significant within group differences for the MFIS (appendix 
R). 
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Table 4-17 MFIS Outcomes at Baseline, Mid-point, Post-intervention, and One-
month Follow-up based on the mixed-effect model 
MFIS Total FES Cycling  Cycling Only Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 42.00(6.19) 
29.23-53.77 
47.13(6.19) 
34.37-59.92 
  0.56 
Post-
intervention 
32.00(6.19) 
19.23-44.77 
39.57(6.19) 
26.80-52.35 
  0.40 
Follow-up 36.71(6.19) 
23.94-49.49 
44.29(6.19) 
31.51-57.06 
F = 0.72,  
p = 0.41 
F = 4.08, 
p = 0.03* 
0.40 
Change over 
Training 
Perioda 
-10 -7.56    
Abbreviations: MFIS= Modified Fatigue Impact Scale, FES = Functional Electrical Stimulation, Btw = 
between, SE = Standard Error  
a =Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
 
 
MSWS-12 
Results for the MSWS-12 for the invention groups are presented in Table 4.18.  
There was no main effect for group or time on the MSWS-12.  There were no significant 
differences within group differences for the MSWS-12 (appendix R).   
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Table 4-18 MSWS-12 Outcomes at Baseline, Mid-point, Post-intervention, and One-
month Follow-up based on the mixed-effect model 
MSWS-12 FES Cycling  Cycling Only Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 64.43(6.78) 
50.44-78.43 
71.43(6.78) 
57.44-85.42 
  0.47 
Post-
intervention 
59.51(6.78) 
45.52-73.50 
69.52(6.78) 
55.53-83.52 
  0.31 
Follow-up 60.46(6.78) 
46.46-74.45 
70.00(6.78) 
56.00-83.99 
F = 0.95,  
p = 0.35 
F = 0.90,  
p = 0.42 
0.33 
Abbreviations: MSWS-12 = 12 item Multiple Sclerosis Walking, FES = Functional Electrical Stimulation,  
Btw = between, SE = Standard Error  
a = Calculated by subtracting post-intervention mean from baseline mean  
b = p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
 
 
ABC 
Results for the ABC for the invention groups are presented in Table 4-19.  There 
was no main effect for group or time on the ABC.  There were no within group differences 
for either group at any time period.  There were no significant differences within group 
differences for the ABC (appendix R).   
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Table 4-19 ABC Outcomes at Baseline, Mid-point, Post-intervention, and One-month 
Follow-up based on the mixed-effect model 
ABC FES Cycling  Cycling Only Pb 
Overall 
Btw Group  
Pc 
Overall 
Btw Time 
Pd  
Btw 
Group 
by time 
 Mean(SE) 
95%CI 
   
Baseline 64.42(8.63) 
46.62-82.23 
52.63(8.63) 
34.83-70.44 
  0.34 
Post-
intervention 
70.27(8.63) 
88.07-52.46 
61.61(8.63) 
43.801-79.41 
  0.49 
Follow-up 
 
68.80(8.63) 
51.00-86.60 
59.08(8.63) 
41.27-76.88 
F = 0.77,  
p = 0.40 
F = 2.18, 
p = 0.14  
0.43 
Change over 
Training 
Perioda 
5.85 8.98    
Note. Values are mean ± SE 
Abbreviations: ABC = Activities-specific Balance Confidence Scale, FES = Functional Electrical Stimulation, 
Btw = between, SE = Standard Error 
a =Calculated by subtracting post-intervention mean from baseline mean  
b= p-value is the overall between groups using a repeated measures analysis of variance 
c = p-value is the overall between time periods using a repeated measures analysis of variance 
d = p-value is the comparison between the FES cycling and Cycling Only group at each time period  
 
Summary  
 
Fourteen PWMS completed 24 training sessions of either FES cycling or Cycling 
Only over an 8-10 week training period.  Participants reported no adverse events or 
increases in MS related symptoms (i.e., spasticity, fatigue, pain) during the training 
period.  A few participants reported fatigue after training but conveyed their fatigue levels 
returned to baseline after rest. 
 
Findings 
  
Medium effect sizes were noted for cycling power output and 5XSST for both the 
FES cycling and Cycling Only groups.  Main effects for time were present for 6MWT and 
5XSST, but there were no statistically significant differences found between groups on 
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any measures.  PWMS also experienced improvements in their quality of life as 
demonstrated by significant improvements in the MFIS over time, the Mental Composite 
subscale of the MSQOL-54, and the Overall QOL subscale of the MSQOL-54. 
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Chapter 5 
 
Introduction 
 
 This chapter will discuss the results as they relate to walking performance and 
quality of life in PWMS.  Findings will also be compared and contrasted to the current 
research.  Limitations of the current study, clinical implications on physical therapist 
practice guidelines, and recommendations for future research will be explored. 
 
Discussion of Results 
 
 This randomized, clinical pilot study investigated the effects of lower extremity 
cycling, with and without FES, in ambulatory people with mild to moderate multiple 
sclerosis (3.0 to 6.0 on the PDDS).  This study further adds to the literature supporting 
that FES Cycling is well-tolerated and beneficial for those with mild to moderate 
MS.36,38,102   To my knowledge, this is the only randomized clinical pilot study to examine 
the effect of FES Cycling versus Cycling Only in PWMS.   The current study included people 
based on their functional classification, whereas some previous FES cycling studies 
focused on individuals with only specific clinical subtypes of MS.36,41 Previous studies 
lacked comparisons or control groups, only stimulated proximal muscle groups, and 
lacked a strong variety of outcome measures to document changes in walking 
performance and QOL.2,34,37,97,166  
 One of the primary aims of this study was to examine if there is a difference in 
scores on clinical and self-report measures when comparing FES Cycling to Cycling Only.  
Although no overall differences between groups were observed, cycling, in general, was 
found to have a positive effect on select aspects of aerobic capacity, sit-to-stand, and 
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quality of life.  Although not statistically significant, the FES group showed a trend toward 
continued improvement at one-month post-training on the 5XSST and the T25FW.   
Cycling Outcomes 
 Overall small changes in mileage were seen within each group. This finding was 
consistent with expected results since resistance was steadily increased, potentially 
making it difficult for subjects to increase their overall mileage.  Evidence for resistance 
training in PWMS is well-supported in the literature, and should continue to be included 
in  treatment approaches for PWMS.85,88   
 In the current study, participants in the FES and Cycling Only groups demonstrated 
significant improvements in cycling power output and, although the mean resistance of 
the FES group was higher at baseline and at the last training session, there was no 
statistically significant differences found between groups.  Backus et al38 also found , 
improvements in cycling power output in a  FES cycling study in PWMS in people with 
severe weakness or paralysis.  Combining the results of this current study and Backus et 
al38 support that cycling power output using FES is an outcome that can be improved 
across a wide range of disability levels in PWMS.  In contrast, a systematic review by Hunt 
et al107 found FES efficiency and cycling power output to be lower when compared to 
volitional cycling in people with spinal cord injury, stroke, or cerebral palsy. One possible 
explanation for these differences could the difference in adjustment of stimulation 
parameters and the amount of voluntary control used by the participants in each of the 
studies.   Based on the findings of this comparison study, the addition of electrical 
stimulation may allow greater power inputs to be achieved with FES by assisting motor 
unit recruitment.    
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Clinical Measures 
Aerobic Capacity 
 Improvements in the 6MWT seen in both the FES cycling and Cycling Only groups 
were consistent with positive changes seen using the 6MWT in other endurance training 
studies in PWMS (treadmill, cycling, etc.).12,15  Janssen et al examined outcomes using FES 
Cycling versus cycling without stimulation in people with chronic stroke and found that 
both groups demonstrated improvements on the 6MWT, but no significant differences 
between groups were found.27 This is similar to the results of the present study where the 
addition of stimulation does not appear to significantly improve aerobic capacity more 
than cycling without stimulation.  Improvements in the 6MWT were consistent with other 
endurance training studies (treadmill, cycling, etc.).12,15  Using animal models that study 
autoimmune encephalopathy, researchers demonstrated that endurance exercise may 
also serve to slow the disease progression and reduce the length of exacerbations.77  
Aerobic exercise may also protect,78 regenerate, and adapt neuronal processes, which can 
reduce long-term disability.46  
 Rampello et al12 had similar findings when using the 6MWT as an outcome when 
exploring an intensive cycling program for PWMS that focused aerobic training.  One of 
the keys to a successful change in walking endurance in this study, and the Rampello et al 
may be attributed to the length of the training session, frequency of sessions, and 
intensity.12  The training protocol in the current study is similar to Rampello et al where 
they trained their participants, 3-times per week, for 8 weeks, using 40-minute training 
sessions and workload up to 80% based on a baseline cardiopulmonary respiratory test.12  
It is well-established that “intensity matters” when looking to make neuroplastic changes 
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in the central nervous system45 and fitness levels when comparisons are made between 
an exercise and control groups in PWMS.50,80   
 Collett et al16 examined the effects of cycling on PWMS using three different cycling 
protocols during a 2-times per week for 12 week training protocol that included baseline 
exercise testing to establish starting workload.  In each protocol participants performed 
the same relative amount of work.  Intensities were either continuous (45% of peak 
power), intermittent (30 seconds on: 30 seconds off at 90% of peak power), or combined 
(10 min intermittent at 90% peak power, then 10min continuous at 45% peak power).  
Although no differences were found between groups on the two-minute walk test 
(2MWT), they found that the intermittent group showed greater improvement at 0 to 6 
weeks, though improvement was not statistically significant.   The current study used an 
interval training protocol where participants cycled for 5 minutes against their set 
workload and then passively cycled 1 minute to recover, supporting that interval training 
should be considered when working with PWMS.  Short rest breaks may allow PWMS to 
train longer, with less fatigue.  Further studies should be conducted to compare interval 
training to continuous training in PWMS. 
 In this study, the range of distance covered during the 6MWT varied considerably 
at baseline, as evidenced by the wide confidence intervals (CI) (FES 95% CI, 246.48-
467.38; Cycling Only 95% CI 257.26 – 477.66).  Similar results were noted in a study by 
Collett et al16 which used the 2MWT as an outcome measure.  In the current study, this 
variability was likely present due to the variability in walking disability of the participants 
(FES range = 143.86-553.21; Cycling only range = 202.39-508.71).  The heterogeneity 
seen in this sample is common in MS and it is one of the reasons why research in PWMS 
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can be challenging.  Further study examining changes in aerobic capacity using sample 
sizes with narrower walking performance as inclusion criteria may be indicated so that 
results can be applied better to individuals of varying disability. 
 
Gait Speed 
 
 Gait speed is considered a critical vital sign in clinical practice and is highly 
correlated with fall risk.131 It is a critical measure since it has been found that even 
individuals with mild MS (EDSS 0 - 2.5, with and without pyramidal signs) demonstrate 
significant changes in gait speed when compared to age and sex matched controls.172  The 
current study did not find any significant changes in gait speed in either training group.   
Ratchford et al36 is the only other FES cycling study in PWMS to report gait speed as an 
outcome measure.  In their home-based FES cycling study, investigators documented a 
36% improvement in the Timed 25-Foot Walk (T25FW).  In the Ratchford et al study, 
individuals were more disabled and trained for 6 months, whereas individuals in the 
current study were household and community ambulators and trained for 8-weeks.36  It is 
possible that there is a greater ability to make changes in gait speed for individuals who 
demonstrate slower gait speeds at baseline.  In a case series examining cycling outcomes 
in three groups of participants with stroke, the two groups with the slower gait speeds 
made greater improvements in gait speed after training.173  Further research needs to be 
conducted to examine the effect of  longer training periods on gait speed in PWMS.    
In addition, it is likely that lack of specificity in the training (i.e. cycling vs. walking), 
impacted a participant’s ability to demonstrate a change in this outcome.  This is 
consistent with other cycling studies in stroke where the effect size for gait speed was 
small after a 3 times per week, 10 week cycling study.174   
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 Based on a study by Alon, Conroy and Donner,23 people with chronic stroke 
improved their gait velocity by 25% (p = .001), and performed FES Cycling at or close to 
60 rpm for 30 minutes for 8 weeks, 3 times per week.  Therefore, it may be important to 
train at higher cycling speeds to see changes in gait speed.  The protocol in the current 
study focused on increasing resistance while participants maintained a minimum speed of 
45 rpm.  This speed may have not been demanding enough to promote changes in gait in 
PWMS.  
 
Functional LE Strength  
 In this study, the 5 Times Sit to Stand (5XSST) was used as a functional measure of 
lower extremity muscle strength since measuring strength isokinetically is not time 
efficient in the clinical environment.  Although other components of movement (e.g. 
coordination, balance, range of motion, and sensation) are integral in sit-to-stand 
movements, in a sample of older adults (mean age = 64.50), McCarthy et al175 found that 
lower extremity strength explained 48% of the variance in sit-to-stand.  The 5XSST, or 
similar measures, have not be used in previous FES studies in PWMS, although Fornusek 
and Hoang41 reported improvements in self-perceived transfer ability on a standardized 
rating scale in PWMS who had weak, but voluntary quadricep contractions (EDSS 7.0 -
7.5).  In the current study, when compared to baseline, only the FES group demonstrated 
improvements in the 5XSST at mid-point, post-intervention, and follow-up, whereas the 
Cycling Only group did not demonstrate improvements until post-intervention.  In 
addition, the FES group demonstrated significant changes continued to show 
improvement one-month post intervention, whereas the Cycling Only group slightly 
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declined during this time period.  Since both groups were receiving resistance during 
their cycling, it is possible that the addition of FES assisted in these early changes in 
muscle strength that were sustained throughout the study period.  In people with 
complete and incomplete SCI, increases in thigh circumference176 and muscle strength93 
have been documented after FES cycling training.  Support for improvements in lower 
extremity muscle performance was also demonstrated in post-acute stroke where 
patients received 3 hours total of either standard inpatient therapy or standard therapy 
plus FES cycling.  The FES cycling group demonstrated significant differences in their 
maximum isometric voluntary contraction of quadriceps, sit-to-stand ability, and the 
Motricity index.25 
 
Functional Mobility 
 In contrast to Collett et al16 who found significant change in the Timed Up and Go 
(TUG) comparing three different intensities of cycling in PWMS, in this study, only the FES 
group experienced significant changes between time periods (baseline to mid-point, post-
intervention, and follow-up), but the changes were not large enough to demonstrate 
significance within groups differences.  The Cycling Only group did not demonstrate a 
significant change in the TUG during any time period.  The TUG is a combination of a sit to 
stand motion, turning, and short distance walking.  It is likely the findings in the FES 
group were due to the sit to stand motion, which is supported by the findings 
demonstrated in the 5XSST especially since there were no significant changes found in 
gait speed nor turning speed.  In a progressive resistance cycling protocol combined with 
balance training, Cakt et al15 also found significant changes in the TUG, but it is difficult to 
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determine if cycling or balance training had a greater impact on their results since 
subjects received a combined intervention.  
 
Spatiotemporal Gait Outcomes 
 While there are no available studies that measured changes in spatiotemporal gait 
using cycling protocols, resistance training protocols have demonstrated improvements 
in step length.85  Resistance, combined with endurance training, was integral to this study 
and may have been the reason changes in stride length were present, but does not explain 
why these changes were only present in the Cycling Only group.  The effect size for power 
output was slightly higher in the Cycling Only group but power output between groups 
was not statistically significant.  Since the task of walking overground was not trained or 
emphasized, it was expected that minimal changes in spatiotemporal gait parameters 
were present. 
 
Self-Report Measures 
 Monitoring quality of life is of great importance in neurodegenerative disease, and 
self-report QOL measures are underutilized in clinical practice.177  When reporting QOL in 
people with a neurodegenerative disease, maintaining QOL, or even a slight improvement, 
can be meaningful to an individual.  Ratchford et al36 found improvements in the overall 
SF-36 scores, as well as improvements in the physical and mental health subscores in a 
cohort of PWMS.  In addition, Backus et al178 found a significant change in the SF-36 social 
subscale score when utilizing FES cycling in PWMS.  After an aerobic training protocol, 
Rampello et al12 also found significant changes in three MSQOL-54 subscales (emotional 
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well-being, energy, and health distress).   
 In this study, significant changes were found at different time periods on the 
various subscale of MSQOL-54 (appendix R).  Only the FES group showed significant 
changes in their overall QOL subscale and the physical composite subscale, whereas only 
the Cycling Only group had changes in mental health composite.  Changes in the physical 
composite might only have been seen in the FES group, since as a group, they were 
slightly more impaired based on baseline comparisons.  Interestingly, neither group had 
significant changes in the social subscale.  Changes in social function may not have been 
present since changes would have to be large enough to impact an individual’s ability to 
socialize more outside the home.   
 MS fatigue that is centrally driven by the disease itself or by secondary sources of 
fatigue such as sleep disturbances, medication side effects, deconditioning, obesity and 
depression179 can be positively impacted by exercise in PMWS.38,54,73  In the current study, 
both groups experienced significant improvements in their MFIS Total Score and the 
Physical subscale.  It is of great importance that clinicians and researchers continue to 
measure fatigue using standardized scales since it is one of the perceived barriers to 
exercise.  An exercise intervention that decreases the overall feeling of fatigue, without 
increasing fatigue, would be a valued contribution.   
 Additional self-report measures, such as the Activities-specific balance confidence 
(ABC), and Multiple Sclerosis Walking Scale (MSWS-12), in this study did yield favorable 
findings.   Although scores on the scales did improve, demonstrating improved perception 
of balance or walking, neither group reached statistical significance.  This may have been 
due to participants not hitting a threshold where they experienced change in their 
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everyday walking, a lack of specificity of the intervention compared to walking and 
postural control, or the need to train for longer time periods.  
 
Clinical Implications  
Several PWMS who demonstrated changes in performance, indicating that the 
intervention had a meaningful change in their endurance, mobility, functional leg 
strength, and/or quality of life.  Table 5.1 shows changes from pre-to-post training on 
measures that have available data for minimal detectable changes (MDC) in other 
populations.  MDCs assist clinicians in setting goals for patients by identifying the smallest 
change in an outcome that is considered clinically relevant to the patient.180  Eleven out of 
14 participants met the threshold for MDC for one or more measures.  Improvements did 
not appear to follow any specific pattern (e.g. those with greater disability improving 
more), but this warrants further statistical investigation.  
Selecting outcome measures that capture change in function and quality of life are 
critical when justifying the interventions in the clinical setting.  A multidisciplinary panel 
recommended core outcome measures for exercise studies, which include the MFIS (or 
Fatigue Severity Scale), 6MWT, TUG, MSQOL-54 (or the MSIS-29), and body mass 
index.16,161  Based on the results of this study, additional outcomes measures that should 
be considered are the T25FW and 5XSST.  Based on other studies, the TUG may have 
questionable value in detecting change.16,74  The combination of the 5XSST and T25FW 
may offer additional information since sit to stand and walking speed are captured 
separately, and may be a good alternative to the TUG.  Other measures that may be 
considered in the clinic would include the 30 second chair stand, as a replacement for the 
5XSST, or a 10-meter walk test, as a replacement for the T25FW.  The ABC, a self-report 
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balance measure, is not commonly used in research in the MS population181 and will likely 
only show minimal change after a cycling protocol.  The MSQOL-54 and MFIS are valuable 
in assisting clinicians to capture all the facets of MS and the disease progression.177  The 
MFIS provides more specific information regarding fatigue, and 42% of the participants in 
this study reported a significant change (> 19.3%) in their fatigue levels 
Based on the both the overall results and individual results of the participants in 
this study, both FES Cycling and Cycling Only appear to have positive benefits.  
Conclusions regarding recommendations for cycling mode cannot be made based on the 
results of this study.  Due to the safety, aerobic and strength training benefits of this 
exercise, cycling should continue to be included in exercise prescription for PWMS.  
Individuals with more significant disability may also benefit from the use of FES but 
patient selection is likely multifactorial (i.e. motivation, fatigue, dosage) and likely not just 
related to disability level.  Finding an exercise that people will invest in is really the key.  
Both interventions require further investigation, over longer periods of time.  
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Table 5.1 Change in outcomes measures from compared to MDC in other patient populations  
Participant 
 ID 
PDDS 6MWTa 6MWTb  Gait 
Speeda 
(T2FW) 
Gait 
Speedb 
(T2FW) 
TUGa TUGb 5XSSTa 5XSSTb MFIS 
Total  
% change 
Cycling 01 4 89.76* 22.5% -0.16 -10.9% 0.98 13.2% -0.49 5.4% 65%* 
Cycling 02 6 -39.01 -19.3% -0.11 -14.4% 3.92 22.6% 1.36 -8.3% 46%* 
Cycling 03 3 -91.44 -27.1 -0.04 -3.1% 1.5 16.3% -1.18 8.4% 12% 
Cycling 04 4 72.24* 15.5% 0.51* 32.5%* -0.92 -9.5% -3.03* 25.1% -29% 
Cycling 05 3 147.52* 45.7% 0.03 1.9% 0.43 5.5% -0.9 8.2% 75%* 
Cycling 06 3 69.49* 20.8% 0.12* 9.4% -1.5 -15.4% -3.34* 29.4% -13% 
Cycling 07 3 17.68 3.48% -0.01 -0.83% 0.11 1.6% -2.28 28.1% 14% 
FES 01 3 33.83 12.0% 0.06 6.2% -2.72 -20.6% -1.64 15.4% -8% 
FES 02 4 80.77* 14.6% 0.11* 5.7% -0.69 -11.6% -0.95 10.5% 41%* 
FES 03 3 36.88* 10.1% 0.14* 9.7% -1.8 -16.8% -1.87 12.9% 11% 
FES 04 5 3.96 2.75% -0.01 -0.6% -1.87 -7.7% -3.37* 18.6% 51%* 
FES 05 3 -15.24 -3.2% -0.07 -4.0% -0.33 -3.5% -3.4* 21.1% 12% 
FES 06 4 35.66 8.45% 0.02 1.7% -0.63 -6.6% -5.88* 46.2% 6% 
FES 07 4 19.51 7.7% 0.16* 20.0%* -4.32* -23.7%* -2.55* 13.3% 26%* 
MDC           
  Chronic 
Stroke 
= 
36.6m, 
Older 
Adult = 
50m182 
Chronic 
Stroke = 
13% 
change183 
Older 
Adult = 
0.1m/s182 
MS = > 
20% 
change135 
Chronic 
Stroke = 
2.9 sec or 
23% 
change183 
MS = 23-
24% 
change141 
Older 
Adult = 
2.5sec184  
 MS = 19.3% 
change158 
Abbreviations: FES = Functional Electrical Stimulation, 6MWT = 6 Minute Walk Test, T25FW = Times 25-Foot Walk, TUG = Timed up and go, 5XSST =5 
times sit to stand, MFIS = Modified fatigue impact scale 
* Participant change score met MDC 
a = Change in score from post to pre-intervention 
b = percent change
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Recommendations for Future Study 
Design of a future research study should consider a larger sample with a sex 
distribution that is similar to the natural epidemiology of the disease.  A more 
homogeneous sample of individuals based on disability level, especially walking speed 
and distance, may have produced more useful results.  In addition, further research is 
needed across all disability levels for longer time periods in order to draw conclusions 
regarding patient selection, dosage, and long-term outcomes.  Although eight weeks is 
commonly a long enough time period to see training effects, it is likely that a longer 
training period would have shown greater improvements.  Ratchford et al36 found strong 
compliance over a 6 month period of home-based FES cycling.  Future studies in the home 
environment would be beneficial for this population since one of the goals of FES cycling 
for this population is to perform this exercise as part of a healthy lifestyle and not for a 
short training period.  A home-based training program would allow PWMS to train at 
their convenience and consult with a therapist, as needed, if they required guidance 
regarding treatment.   
Continued use of the following outcome measures are recommended: an aerobic 
capacity measurement (6MWT with or without VO2max testing), a gait speed 
measurement (T24FW or 10MWT), functional LE strength measurement (5XSST or 30-
second chair stand), disease-specific QOL scale (MSQOL-54, Multiple Sclerosis Functional 
Composite (MSFC) or Multiple Sclerosis Quality of Life Inventory (MSQLI)) and a fatigue 
measure (MFIS or Fatigue Severity Scale) are recommended.  All participants completed 
the training sessions and tolerated cycling three times per week, and all were able to 
complete the 45-minute interval training session on their first training day.  This was 
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unexpected and was likely due to the short rest intervals provided, the participant’s 
ability to select a comfortable cycling speed (minimum was 45 rpm), and the customized 
training protocol.  All participants were given at least one day of rest in between training 
sessions.  It is unknown if this rest is necessary since other training configurations were 
not explored. 
Four subjects reached 80% of their submaximal test in 4 weeks and likely could 
have progressed further by either challenging them to cycle for longer periods, applying 
greater resistance, or increasing speeds, but continued progression was limited due to 
research protocol.  Two participants who presented at higher disability levels (dependent 
on a walker for ambulation), may have benefited from smaller adjustments in resistance.  
For these individuals, resistance was progressed more slowly over the training period, 
and therefore both individuals did not reach their maximum allowable resistance (80% of 
maximum workload).  Data needs to be further analyzed to examine how many of the 
participants achieved their target heart rate range during the study since not all 
participants achieved their target HR for long enough periods during each training 
session. 
 Voluntary contractions recruit muscle fibers in a specific pattern – small, less 
fatigable motor units (Type I), followed by larger, more fatigable motor units (Type IIa 
and IIb).  In contrast, electrical stimulation recruits muscle fibers in a more non-selective 
and random manner.105,185  The exact mechanism of how FES cycling may specifically 
benefit PWMS is unknown, and more research is warranted in this area.  A possible 
hypothesis is that stimulation helps to strengthen the more fatigable muscle fibers (e.g. 
Type IIa) that may not be used in everyday life, due to either restrictions on mobility or 
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fatigue.    
 There is emerging evidence that FES training can improve oxidative muscle 
metabolism in people with moderate to severe MS,178 but this concept needs to be further 
explored in the mild to moderate population.  Possible future research questions include: 
Would a more intensive cycling protocol carryover over more to walking ability?  Do 
participants need to cycle at higher speeds (i.e. intensities) in order to see changes in 
walking performance and QOL?  Would a combination of cycling and overground training 
produce better walking outcomes? 
 
Study Limitations  
 
The study was limited to a sample of convenience based on location of the research 
lab.  This sample method may have skewed the results to be less representative of the 
variety of PWMS living in the community.  Those who volunteered for this study may have 
been more motivated to improve their health compared to those who did not volunteer.  
Participant attendance was excellent, and possibly due to the stipend participants 
received, which may have let to heightened exercise compliance that may not be 
maintained outside a research environment. 
Due to the small sample size, interpretation of the findings is limited.  The sample 
was not representative of the female to male ratio seen in the general MS population, and 
therefore is not an accurate representation of the population of people living with MS.  
Results can only be generalized to individuals who fit the inclusion/exclusion criteria.  
The PDDS range of 3.0 – 6.0 was chosen to recruit a more homogeneous sample, but there 
was still a large amount of variability among the participants.  This range was selected to 
investigate individuals with mild to moderate disability level and the desire to look at an 
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intensive protocol.  In addition, those with greater disability were more likely to have 
difficulty attending regular sessions outside of their home environment.   
Data collection was limited to certain time periods due to lab space availability and 
the schedule of the PI.  Most participants completed their training during the same time of 
day.  All clinical outcome measure testing was performed during the same time of day.  
The PI collected all the clinical outcome measures and was not blinded to group 
assignment.  In addition, study participants were not blinded to group assignment.  
Activity levels outside of the intervention were not monitored and may have impacted the 
results.  Participants were instructed not to start any new activities and to inform the PI 
regarding any changes in medication.   
The dosage of cycling may not have been intense enough to promote changes in 
the chosen clinical and self-report measures.  Cycling for longer periods, greater than 3 
times per week for 45 minutes, may be indicated for select individuals and warrants 
further investigation.   
Summary 
Exercise is known to be an effective means of maintaining and improving function 
in PWMS.  Finding an exercise regime that is enjoyable, safe, and effective for PWMS is 
critical in prevention of the degenerative effects of the disease, and for maintaining 
overall wellness.  This study is unique in that it addressed the efficacy of FES cycling 
versus Cycling Only for PWMS over an 8-week training period using an intensive 
customized progression protocol.  The results of this pilot study support that exercise in 
the form of FES Cycling or Cycling Only is beneficial and helps to maintain and improve 
aerobic capacity, functional LE strength, and QOL in people with mild to moderate MS.  
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FES is well-tolerated in this population, and the addition of FES to cycling may impact 
muscle strength more than cycling without FES, but further investigation is warranted. 
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Appendix A: Recruitment Flyer and Letter 
 
Research Volunteers Needed 
 
 
People at least 18 years of age with a diagnosis of multiple 
sclerosis are needed to participate in a cycling study.  
Individuals must be ambulatory and have transportation. 
 
Participation involves eight weeks of training on an exercise bike with or 
without electrodes stimulating muscles in both legs.  It also involves 2 
sessions of functional testing that includes walking and other daily activities. 
All session will be supervised by a licensed physical therapist. No significant 
risks are associated with this study.   You may experience benefits consistent 
with exercising on a stationary bike. 
 
Duration: 8 weeks, 3 times per week for 1 ½ hour sessions and 2 testing 
session approximately 2 hours in length. 
Location: Stony Brook University, The RRAMP Lab, Development Drive, 
Building 17, Suite 120, Stony Brook, NY 11794-6018 
 
Compensation: Participants will receive up to $250 for participation in the 
study.  
 
This study has been approved by the IRB at Stony Brook University. 
 
For more information, or if you are interested in participating, please contact 
Lori Hochman, (631)444-1193, lori.hochman@stonybrook.edu  
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Dear Healthcare Practitioner, 
I am writing to tell you about a research study being conducted at Stony Brook University.  I 
am a faculty member in the Doctor of Physical Therapy Program and I am working toward 
completing my PhD through Nova Southeastern University in Ft. Lauderdale, Fl.   This 
research study is being conducted as part of my doctoral dissertation.  This study has been 
approved by the IRB at Stony Brook University and Nova Southeastern University. 
The study involves an exercise-training program using a Functional Electrical Stimulation 
(FES) cycle.  Participants who meet the inclusion/exclusion criteria will train for 3 times per 
week for 8 weeks and will receive either 8 weeks of FES cycling OR 8 weeks of cycling 
without FES.  Participants will not a stipend to participate in the study. 
I am looking for participants who are at least 18 years of age who have a definite 
diagnosis of multiple sclerosis (MS) and whose symptoms interfere with their walking 
ability and who can walk at least 25 feet with or without an assistive device.   
Participants will not be able to take part in the study if they have:  
a. Cognitive deficits that would limit their ability to participate in cycling 
b. Received physical therapy within the last 4 weeks prior to the study  
c. Inadequate range of motion at the hip and knee for cycling 
d. Significant spasticity in the lower extremities that may interfere with the cycling 
motion 
e. Received immunosuppressive or steroid therapy within the past 4 weeks 
f. History of an acute exacerbation of their MS symptoms 4 weeks prior to the study  
g. Coronary artery disease 
h. History of congestive heart failure 
i. Uncontrolled hypertension 
j. History of epilepsy or history of seizures 
k. Cardiac demand pacemaker 
l. Implanted defibrillator 
m. Unhealed fractures in the lower extremities 
n. Pressure sores or open wounds in the area of treatment (buttocks, thighs, shin, and 
calves) 
o. Pregnant or trying to conceive.     
If you know a person who meets the above criteria and is interested in participating, please ask 
them to contact me at lori.hochman@stonybrook.edu or 631-444-1193. 
 
Sincerely, 
Lori Hochman, PT, MS, NCS 
Lori Hochman, PT, MS, NCS 
Clinical Assistant Professor 
Physical Therapy Program 
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Appendix B: Phone Screening Form and PDDS  
 
Phone Screening Form   Today’s date/time: ______________________ 
Person screening: ____________________________ 
Participant Name: ______________________________________________ Age: _________ 
Sex: M   F    Cell #: ___________________  Other #: _____________(Home or Work) 
E-mail (primary): _________________________________(secondary): __________________ 
 
 
1. Do you have a diagnosis of MS? 
 Yes  No 
 
2. Do you utilize an assistive device? 
 Yes  No 
If yes, what device and how often? 
_______________________________________________________________________________________________ 
 
3. Do you have any other neurological pathologies (e.g. stroke, h/o Guillian-
Barre, TBI)? 
 Yes  No 
______________________________________________________________________________ 
 
4. Have you received PT within the last 4 weeks or are you currently receiving 
PT?   
 Yes  No 
If yes, what was the date of your last session? 
_______________________________________________________________________________________________ 
5. Have you had an exacerbation within the last 4 weeks?   
 Yes  No 
If yes, what was the date of your last exacerbation?  Did you receive steroids or other 
medications during this time? 
 
 
6. Do you have a history or currently have of any of the following medical 
issues? 
Congestive Heart Failure:  Yes  No 
Heart Disease:   Yes  No 
High Blood Pressure:  Yes   No 
Epilepsy:  Yes  No 
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Seizures:  Yes  No 
Pacemaker:  Yes  No 
Defibrillator:  Yes  No 
Leg fractures:  Yes  No 
Wounds or sores on legs:   Yes  No 
 
7. Are you pregnant or trying to conceive? (women only) 
 Yes  No 
 
8. Do you have, or have you had any recent musculoskeletal injuries that would 
affect your ability to pedal a seated stationary bicycle? (i.e., muscle strains, 
sprains) 
 
 Yes  No 
If yes, explain the circumstances in which this occurred. 
_______________________________________________________________________________________________ 
 
9. This study will take approximately 8 weeks and attendance is required three 
times per week for approx. 1-11/2 hours.  In addition, there will be three 
sessions for data collection, one at the beginning, one at the end of the 8 
weeks and one-month after training.  Are you able to consistently attend 
sessions? 
 
 Yes  No 
 
 
Initial Visit Scheduled: ___________________________ 
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Patient Determined Disease Steps (PDDS) 
Please read choices listed below and choose the one that best describes your own situation.  
This scale focuses mainly on how well you walk.  You might not find a description that 
reflects your condition exactly, but please mark the one category that describes your situation 
the closest. 
☐ 0 Normal:  I have some mild symptoms, mostly sensory due to MS but they do not limit 
my activity.  If I do have an attack, I return to normal when the attack has passed. 
☐ 1 Mild Disability:  I have some noticeable symptoms from my MS but they are minor 
and have only a small effect on my lifestyle. 
☐ 2 Moderate Disability:  I don’t have any limitations in my walking ability.  However, I 
do have significant problems due to MS that limit daily activities in other ways. 
☐ 3 Gait Disability:  MS does interfere with my activities, especially my walking.  I can 
work a full day, but athletic or physically demanding activities are more difficult that they used 
to be.  I usually don’t need a cane or other assistance to walk, but I might need some assistance 
during an attack. 
☐ 4 Early Cane:  I use a cane or a single crutch or some other form of support (such as 
touching a wall or leaning on someone’s arm) for walking all the time or part of the time, 
especially when walking outside.  I think I can walk 25 feet in 20 seconds without a cane or 
crutch.  I always need some assistance (cane or crutch) if I want to walk as far as 3 blocks.   
☐ 5 Late Cane:  To be able to walk 25 feet, I have to have a cane, crutch or someone to 
hold onto.  I can get around the house or other buildings by holding onto furniture or touching 
the walls for support.  I may use a scooter or wheelchair if I want to go greater distances. 
☐ 6 Bilateral Support:  To be able to walk as far as 25 feet I must have 2 canes or 
crutches or a walker.  I may use a scooter or wheelchair for longer distances. 
☐ 7 Wheelchair/Scooter:  My main form of mobility is a wheelchair.  I may be able to 
stand and/or take one or two steps, but I can’t walk 25 feet, even with crutches or a walker. 
☐ 8 Bedridden:  Unable to sit in a wheelchair for more than one hour. 
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Appendix C: Montreal Cognitive Assessment, Administration and 
Scoring  
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Montreal Cognitive Assessment 
(MoCA) 
Administration and Scoring Instructions 
 
The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild 
cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive 
functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and 
orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 
points; a score of 26 or above is considered normal. 
 
1. Alternating Trail Making: 
 
Administration: The examiner instructs the subject: "Please draw a line, going from a number 
to a letter in ascending order. Begin here [point to (1)] and draw a line from 1 then to A 
then to 2 and so on. End here [point to (E)]." 
 
Scoring: Allocate one point if the subject successfully draws the following pattern: 
1 −A- 2- B- 3- C- 4- D- 5- E, without drawing any lines that cross. Any error that is not 
immediately self-corrected earns a score of 0. 
 
2. Visuoconstructional Skills (Cube): 
 
Administration: The examiner gives the following instructions, pointing to the cube: “Copy this 
drawing as accurately as you can, in the space below”. 
 
Scoring: One point is allocated for a correctly executed drawing. 
• Drawing must be three-dimensional 
• All lines are drawn 
• No line is added 
• Lines are relatively parallel and their length is similar (rectangular prisms are accepted) 
A point is not assigned if any of the above-criteria are not met. 
 
3. Visuoconstructional Skills (Clock): 
 
Administration: Indicate the right third of the space and give the following instructions: “Draw 
a clock. Put in all the numbers and set the time to 10 past 11”. 
 
Scoring: One point is allocated for each of the following three criteria: 
• Contour (1 pt.): the clock face must be a circle with only minor distortion acceptable (e.g., 
slight imperfection on closing the circle); 
• Numbers (1 pt.): all clock numbers must be present with no additional numbers; numbers 
must be in the correct order and placed in the approximate quadrants on the clock face; Roman 
numerals are acceptable; numbers can be placed outside the circle contour; 
• Hands (1 pt.): there must be two hands jointly indicating the correct time; the hour hand must 
be clearly shorter than the minute hand; hands must be centered within the clock face with their 
junction close to the clock center. 
A point is not assigned for a given element if any of the above-criteria are not met. 
 
4. Naming: 
 
Administration: Beginning on the left, point to each figure and say: “Tell me the name of this 
animal”. 
Scoring: One point each is given for the following responses: (1) lion (2) rhinoceros or rhino 
(3) camel or dromedary. 
 
5. Memory: 
 
Administration: The examiner reads a list of 5 words at a rate of one per second, giving the 
following instructions: “This is a memory test. I am going to read a list of words that you 
will have to remember now and later on. Listen carefully. When I am through, tell me 
as many words as you can remember. It doesn’t matter in what order you say them”. 
Mark a check in the allocated space for each word the subject produces on this first trial. When 
the subject indicates that (s)he has finished (has recalled all words), or can recall no more 
words, read the list a second time with the following instructions: “I am going to read the same 
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list for a second time. Try to remember and tell me as many words as you can, including words 
you said the first time.” Put a check in the allocated space for each word the subject recalls 
after the second trial. 
At the end of the second trial, inform the subject that (s)he will be asked to recall these words 
again by saying, “I will ask you to recall those words again at the end of the test.” 
 
Scoring: No points are given for Trials One and Two. 
 
6. Attention: 
 
Forward Digit Span:  
 
Administration: Give the following instruction: “I am going to say some 
numbers and when I am through, repeat them to me exactly as I said them”. Read the five 
number sequence at a rate of one digit per second. 
Backward Digit Span: Administration: Give the following instruction: “Now I am going to say 
some more numbers, but when I am through you must repeat them to me in the backwards 
order.” Read the three number sequence at a rate of one digit per second. 
 
Scoring: Allocate one point for each sequence correctly repeated, (N.B.: the correct response for 
the backwards trial is 2-4-7). 
 
Vigilance:  
Administration: The examiner reads the list of letters at a rate of one per second, 
after giving the following instruction: “I am going to read a sequence of letters. Every time I 
say the letter A, tap your hand once. If I say a different letter, do not tap your hand”. 
 
Scoring: Give one point if there is zero to one errors (an error is a tap on a wrong letter or a 
failure to tap on letter A). 
 
Serial 7s:  
Administration: The examiner gives the following instruction: “Now, I will ask you to 
count by subtracting seven from 100, and then, keep subtracting seven from your answer until I 
tell you to stop.” Give this instruction twice if necessary. 
 
Scoring: This item is scored out of 3 points. Give no (0) points for no correct subtractions, 1 
point for one correction subtraction, 2 points for two-to-three correct subtractions, and 3 points 
if the participant successfully makes four or five correct subtractions. Count each correct 
subtraction of 7 beginning at 100. Each subtraction is evaluated independently; that is, if the 
participant responds with an incorrect number but continues to correctly subtract 7 from it, give 
a point for each correct subtraction. For example, a participant may respond “92 – 85 – 78 – 71 
– 64” where the “92” is incorrect, but all subsequent numbers are subtracted correctly. This is 
one error and the item would be given a score of 3. 
 
7. Sentence repetition: 
 
Administration: The examiner gives the following instructions: “I am going to read you a 
sentence. Repeat it after me, exactly as I say it [pause]: I only know that John is the one to 
help today.” Following the response, say: “Now I am going to read you another sentence. 
Repeat it after me, exactly as I say it [pause]: The cat always hid under the couch when dogs 
were in the room.” 
 
Scoring: Allocate 1 point for each sentence correctly repeated. Repetition must be exact. Be 
alert for errors that are omissions (e.g., omitting "only", "always") and substitutions/additions 
(e.g., "John is the one who helped today;" substituting "hides" for "hid", altering plurals, etc.). 
 
8. Verbal fluency: 
 
Administration: The examiner gives the following instruction: “Tell me as many words as you 
can think of that begin with a certain letter of the alphabet that I will tell you in a moment. You 
can say any kind of word you want, except for proper nouns (like Bob or Boston), numbers, or 
words that begin with the same sound but have a different suffix, for example, love, lover, 
loving. I will tell you to stop after one minute. Are you ready? [Pause] Now, tell me as many 
words as you can think of that begin with the letter F. [time for 60 sec]. Stop.” 
 
Scoring: Allocate one point if the subject generates 11 words or more in 60 sec. Record the 
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subject’s response in the bottom or side margins. 
 
9. Abstraction: 
 
Administration: The examiner asks the subject to explain what each pair of words has in 
common, starting with the example: “Tell me how an orange and a banana are alike”. If the 
subject answers in a concrete manner, then say only one additional time: “Tell me another way 
in which those items are alike”. If the subject does not give the appropriate response (fruit), 
say, “Yes, and they are also both fruit.” Do not give any additional instructions or clarification. 
After the practice trial, say: “Now, tell me how a train and a bicycle are alike”. Following the 
response, administer the second trial, saying: “Now tell me how a ruler and a watch are alike”. 
Do not give any additional instructions or prompts. 
 
Scoring: Only the last two item pairs are scored. Give 1 point to each item pair correctly 
answered. The following responses are acceptable: 
Train-bicycle = means of transportation, means of travelling, you take trips in both; 
Ruler-watch = measuring instruments, used to measure. 
The following responses are not acceptable: Train-bicycle = they have wheels; Rulerwatch 
= they have numbers. 
 
10. Delayed recall: 
 
Administration: The examiner gives the following instruction: “I read some words to you 
earlier, which I asked you to remember. Tell me as many of those words as you can 
remember.” Make a check mark ( √ ) for each of the words correctly recalled spontaneously 
without any cues, in the allocated space. 
 
Scoring: Allocate 1 point for each word recalled freely without any cues. 
 
Optional: Following the delayed free recall trial, prompt the subject with the semantic category cue 
provided below for any word not recalled. Make a check mark ( √ ) in the allocated space if the 
subject remembered the word with the help of a category or multiple-choice cue. Prompt all 
non-recalled words in this manner. If the subject does not recall the word after the category cue, 
give him/her a multiple choice trial, using the following example instruction, “Which of the 
following words do you think it was, NOSE, FACE, or HAND?” 
Use the following category and/or multiple-choice cues for each word, when appropriate: 
FACE: category cue: part of the body multiple choice: nose, face, hand 
VELVET: category cue: type of fabric multiple choice: denim, cotton, velvet 
CHURCH: category cue: type of building multiple choice: church, school, hospital 
DAISY: category cue: type of flower multiple choice: rose, daisy, tulip 
RED: category cue: a colour multiple choice: red, blue, green 
Scoring: No points are allocated for words recalled with a cue. A cue is used for clinical 
information purposes only and can give the test interpreter additional information about the 
type of memory disorder. For memory deficits due to retrieval failures, performance can be 
improved with a cue. For memory deficits due to encoding failures, performance does not 
improve with a cue. 
 
11. Orientation: 
 
Administration: The examiner gives the following instructions: “Tell me the date today”. If the 
subject does not give a complete answer, then prompt accordingly by saying: “Tell me the 
[year, month, exact date, and day of the week].” Then say: “Now, tell me the name of this 
place, and which city it is in.” 
 
Scoring: Give one point for each item correctly answered. The subject must tell the exact date 
and the exact place (name of hospital, clinic, office). No points are allocated if subject makes 
an error of one day for the day and date. 
 
TOTAL SCORE: Sum all subscores listed on the right-hand side. Add one point for an 
individual who has 12 years or fewer of formal education, for a possible maximum of 30 points. 
A final total score of 26 and above is considered normal. 
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Appendix D: Demographic and Medical Questionnaire 
Participant ID#: ____________________________ 
PERSONAL INFORMATION: 
Name:   ______________________________________________________________________________________  
Address: ______________________________________________________________________________________ 
  
Contact phone numbers: Home:  _________________________________ 
Cell phone:  ____________________________________ 
Preferred method of communication:  ☐Home  ☐Cell  ☐Text Message ☐Email 
  
Family Physician and/or Primary Health Care Provider: 
Doctor/Other _________________________________  Phone  ____________________________________  
Address  _______________________________________  City  ______________________________________  
 
Neurologist: 
Name  ________________________________ Phone  ____________________________________________ 
Address  _______________________________________  City  ______________________________________  
 
DEMOGRAPHICS: 
Age: ______      
Date of Birth:  ___________________________ 
Gender:  ☐Male,     ☐Female 
Marital Status:  ☐Married  ☐Single  ☐Divorced  ☐Widowed 
Education: 
☐Grade School     ☐Jr. High School   ☐High School   
☐College (2-4 years)   ☐Graduate School  
Occupation: ___________________________________________________________________ 
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MS DIAGNOSIS: 
Date of first diagnosis: _________________ 
Age when first symptoms of MS occurred: ______________ 
Do you know which category you currently fit in? 
☐Relapsing Remitting 
☐Secondary Progressive 
☐Primary Progressive 
☐Progressive Relapsing 
MEDICATIONS: 
Currently Prescribed Medications (include name, dosage, and frequency) 
Name  Dosage Frequency 
   
   
   
   
   
   
   
   
   
   
List any self-prescribed medications, dietary supplements, or vitamins you are now 
taking: _______________________________________________________________________________________________  
 _______________________________________________________________________________________________________  
 _______________________________________________________________________________________________________  
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Are you currently on any of the disease modifying drugs?  (Copaxone, Rebif, Avonex, 
Betaseron)? 
If yes, which ones: 
____________________________________________________________________________ 
If not, have you ever been and which ones?  
____________________________________________________________________________ 
SYMPTOM INFORMATION:   
When was your last exacerbation? 
______________________________________________________ 
How many exacerbations have you had? 
_______________________________________________ 
How often do they occur? 
_________________________________________________________________ 
Which of the following MS symptoms have you experienced? 
☐Fatigue ☐Depression 
☐Numbness/Tingling  ☐Cognitive Problems 
☐Pain ☐Balance Problems 
☐Visual Problems ☐Coordination Problems 
☐Muscle Spasms/Spasticity ☐Gait Problems 
☐Bladder Problems  ☐Dizziness 
☐Bowel Problems ☐Tremors 
☐Sexual Dysfunction ☐Slurred Speech 
☐Weakness ☐Heat Sensitivity 
Other symptoms: 
____________________________________________________________________________ 
 
Have you received Physical Therapy within the last 4 weeks?  
☐ Yes, date of last session was: _____________________ 
☐ No 
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Present Medical History: 
Check those questions to which your answer is yes (leave others blank). 
 High Blood Pressure 
 Heart attack, if so, how many years ago? ________ 
 Rheumatic Fever 
 Heart murmur 
 Congestive Heart Failure 
 Diseases of the arteries 
 Varicose veins 
 Arthritis of legs or arms 
 Diabetes or abnormal blood-sugar tests 
 Phlebitis (inflammation of a vein) 
 Dizziness or fainting spells 
 Epilepsy or seizures 
 Stroke 
 Diphtheria 
 Scarlet Fever 
 Infectious mononucleosis 
 Nervous or emotional problems 
 Anemia 
 Thyroid problems 
 Pneumonia 
 Bronchitis 
 Asthma  
 Abnormal chest X-ray 
 Other lung disease 
 Injuries to back, arms, legs or joint 
 Broken bones 
 Jaundice or gall bladder problems 
Comments:  ___________________________________________________________________  
_____________________________________________________________________________  
_____________________________________________________________________________  
_____________________________________________________________________________  
Do you have a cardiac pacemaker or defibrillator? _______________________________________  
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Check the box next to ☐YES or ☐NO for each question. 
Has a doctor ever said your blood pressure was too high?  ☐YES,  ☐NO 
Do you ever have pain in your chest or heart?  ☐YES,  ☐NO 
Are you often bothered by a thumping of the heart? ☐YES,  ☐NO 
Does your heart often race?  ☐YES,  ☐NO 
Do you ever notice extra heartbeats or skipped beats?  ☐YES,  ☐NO 
Are your ankles often badly swollen?  ☐YES,  ☐NO 
Do cold hands or feet trouble you even in hot weather?  ☐YES,  ☐NO 
Has a doctor ever said that you have or have had heart trouble, an abnormal 
electrocardiogram (ECG or EKG), heart attack or coronary?  ☐YES,  ☐NO 
Do you suffer from frequent cramps in your legs?  ☐YES,  ☐NO 
Do you often have difficulty breathing?  ☐YES,  ☐NO 
Do you sometimes get out of breath when sitting still or sleeping?  ☐YES,  ☐NO 
Has a doctor ever told you your cholesterol level was high?  ☐YES,  ☐NO 
Comments:  _________________________________________________________________________________________  
 _______________________________________________________________________________________________________  
 
Do you now have or have you recently experienced: 
 Chronic, recurrent or morning cough? 
 Episode of coughing up blood? 
 Increased anxiety or depression? 
 Problems with recurrent fatigue, trouble sleeping or increased irritability? 
 Migraine or recurrent headaches? 
 Stiff or painful joints? 
 Pain in your legs after walking short distances? 
 Foot problems? 
 Back problems? 
 Stomach or intestinal problems, such as recurrent heartburn, ulcers, 
constipation or diarrhea? 
 Significant vision or hearing problems? 
 Significant unexplained weight loss? 
 A deep vein thrombosis (blood clot)? 
 A hernia that is causing symptoms? 
 Foot or ankle sores that won’t heal? 
 Persistent pain or problems walking after you have fallen? 
Comments:  _________________________________________________________________________________________  
 _______________________________________________________________________________________________________  
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Women only, please answer the following. Do you have: 
 Menstrual period problems? 
 Significant childbirth - related problems? 
 Urine loss when you cough, sneeze or laugh? 
 
List any other medical or diagnostic test you have had in the past two years:  _______________  
 _______________________________________________________________________________________________________  
 
List hospitalizations, including dates of and reasons for hospitalization: _____________________  
 _______________________________________________________________________________________________________  
 
List any drug allergies: _____________________________________________________________________________  
 _______________________________________________________________________________________________________  
 
Familial Diseases 
Do you have any biological relatives with the diagnosis of MS?  How are they related to you? 
____________________________________________________________________________ 
____________________________________________________________________________ 
 
If there is any other information you would like to share with us, please let us know.  Signing 
this indicated the information you have given is accurate by your account. 
 
Print Name:  ____________________________________ 
Signature: ______________________________________ 
Date: ___________________ 
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Appendix E: Physical Assessment 
Participant ID#: ____________________________ 
Evaluation 
Strength and Range of Motion Assessment: 
 Hip 
Flex. 
Hip 
Abd 
Hip 
Extension 
Knee 
Flex. 
Knee 
Extension 
Ankle 
DF 
Right 
LE 
      
PROM       
AROM       
Strength /5 /5 /5 /5 /5 /5 
Left LE       
PROM       
AROM       
Strength /5 /5 /5 /5 /5 /5 
KEY:  AROM= Active Range of Motion, PROM= Passive Range of Motion, Flex= flexion, / = 
Extension, WNL= Within Normal Limits, WFL= Within Functional Limits. 
Comments:  __________________________________________________________________ 
 
Does the subject have adequate him, knee, and ankle ROM for cycling? 
☐Yes ☐No  
 
Sensation:  
 Light Touch Proprioception 
Right Leg ☐Impaired  ☐Intact  ☐Absent ☐Impaired  ☐Intact  ☐Absent 
Left Leg ☐Impaired  ☐Intact  ☐Absent ☐Impaired  ☐Intact  ☐Absent 
Comments: 
____________________________________________________________________ 
 
 
Muscle Tone:   
Ankle Clonus: ☐Absent ☐Present R/L ☐Sustained ☐ Un-sustained: ___ beats       
 Right Left 
Lower 
Extremity 
☐Normal  ☐Hypertonic ☐Rigid  
☐Hypotonic  ☐Flaccid ☐Mixed  
☐Normal  ☐Hypertonic ☐Rigid  
☐Hypotonic  ☐Flaccid ☐Mixed   
Upper 
Extremity 
☐Normal  ☐Hypertonic ☐Rigid  
☐Hypotonic  ☐Flaccid ☐Mixed  
☐Normal  ☐Hypertonic ☐Rigid  
☐Hypotonic  ☐Flaccid ☐Mixed  
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Balance: 
Sitting  
Supported ☐Stable  ☐Requires Assistance 
_____________________________________ 
Unsupported ☐Stable  ☐Requires Assistance 
_____________________________________ 
Dynamic ☐Stable  ☐Requires Assistance 
_____________________________________ 
 
Standing  
Supported ☐Stable  ☐Requires Assistance 
_____________________________________ 
Unsupported ☐Stable  ☐Requires Assistance 
_____________________________________ 
Dynamic ☐Stable  ☐Requires Assistance 
_____________________________________ 
 
Cardiopulmonary Status: 
Vitals HR BP Oxygen 
Saturation 
RPE Comments 
Resting      
After gait 
evaluation 
     
 
Circulation:  Edema? ☐Yes  ☐No, Location: ______________________________________ 
Additional Information: ________________________________________________________ 
 
Functional Mobility: KEY:  Levels of Assistance   Total A = Total Assistance, Max 
Maximal Assist,  Mod A =  Moderate Assistance, Min A = Minimal Assistance, CG = 
Contact Guard,  CS = Close Supervision, S = Supervision,  
DS = Distant Supervision, Modified I = Modified Independent. I =Independent.  
Devices WBQC = Wide Base Quad Cane, NBQC = Narrow Base Quad Cane, HC = 
Hemicane, SAC = Single Axis Cane 
 
Bed Mobility and Transfers: 
Activity Level of Assistance 
Overall bed 
mobility 
 
Sit Stand  
Stand  Sit  
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Ambulation  
Device  
Distance  
Level of Assistance  
Gait Quality  
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Committees on Research Involving Human Subjects 
Established 1971 
RESEARCH CONSENT FORM 
 
Project Title: Effects of Functional Electrical Stimulation Cycling versus Cycling Only on 
Walking Performance and Quality of Life in Individuals with Multiple Sclerosis: A Pilot 
Study 
 
Principal Investigator:  Lori Hochman, PT, MS, NCS, Clinical Assistant Professor 
Co-Investigators:   Lisa Muratori, PT, PhD, Clinical Associate Professor 
Department:  Department of Physical Therapy 
You are being asked to be a volunteer in a research study.  
PURPOSE  
The purpose of this study is:  
 To study the effects of cycling with and without the use of electrical stimulation to 
the leg muscles on walking performance and quality of life in people with multiple 
sclerosis. 
 20 individuals will be enrolled in the study and will be randomly assigned to one of 
the two treatment groups. 
PROCEDURES  
If you decide to be in this study, your part will involve: 
 You will begin with filling out questionnaires about your medical history and your 
ability to perform daily activities. 
 You will then undergo a brief exam that will test your muscle strength, sensation, 
and movement. 
 You will be randomly assigned to one of the treatment groups (cycling with 
electrical stimulation or cycling without stimulation). 
 
Appendix F: Research Consent Form 
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Procedures for FES cycling group: 
 Functional Electrical Stimulation (FES) passes a very low level of electrical current 
through peripheral nerves to stimulate muscles to contract.  FES cycling creates a 
rhythmical lower leg cycling pattern.   
 Five muscle groups will be stimulated during every session (buttocks, front of the 
thigh, back of the thigh, front of the lower leg, back of the lower leg).  Stimulation 
will be adjusted to ensure comfort during cycling. 
 You will be seated in an armchair during all intervention sessions. 
 You will be permitted to take a break or stop cycling during intervention sessions. 
Procedures for Cycling only group: 
 If you are in the cycling-only group you will not receive electrical stimulation. 
 You will be seated in an armchair during all intervention sessions. 
 You will be permitted to take a break or stop cycling during intervention sessions. 
Participation Requirements for both groups: 
Visit # Session Summary Time  
1 Screening (questionnaires) and Baseline 
testing (walking performance and functional 
leg strength measures) 
2 hours 
2-12 Cycling intervention 1.5 hour each 
13 Outcome measure testing (walking 
performance and functional leg strength 
measures) followed by a cycling intervention 
session 
2.5 hours 
14-25 Cycling intervention 1.5 hour 
26 Outcome Measure Testing (walking 
performance and functional leg strength) 
1 hour 
27 Post-intervention outcome measures (one 
month after visit #25) 
1 hour 
  Total Time:  41 hours 
 Participation involves 8-10 consecutive weeks of training. Cycling interventions 
(visit 2-25) must be scheduled with at least one day in between (e.g. Monday, 
Wednesday, Friday).  Sessions may take place on the weekend 
 With your permission, we may videotape you during the cycling or outcome 
testing sessions. 
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RISKS / DISCOMFORTS 
The following risks/discomforts may occur as a result of you being in this study: 
If you are randomly selected to be in the FES cycling training group: 
 You will feel a prickling sensation under the electrodes and most people tolerate 
this well.  The setting of the stimulation will be increased according to a protocol 
and adjusted for comfort.  
 You may also experience your muscles tensing up and relaxing while you are 
cycling.  This is a normal reaction to electrical stimulation. 
 You may have red areas on your skin after the electrical stimulation treatment. The 
red area would be under the electrodes where the current was being delivered. 
This red area should disappear after 15 minutes. Your skin will be monitored 
throughout the study.  
 You may experience fatigue from exercise and this will be monitored throughout 
the study.  This is a temporary exercise induced fatigue rather than the central 
fatigue that you may experience as part of MS. 
 You may experience a temporary increase in leg spasms after using the cycle. 
If you are randomly selected to be in the cycling only training group: 
 You may experience fatigue from exercise and this will be monitored throughout 
the study.  This is a temporary exercise induced fatigue rather than the central 
fatigue that you may experience as part of MS. 
 You may experience an increase in leg spasms after using the cycle. 
BENEFITS  
There is no direct benefit expected as a result of you being in this study.  You may 
experience benefit similar to exercising on a bike three days per week. 
PAYMENT TO YOU   
You will be paid a total of $250.00 for this study.   
The payment schedule is as follows: 
Timeline Payment 
After week 2 $55 
After week 4 $55 
After week 6 $55 
After week 8 $55 
After week 12 $30 
Total: $250 
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PAYMENT TO THE INSTITUTION  
This project is funded, in part, by a grant from the New York Physical Therapy Association, to 
the Research Foundation of Stony Brook University, in support of the Investigators' work on 
this study.   
CONFIDENTIALITY   
Protecting Your Privacy in this Study 
All information obtained in this study is strictly confidential unless disclosure is required 
by law.  We will take steps to help make sure that all the information we get about you is 
kept private. Your name will not be used wherever possible. We will use a code instead. 
All the study data that we get from you will be kept locked up for a period of at least three 
(3) years. The code will be locked up too. If any papers and talks are given about this 
research, your name will not be used and your face will not be visible on video.  All video 
recordings will also be kept locked up and stored in the Rehabilitation Research and 
Movement Performance (RRAMP) Laboratory. 
We want to make sure that this study is being done correctly and that your rights and 
welfare are being protected. For this reason, we will share the data we get from you in 
this study with the study team, the sponsor of this study (New York Physical Therapy 
Association), Stony Brook University's Committee on Research Involving Human Subjects, 
applicable Institutional officials, and certain federal offices. However, if you tell us you are 
going to hurt yourself, hurt someone else, or if we believe the safety of a child is at risk, 
we will have to report this.  
In a lawsuit, a judge can make us give him the information we collected about you.  
While you are in this study you will need to provide us with data about your health. We 
will also get health data from the results of the tests you will have done in this study. You 
have a right to privacy but the data we get about your health in this study can be shared 
with the people referenced above (the study team, Stony Brook University's Committee 
on Research Involving Human Subjects, applicable institutional officials, and certain 
federal offices).  
Your health data are shared to make sure the study is being done correctly, costs are 
charged correctly, and to make sure your rights and safety are protected. Not all of these 
people are required by law to protect your health data. They might share it with others 
without your permission.  
Some of the health information we get from you in this study cannot be shared with you 
until the end of the study.  
You have the right to stop allowing us to use or give out your health data. You can do this 
at any time by writing to Lori Hochman. If you do this, we will stop collecting any new 
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health data from you, except if we need to keep an eye on a bad side effect you were 
having in the study. We will use any data we collected before you wrote your letter. When 
you sign the consent form at the end, it means:  
 That you have read this section.  
 That you will allow the use and reporting of your health data as described above.  
 If you are paid $600 or more a year as a research subject, your social security number 
will be reported to those in charge of taxes. You may have to pay taxes on this money. 
Clinical Trial Registry  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law.  This Web site will not include information that can identify you.  At 
most, the Web site will include a summary of the results.  You can search this Web site at 
any time. 
COSTS TO YOU   
 You are responsible for transportation to and from the research lab. 
ALTERNATIVES  
 Your alternative to being in this study is to simply not participate. 
IN CASE OF INJURY  
If you are injured as a result of being in this study, please contact Lori Hochman, PT at 
631-444-1193.  The services of Stony Brook University Hospital will be open to you in 
case of such injury.  However, you and/or your insurance company will be responsible for 
payment of any resulting treatment and/or hospital stay. 
REMOVAL FROM STUDY  
 You will be removed from the study if you fail to attend scheduled training 
sessions within the allotted time period. 
 You will be removed from the study if you experience a worsening of symptoms. 
 You will be removed from the study if you report that you are pregnant or trying to 
conceive. 
YOUR RIGHTS AS A RESEARCH SUBJECT   
 Your participation in this study is voluntary. You do not have to be in this study if 
you don't want to be. 
 You have the right to change your mind and leave the study at any time without 
giving any reason, and without penalty. 
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 Any new information that may make you change your mind about being in this study 
will be given to you. 
 You will get a signed and dated copy of this consent form to keep. 
 You do not lose any of your legal rights by signing this consent form. 
Video Recording 
 This research project may include video recording during any outcome measure 
testing or cycling sessions for periods of minute or less. This video recording will 
be available to be seen by the researcher, Stony Brook University Committee on 
Research Involving Human Subjects, any granting agencies, my dissertation 
committee, physical therapists and physical therapy students.  If this video is used 
in papers or talks, we will make sure your face is not visible.  Video will be 
recorded on a password protected mobile device and then transferred to a 
password protected computer.  Video will then be deleted from the mobile device.  
You can request not to be videotaped and this will not affect your eligibility or 
participation in the study. 
☐   I give permission to be video recorded.  Initials:  ______ Date:  ______ 
☐   I do not give permission to be video recorded.  Initials:  ______ Date:  ______ 
QUESTIONS ABOUT THE STUDY OR YOUR RIGHTS AS A RESEARCH SUBJECT    
 If you have any questions, concerns, or complaints about the study, you may contact 
[Lori Hochman, Investigator], at telephone # (631-444-1193). 
 If you have any questions about your rights as a research subject or if you would like to 
obtain information or offer input, you may contact Ms. Judy Matuk, Committee on 
Research Involving Human Subjects, (631) 632-9036, OR by e-mail, 
judy.matuk@stonybrook.edu.  
 Visit Stony Brook University’s Community Outreach page, 
http://www.stonybrook.edu/research/orc/community.shtml for more information about 
participating in research, frequently asked questions, and an opportunity to provide 
feedback, comments, or ask questions related to your experience as a research subject. 
If you sign below, it means that you have read (or have had read to you) the information 
given in this consent form, and you would like to be a volunteer in this study.  
 
 
____________________________________________________________________________ 
Subject Name (Printed)                    Subject Signature                                            Date 
 
 
Name of Person Obtaining Consent                Signature of Person Obtaining Consent         Date 
(Printed)      
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Appendix G: Procedure Manual 
 
 
 
 
 
 
 
 
 
 
 
Effects of Functional Electrical Stimulation Cycling 
versus Cycling Only on Walking Performance and 
Quality of Life in Individuals with Multiple Sclerosis:  A 
Randomized, Clinical Pilot Study 
 
 
Lori Hochman, PT, MS, NCS, PhD(c) 
 
 
  
 
PROCEDURE MANUAL 
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Procedures 
 
A. Phone Screening 
1. Potential participants will undergo a phone screening prior to their initial 
visit to see if they meet all the inclusion/exclusion criteria (Phone Screening 
and PPDS). 
2. If they meet the initial criteria they will be asked to set-up an appointment 
to meet with the primary investigator at the RRAMP LAB for a 2-hour 
session. 
3. Sent participants directions and tell them to wear comfortable shoes and a 
loose pair of shorts with an elastic waistband. 
 
B. First Meeting/Baseline Session Overview 
1. Administer MoCA (must score 22 or greater) 
2. Participant completes the PDDS again (must score between 3.0 and 6.0) 
3. Participant completes Demographic/History Form (PI reviews form for 
eligibility) 
4. Review consent forms and give the participant an opportunity to bring it 
home if they would like.  They can also choose to sign on the spot and 
continue with baseline measurements during this meeting. 
5. If they sign consent during this first visit, they will then be randomized into 
either the FES Cycling group or the Cycling Only group before all evaluation 
and testing begins.  Blocked randomization will be used, and 4 papers were 
put in a hat where 2 choices are FES and 2 are Cycling only.  After the first 4 
participants select all 4 choices will be returned to the hat.  This will help 
ensure even groups by the end of the pilot study.   
6. PI performs physical examination and completes examination form 
7. Objective baseline measures will be obtained in the following order:  6MWT, 
T25W(2 trials), TUG, 5XSST. 
8. Sub-Maximal Exercise Test on the cycle 
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9. FES group: Electrode set-up and baseline stimulation levels will be 
obtained; Cycling only group- no set-up during this meeting 
10. Set-up training schedule 
11. Subjective outcome measures (GLTQ, MFIS, MSQOL-54, 12 Item MSWS, 
ABC) will be given to participants at the end of the baseline session and 
they can either stay and fill them out in the lab or bring them home and 
bring them back completed before their first training session. 
Outcome Measures 
Selected outcome measures will be performed at the follow intervals (see table)  
 baseline- within one-week prior to the first training session;  
 mid-point of training- between 1-3 days after the 12th training session; 
 post-training- between 1-3 days after the 24th training session, and  
 one-month after the last training session. 
Physical tests were administered in the following order for each participant 
1. 6MWT* 
2. T25W* 
3. TUG* 
4. 5STS (no GWALK) 
*BTS G-Walk worn during measurement 
 
Participants will be provided at least a five-minute rest period between all physical 
tests.  Safety precautions during testing will include: a quiet area free of distractions, gait 
belt, guarding and assistance as needed.  
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Outcome Measure Collection of Data 
Godin Leisure-Time Exercise Questionnaire (GLTEQ) 
 
 Baseline 
12 Item Multiple Sclerosis Walking Scale (MSWS-12)  Baseline 
 Post-training 
 1 month after training 
Modified Fatigue Impact Scale (MFIS)  Baseline 
 Post-training 
 1 month after training 
Multiple Sclerosis Quality of Life Inventory (MSQOL 
54) 
 Baseline 
 Post-training 
 1 month after training 
Activities Specific Balance Scale (ABC)  Baseline 
 Post-training 
 1 month after training 
Timed Up and Go (TUG)  Baseline 
 Mid-point  
 Post-training 
 1 month after training 
Five Times Sit-to-Stand (5STS)  Baseline 
 Mid-point 
 Post-training 
 1 month after training 
6 Minute Walk (6MWT)  Baseline 
 Mid-point  
 Post-training 
 1 month after training 
Gait Speed 
Time 25-Foot Walk (T25FW) 
 
 Baseline 
 Mid-point  
 Post-training 
 1 month after training 
 
BTS G-WALK SET-UP 
Laptop 
1. Double click on G-Studio Icon and allow it to open 
G-Walk Sensor 
 Make sure Bluetooth is enabled by clicking the Bluetooth Icon under the “Sensor 
Management”  
 Make sure G-Walk sensor is charged (hover over battery icon to check %).  If not 
charged, plug USB into computer and wire into the sensor. 
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Database Selection 
1. Click “Database Management” tab at top 
2. Click on icon that has the yellow folder (looks like a hard drive with a yellow folder on 
top on it).  If you hover over it, it says “Select Database” 
3. Select “FES Cycling” and click ok 
4. You will see collect patients on the left 
Software Set-up for a New Patient 
1. Click on the New Patient Icon on the far left (Blue plus sign) 
2. Under “Personal Data” tab- fill in the following fields 
 Surname/Last Name: “FES Cycling” or “Cycling” depending on group 
 First Name: 01, 02, 03 
 Weight- lbs. 
 Height-ft./inches 
 Gender:  
 Shoe size- US sizes (e.g. 7.5) 
 Leg Length 
3. Under “Anthropometrics” tab-  Enter height in inches of Greater trochanter to lateral 
malleolus of both the right and left legs 
4. Click “Save” at the bottom of the screen 
Set-up for Collection  
1. Click on that patient (e.g. Cycling 01) on the left side and that will open their folder 
and you will see all of their data in the middle panel if they are a continuing patient.  If 
they are new, it will be empty. 
2. To start collection, click the “Walk” icon on the left when doing the 6MW.  Before 
saving, record type 6 MWT= ___________ft. 
3. For T25 W, click the “Walk” icon on the left when doing the T25W.  Before saving, type 
“T25FW= _____________seconds.”  Do two trials. 
4. For the TUG, click on the “Timed Up and Go Icon”.  Before saving, type, TUG= ________ 
seconds. 
5. Do a Five Times Sit to stand but do not use the G-Walk for this, just a stopwatch.  
Placement of Sensor 
1. Place the sensor in the pouch.  The port goes to the sky and serial # goes to the 
back on bare skin. 
2. Belt goes at L5.  Tighten belt so sensor does not move. 
Data Collection 
1. Click arrow next to START ON-LINE (to check if it is working).  You should see 6 
lines going across the screen. 
2.  Then click STOP STORAGE 
3. When ready, click START ON-LINE again “START STORAGE” when you are ready to 
collect. 
4. It will say “Waiting for Stabilization” 
5. Then press “Stop Storage” when done collecting. 
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6. Then at the bottom of the screen click “(OK) Save” 
7. Put notes in analysis screen.  (e.g. 6MW- 2250 feet, 25FW- 5 seconds, TUG- 6 
seconds) 
TEST 1: 6MWT 
 
Set-up: The testing will be an area of 40-foot straight walkway that will include 90 turns 
at each end.  
 
 
 
 
 
 
 
 
 
 
 
The area has purple tape markers at the corners to mark the turn points.  The total 
distance of the walking area is 104 feet.  Laps will be counted and the distance after the 
start line will be measured with a measuring wheel after the test is complete. 
Equipment:  
 gait belt 
 stop watch 
 pulse oximeter 
 rate of perceived exertion scale 
 a chair that can be easily moved along the walking course 
 sphygmomanometer 
40 feet 
12 feet 
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Participant Instructions:  
“The object of this test is to walk as far and as fast as possible for 6 minutes with 
consideration for safety while you are walking.  You will around the rectangle and turn at 
each corner.  Six minutes is a long time to walk, so you will be exerting yourself.  You 
should turn at each end corner of the rectangle and continue along the pathway.  Now I’m 
going to show you.” 
(Investigator demonstrates) 
“Are you ready to do that?  I am going to use this stopwatch and this clipboard to keep 
track of time and the number of laps you complete.  I will notify you of your time at 2 
minutes and every minute after that.  Remember that the object is to walk as far as and as 
fast as possible for 6 minutes, but don’t run or jog.  Start when you are ready.” 
When the timer shows 4 minutes: “Two minutes have passed, you have 4 minutes to go.” 
When the timer shows 3 minutes: “Three minutes have passed, you have three minutes to 
go.” 
When the timer shows 2 minutes: “Four minutes have passed, you have two minutes to 
go.” 
When the timer shows 1 minute: “Five minutes have passed, you only have one-minute 
left.”   
When the timer is 15 seconds from completion: “In a moment, I am going to tell you to 
stop.  When I do, just stop where are and I will come to you.” 
The place where the person stopped will be marked and a chair will be brought 
over to them, so they can safely sit. 
If the person stops walking during the test, the following phrase will be used: 
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“You are doing well.  You should keep walking if you are able.” 
***If the person feels they cannot continue or the investigator feels they should no longer 
continue, a chair will be brought over to the person and the spot they stopped will be 
marked. *** 
Reason for stopping and RPE will be recorded. 
 ****GIVE PARTICIPANTS A MINIMUM OF A 5-MINUTE REST BEFORE STARTING THE 
NEXT TEST**** 
 
TEST 2: T25W 
General Information:  
 
Individuals can walk with or without an assistive device for 25 feet. 
 
 If an assistive device is used it should be kept consistent and documented from 
trial to trial 
 Two trials will be collected, and an average will be calculated 
 The subject will wear a gait belt during this test. 
 
Trial 1 and 2 
Set the stopwatch at zero.  The subject will be directed to the starting line that is clearly 
marked on the floor and will be asked to start 10 feet behind the line.  The researcher will 
then point out where the course ends, and the subject will be given the following 
instructions. 
 
“I’d like you to walk 25 feet as quickly as possible, but safely.  Do not slow down until you 
have passed the finish line.  Ready?  Go.” 
 
Timing will begin when the lead foot is lifted and crosses the starting line. The examiner 
will walk along with the subject as he/she completes the task. Timing will stop when the 
lead foot crosses the finish line. The examiner will record the subject’s walk time to within 
0.1 second, rounding as needed. Round up to the next tenth if hundredth’s place is> = .05, 
round down if hundredth’s place is <.05 (e.g., 32.45" would round to 32.5" but 
32.44"would round to 32.4"). Once the time is recorded, be sure to reset the stopwatch.  
Do two trials. 
 
 
****GIVE PARTICIPANTS A MINIMUM OF A 5-MINUTE REST BEFORE STARTING THE 
NEXT TEST**** 
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TEST 3: TUG  
Equipment needed:  The participant will sit on a standard armchair, placing his/her back 
against the chair and resting his/her arms chair’s arms. Any assistive device used for 
walking will be nearby. Regular footwear and customary walking aids will be used. An 
iPhone stopwatch will be used to time the test (in seconds). 
 
Set-up: A 3-meter (9.8 feet) walkway will be measured and marked.  A standard height 
chair (seat height 17 inches, arm height 26 inches- use black cycling chair) will be placed 
at the beginning of the walkway. 
 
Test: The participant walks to a line that is 3 meters (9.8 feet) away, turns around at the 
line, walk back to the chair, and sits down. The test ends when the participant’s buttocks 
touch the seat. Participants will be instructed to use a comfortable and safe walking 
speed. One trial only. 
 
Patient Instructions: 
“Please sit in the chair and place your I back against the chair and rest your arms chair’s 
arms.  When I say go, walk at comfortable and safe walking speed.  Walk to the line and 
turn at the line and then come back to the chair and sit down.  Let me demonstrate for you 
first” 
 
****GIVE PARTICIPANTS A MINIMUM OF A 5-MINUTE REST BEFORE STARTING THE 
NEXT TEST**** 
 
TEST 4: 5XSST 
Equipment: 
 Straight back chair with an 18 1/2” seat to floor height 
 Stop watch (iPhone) 
 
Instructions: 
“Stand up and sit down as quickly as possible 5 times, keeping your arms folded across 
your chest.” “Ready, go.” 
 
Measurement: 
Start timing when the participant’s buttocks leave the seat.  Stop timing when the 
participant stands the 5th time.  One trial only. 
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RTI Data Link Set-up 
Basic demographic information (age, weight, and diagnosis) will be entered into 
Restorative Therapies Internet (RTI) Data Link and a random ID number will be 
generated, and subjects will choose their own 4-digit pin number.  The participant 
number will be used as the participant ID number on all paperwork associated with the 
study.  
 
1. Go to www.rtidatalink.com 
2. Put in username: ____________, password: ________________ 
3. Click “Log In” 
4. Click on “Patients” at the top tool blue tool bar
 
5. Click on “Add Patient” located on the upper left-hand side  
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6. Enter the following information for each participant 
a. Patient email: __________________________ 
b. Subscribe to progress email- UNCHECK BOX (patient should not receive 
progress reports during the study) 
 
c. Month and Year Born (month/year) (click on the month and scroll to the 
year and double click until the year appear in box).  This generates the 
patients PIN Number which is the month and year of their birthday.  (E.g. 
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April 1973, PIN will be 0473) 
 
d. Enter weight in lbs. by scrolling down. 
e. Condition- scroll down to “MS” 
f. Patient Clinic ID#   ________________________ (this will be generated by the 
system after you save) 
g. Clinician: lhochman 
h. Patient Therapies:  
Therapy Template- Select Bilateral- “MS Submaximal Exercise Test – No 
Stim – Adult”  
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i. At the bottom on the screen click “SAVE” 
 
j. After you save, the following screen will appear 
 
k. Click on the “Therapies” tab at the top and Click on “MS Submaximal 
Exercise Test- No Stim - 1” 
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l. Under Therapy, please insert Pulse Upper Limit ((HR max = 220 – age x .85) (e.g. 
HR max = 220 – 42 x .85= 151) and Lower Limit as 10 bpm below baseline HR 
  
.  
m. On the next screen click “Save” 
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RT300/SAGE CONTROLLER PROCEDURE 
1. Plug in RT300 into outlet (screen will automatically turn on) 
2. On the top left, tap on “Clinician” and then “Clinician Log In” 
3. Enter Password “1776” 
4. Look at globe on bottom of the screen.  There should be a green check mark.  If 
there is a red “X” than it is not connected to the network.  (Try System—
Synchronize) 
5. If there is a red “X” then tap the globe.   
 
 
Opening Patient 
1. Click on “Patient” and Open Patient- (There will be a check mark next to “Use with 
Patient ID”) 
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1. Enter Patient ID, Click “OK 
 
2. Enter Pin, Click “OK” 
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2. Click on “Therapies” and Click on “Leg – MS Submaximal Exercise Test – No Stim” 
 
 
3. Clip Pulse Ox on participants ear and check connection (under System- Pulse 
Oximeter) 
4. Set up participant on bike. 
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a. Position the participant in the chair with their legs will be positioned on the 
pedals and secured with Velcro strapping.   
b. The bike and chair should be positioned to maintain 5-15 degrees of knee 
flexion when in the fully extended position of cycling.  (note and write down 
the distance between the base of the bike and the front leg of the chair) 
c. Adjust the height of the ergometer so that the rear of the participant’s thigh 
does not press into the seat cushion as they cycle.   
d. Add back support if need needed.  
e. Adjust the seat height and depth by utilizing cushions in order to optimize 
positioning and cycling angles.   
Participant Instructions for SXTT 
“This part of the study will be obtaining your baseline exercise tolerance and your 
starting parameters for the study.  You will be cycling for no more than 23 minutes.  The 
first 2 minutes are a warm-up period in which the cycle is taking you through the cycling 
motion, so just relax and let the bike do the work.  After the warm-up, start to actively 
cycle while keeping your control speed over 45 rpm.  Every 3 minutes the resistance will 
increase.  You may stop at any time due to fatigue or any other symptom exacerbation - 
including headache, change in vision, numbness, sudden paralysis, dizziness, or vertigo.  I 
will stop the test if you report or experience chest pain, shortness of breath, wheezing, 
and leg cramps.   I will also stop the test if your HR, pulse oxygen or BP are outside set 
parameters.  Are you ready?” 
Exercise Tolerance Testing Procedure (SXTT) 
1. Participants will be asked to cycle at or above the 45 rpm target speed. 
2. Participants will start with unloaded cycling and every 3 minutes the 
resistance will be increased by 3 Newton-meters (Nm) per stage (which is 
approximately 14 Watts per stage). 
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3. The SXTT will be discontinued when the participant reaches self-reported 
fatigue or if their vital signs fall outside a safe range.  Maximal workload is 
defined at the last completed interval before termination. 
4. HR and pulse oxygen will be measured in sitting at baseline and then 
recorded in during the last 5 seconds of each interval during clinical testing. 
5.  BP will be measured and recorded in sitting at baseline and during the last 
45 seconds of each interval. 
6.  The RPE scale will be explained to participants at rest and recorded during 
the last 15 seconds of each interval.  
7. Data from the exercise tolerance test will be recorded on the participant 
data sheet. 
SXTT will be terminated if the participant:  
 Reports fatigue- participant expresses they can no longer pedal due to fatigue.  
 Reaches 70% heart rate reserve which is 85% of age-predicted HRmax, (HR max = 
220 – age x .85).   
 Fails to conform to exercise protocol, which for this study will be defined as 
falling 10 rpm below the target rpm speed of 35 for greater than 10 seconds. 
 Has a hypotensive response- systolic blood pressure drops ≥ 10 mmHg from 
baseline  
 Has a hypertensive response- systolic blood pressure > 250 mmHg and/or a 
DBP of > 115mmHg.  
 Experiences symptom exacerbation- including headache, change in vision, 
numbness, sudden paralysis, dizziness, vertigo 
 Reports chest pain, shortness of breath, wheezing, and leg cramps.  
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Training Protocols 
Participants will train for 45 minutes, three-days per week, for eight-weeks using an FES-
LE cycle. 
RTI Data Link Set-up for Baseline Stim Settings 
1.  Go to: rtidatalink.com 
2. Click on Patient on top bar 
3. Click on the Patient ID # __________________________ 
4. On the left-hand side click “Patient Therapies” and select the last session which 
will be “MS Submaximal Exercise Test – No Stim – Adult” 
 
5. On the Left-hand side of screen click “Apply Template” 
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6. From the drop down menu select “MS Interval Training with Stim – Adult” (this 
puts the template under the patient therapies, but it will be under the name of the 
previous therapy MS Submaximal Exercise Test – No Stim – Adult and you will 
need to rename- see next step) 
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7. Go to Patient Therapies on left and select the first therapy and on the left-hand side 
click “copy therapy” and rename it “MS Interval training with Stim - Adult” 
8. Open up the renamed template and set-up the following parameters under the 
“Therapy” tab 
a. Pulse upper limit (220-age X .85) 
b. Pulse lower limit (10 beats below baseline) 
c. O2 sat lower limit= 88% 
d. Ergometer:  Change “Resistance” and “Target Resistance” to 60% of the max 
torque from the SXXT (e.g. If person stopped SXXT at 6NM then set starting 
torque at 3.6 NM) 
 
 
9. Under the intervals tab- check of the intervals box and change the resistance to 
60% of the SXXT.  Then uncheck the box!!! Under the intervals tab make sure the 
box is not checked in order to turn the intervals off while you are doing the 
baseline stim setting. 
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FES GROUP 
Opening Patient 
1. Click on “Patient” 
2. Open Patient- Enter Patient ID, Click “OK” 
3. Enter Pin, Click “OK” 
4. Click on “Therapies” 
5. Click on “MS Interval Training with Stim” 
6. Clip Pulse Ox on participants ear and check connection 
For FES-LE cycling, stimulated muscles are standardized and include the gluteals, 
hamstrings, quadriceps, anterior tibialis, and gastrocnemius.  Each participant will have 
their own set of electrodes that will be labeled with their participant number and will be 
stored at the research lab.  Electrodes will be placed according to the guidelines outlined 
and participant morphology (see table below).    
 
Electrode and Chair Set-up 
1. Clean skin with alcohol and make sure it is dry prior to placing the electrodes 
on the skin. Before and after each training session, inspect skin for erythema, 
breakdown and/or irritation.    
 179 
 
2. Check expiration dates on the electrodes prior to the commencement of 
training.  The manufacturer of the electrodes recommends that each 
electrode can be used for a maximum of 10-15 sessions.  If an electrode no 
longer adheres appropriately to the skin, discard the electrode and use a new 
electrode. 
3. Label each participant’s package of electrodes with the date and participant 
identification number. 
Muscle Electrode 
Size 
Location of placement 
Quadriceps 3” X 4” One electrode was placed a hand width above the knee 
centered on the belly of the quad and the second electrode 
was placed at least a hand width above the first electrode. 
For participants with a longer thigh length, it was placed 
higher on the quadriceps belly. 
Hamstrings 3” X 4” Electrodes were placed in line with the quadriceps 
electrodes, but on the back of the thigh and were centered in 
the middle of the hamstrings.   
Gluteals 2” X 3.5” One electrode was placed vertically with the top of the 
electrode parallel to the top gluteal cleft and the second 
electrode two-finger widths lateral to the first electrode.   
Anterior 
Tibialis 
2” X 3.5” One electrode was placed proximally on the muscle belly and 
the second electrode was placed distally about 2/3 way 
down the shin. 
Gastrocnemius 2” X 3.5 One electrode was placed horizontally across the calf, just 
below the knee and the second electrode was placed just 
distal to the gastrocnemius belly. 
*The electrode sizes above were used as  guidelines and individual adjustments were made based 
participant morphology.  
 
4. Position the participant in the chair with their legs will be positioned on the 
pedals and secured with Velcro strapping.   
5. The bike and chair should be positioned to maintain 5-15 degrees of knee 
flexion when in the fully extended position of cycling.   
6. Adjust the height of the ergometer so that the rear of the participant’s thigh 
does not press into the seat cushion as they cycle.   
7. Add back support if need needed.  
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8. Adjust the seat height and depth by utilizing cushions in order to optimize 
positioning and cycling angles.   
9. Secure foot strap in a cross pattern  
10. Match electrode to the appropriate number lead from the bike. 
#1 Left Quad 
#2 Right Quad 
#3 Left Hamstring 
#4 Right Hamstring 
#5 Left Glut 
#6 Right Glut 
RT 50A Left Ant Tib 
RT 50B Right Ant Tib 
RT 50C Left Gastroc 
RT 50 D Right Gastroc 
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Initial Stimulation Settings 
1. Pre-set Frequency= 43.5Hz for all muscle groups and will not be changed 
throughout the study. 
2. Pre-set Pulse width = 250μsec for all muscle groups and will be adjusted as 
needed. 
3. During this baseline session all muscle groups will be turned on at the same 
time while the participant passively cycles (i.e. motor of the cycle is moving 
their legs). 
4. Amplitude will ramp up at 1% per second and the participant will be 
instructed to tell the investigator to limit the stimulation when the feel any 
of their muscles reach a point where the stimulation is starting to get 
uncomfortable.   
5. The investigator will then adjust each muscle group individually to its 
maximal tolerable stimulation while the participant continues to passively 
cycle.   
6. Adjust amplitude in increments of 1mA increments until a participant 
achieves a maximal but tolerable muscle contraction.   
7. If a participant’s tolerance to stimulation is reached before a detectable 
contraction is palpated decrease pulse width by 10μsec increments and 
then adjust amplitude by 1mA increments until a maximal muscle 
contraction to their tolerance is achieved.   
8. The maximum level will be set at the value that has been determined to 
create a strongest tolerable motor response.   If a participant is still unable 
able to achieve a muscle contraction due to discomfort, the highest 
stimulation parameters they reached will be used and parameters will be 
adjusted during training sessions as they accommodate to the stimulation.   
9. All initial settings will be automatically saved in RTI Data Link.  
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Instructions to Participant 
The following instructions will be used prior to the baseline stimulation set-up: 
 “You will be cycling for a short period of time in order for us to set-up your 
initial stimulation levels for your first training session.  The first 2 minutes are 
a warm-up period in which the cycle is taking you through the cycling motion, 
so just relax and let the bike do the work.  After the warm-up, start to actively 
cycle at a moderate effort level.  The stimulation will slowly ramp up.  When 
the stimulation gets uncomfortable in any of the muscle groups, please let me 
know and we will then adjust each muscle group.  The goal is to create a strong, 
but tolerable muscle contract.  This might take a few sessions for you to get 
used to the feeling” 
 
FES Training Session Protocol 
 
The participant’s stimulation levels from their previous session will be used as 
starting parameters for each session.  If during training sessions the participant can 
tolerate more stimulation, amplitude will be increased in 1 mA increments.  If they reach 
the maximum amplitude level of 140ma and can tolerate more stimulation, pulse width 
will be increased by 10μsec increments. 
Participants will experience a 2-minute warm-up period in which the ergometer’s 
motor provides passive cycling and moves the participants’ legs.  The ergometer will then 
transition into “active mode” in which the electrical stimulation slowly ramps up to allow 
the individual to accommodate to the stimulation.  During this period, the participant will 
receive stimulation while also using their own muscle power against a set resistance 
while working to maintain a set target speed of 45.  In order to have participants working 
at a moderate intensity, starting resistance will be set at 60% of the maximal workload 
from the submaximal clinical exercise tolerance test (SXTT).    
Participants will be encouraged to cycle continuously for at least 45 minutes using 
an interval training protocol. They will cycle for 5 minutes with stimulation and then 1 
minute without stimulation with light (.5nm) resistance.  This 5:1 (5 minutes of active 
cycling with stimulation: 1-minute cycling without stimulation) cycle will repeat 7 times 
 183 
 
during the session.  Participants will then receive a 1-minute cool-down at the end where 
they receive no stimulation and the cycles motor passively moves the lower limbs.  
Since individuals in this study will have some degree of volitional control to cycle 
faster than their control speed, stimulation minimums/maximums will be set to the same 
level to ensure stimulation does not drop below the therapeutic level for each muscle 
group, therefore no matter how fast the participant cycles the stimulation will remain on 
during the 5-minute stimulation period.  The RT300 can provide ‘motor support” and the 
ergometer will be set for the participant to receive ‘motor support’ throughout the cycling 
period if they are not maintaining their target speed.    
If at any time during training a participant reports fatigue and needs to discontinue 
cycling, stimulation will be discontinued, and the participant will continue the rest of their 
session in passive mode with the motor fully assisting their movement for the remainder 
of the therapy session. Once a participant can cycle the full 45 minutes using the 5:1 
protocol, resistance will be increased by 5% increments every 3 sessions.   
 
10. On the left-hand side click “Patient Therapies” and select the last session which 
will be “MS Interval Training – Stim” 
 
11. Go to Patient Therapies on left and select the first therapy and on the left-hand side. 
Under the intervals tab make sure the box is checked in order to turn the intervals 
ON for training. 
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Instructions to Participant 
The following instructions will be used prior to each training session: 
“You will be cycling for 45 minutes.  The first 2 minutes are a warm-up period in 
which the cycle is taking you through the cycling motion, so just relax and let the bike 
do the work.  After the warm-up, start to actively cycle at a moderate effort level.  The 
stimulation will slowly ramp up over a 2-minute period to the stimulation levels we 
set during the previous session.  If at any time the stimulation gets uncomfortable, 
please let me know and we can adjust the stimulation for each muscle group.   You will 
cycle actively for 5 minutes and then receive a 1-minute break where the cycle will do 
all the work.  This pattern of 5 minutes on, 1 minute off, will repeat 7 times during 
your training session.  If at any time you experience fatigue, please let me know and 
you can take a break for up to 5 minutes and then continue where you left off.  The 
cycle is set to go into a passive cycling mode if your speed falls 10 rpm below the set 
target speed of 45 rpm.  The stimulation will be turned off and you will finish the 
remainder of the session allowing the bike to do all the work or you can stop the 
session.” 
 
During Cycling for 1st session explain to participant the feedback they receive from the 
screen: 
1. Target Speed 
2. Speed 
3. Resistance 
4. Asymmetry Display 
5. Motor Support Indicator-  Gray- motor support is not assisting the motion, Blue- 
motor support is enabled and being used. 
6. Stimulation- present stimulation level 
 
Cycling-only Protocol 
Participants in this training group the will be set-up on the RT300 in the same 
manner as those in the FES training group, but they will not receive electrical stimulation 
nor wear stimulation pads; they will use the RT300 as an ergometer only.  During the 
cycling-only phase, participants will cycle continuously for 45 minutes using an interval 
training protocol (5 minutes of active cycling: 1-minute passive cycling) at a set target 
speed of 45 rpm.  This 5:1 cycle will repeat 7 times and then go into a 1-minute cool-
down.  Total active cycling time will be 35 minutes.  If a participant needs a rest the cycle 
can go into passive mode and the motor of the cycle will provide full support.   Once the 
participant is able to tolerate 45 minutes of cycling without rests at or above the specified 
target speed, the resistance will be increased in 5% increments every 3 sessions.  
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Participants in both groups will receive feedback from the screen on the bike 
during and after their treatment sessions, including distance traveled, right to left cycling 
symmetry, heart rate and oxygen saturation.   
The following instructions will be used prior to each training session: 
“You will be cycling for 45 minutes.  The first 2 minutes are a warm-up period in 
which the cycle is taking you through the cycling motion, so just relax and let the bike 
do the work.  After the warm-up, start to actively cycle at a moderate effort level.   You 
will cycle actively for 5 minutes and then receive a 1-minute break where the cycle 
will do all the work.  This pattern of 5 minutes on, 1 minute off, will repeat 7 times 
during your training session.  If at any time you experience fatigue, please let me know 
and you can take a break for up to 5 minutes and then continue where you left off.  The 
cycle is set to go into a passive cycling mode if your speed falls 10 rpm below the set 
target speed of 45 rpm.  If that occurs, will finish the remainder of the session allowing 
the bike to do all the work or you can stop the session.” 
 
RT 300 Features 
 
The RT300 has several features that will be utilized during this study.  One feature 
is the “control speed offset.” If a participant’s cycling speed falls below the target speed 
the ergometer’s motor will take over for the remainder of the session and assist the 
participant.  The control speed offset will be set at –10 rpm for all participants.  The target 
speed for all participants will be 45 rpm and if a participant’s speed falls below 35 rpm 
the ergometer’s motor will take over and the cycle will finish the session in passive mode.     
The SAGE stimulator also monitors electrode adherence and if an electrode falls off 
the system pauses and ceases stimulation and the motor turns off.   An error message will 
be displayed on the screen telling the user which electrode needs to be checked.  Once the 
electrode is secured, the session can continue.  
If at any time a participant feels light-headed, nauseous, or dizzy during the 
training session or if their parameters fall outside the ACSM exercise guidelines, training 
will be discontinued for the remainder of the session.   
All participants will be continuously monitored by a wireless heart rate and pulse 
oximeter with set parameters. Target HR goal for each participant will be set at 65% of 
their age-adjusted max HR (200 - age x .65). The maximum heart rate with set at 85% of 
age-adjusted max HR (220-age x .85).  Participants will be encouraged to keep their HR 
within a 65% to 85% range.  If a participant goes above their maximum heart for greater 
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than 10 seconds, the ergometer and session will be paused, and the participant will be 
given a 3-minute rest until their HR comes down to their target heart rate.  If their HR 
does not come down into the appropriate range, they will continue the remainder of the 
session in the passive cycling mode.  The minimum heart rate will be set at 5 bpm below 
the participants resting baseline to allow for normal HR variability that can occur from 
day-to-day. 
If oxygen saturation (SPO2) falls below 88% the session will be paused, and the 
participant will be instructed to perform deep breathing.   Once the participant is back to 
their baseline SPO2 saturation, they will be permitted to resume.  They will be allowed a 
maximum of 5 minutes to achieve baseline.  If they do not achieve their baseline within 5 
minutes, they will continue the remainder of the session in the passive cycling mode.   
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Appendix H: Godin Leisure-Time Exercise Questionnaire 
 
 
Date: ____________________  Participant #: _________________ 
 
Godin Leisure-Time Exercise Questionnaire 
 
1. During a typical 7-Day period (a week), how many times on the average do you do the 
following kinds of exercise for more than 15 minutes during your free time (write on each line 
the appropriate number)? 
Times Per Week 
a) STRENUOUS EXERCISE 
 (HEART BEATS RAPIDLY) __________ 
 (e.g., running, jogging, hockey, football, soccer, 
 squash, basketball, cross-country skiing, judo, 
 roller skating, vigorous swimming, 
  vigorous long distance bicycling) 
 
b) MODERATE EXERCISE 
 (NOT EXHAUSTING) __________ 
 (e.g., fast walking, baseball, tennis, easy bicycling, 
 volleyball, badminton, easy swimming, alpine skiing, 
 popular and folk dancing) 
 
c) MILD EXERCISE 
 (MINIMAL EFFORT) __________ 
 (e.g., yoga, archery, fishing from river bank, bowling, 
 horseshoes, golf, snow-mobiling, easy walking) 
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2. During a typical 7-Day period (a week), in your leisure time, how often do you engage in 
any regular activity long enough to work up a sweat (heart beats rapidly)? 
☐OFTEN   
☐SOMETIMES   
☐NEVER/RARELY 
INSTRUCTIONS 
 
In this excerpt from the Godin Leisure-Time Exercise Questionnaire, the individual is asked to 
complete a self-explanatory, brief four-item query of usual leisure-time exercise habits. 
 
CALCULATIONS 
 
For the first question, weekly frequencies of strenuous, moderate, and light activities are 
multiplied by nine, five, and three, respectively, the total weekly leisure activity is calculated 
in arbitrary units by summing the products of the separate components, as shown in the 
following formula: 
 
 Weekly leisure activity score = (9  Strenuous) + (5  Moderate) + (3  Light) 
 
 The second question is used to calculate the frequency of weekly leisure-time activities 
pursued “long enough to work up a sweat” (see questionnaire). 
 
EXAMPLE 
 
Strenuous = 3 times/wk 
 
Moderate = 6 times/wk 
 
Light = 14 times/wk 
 
Total leisure activity score = (9  3) + (5  6) + (3  14) = 27 + 30 + 42 = 99 
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Appendix J: Modified Fatigue Impact Scale 
 
MODIFIED FATIGUE IMPACT SCALE (MFIS) 
 
Following is a list of statements that describe how fatigue may affect a person. Fatigue is a 
feeling of physical tiredness and lack of energy that many people experience from time to time. 
In medical conditions like MS, feelings of fatigue can occur more often and have a greater 
impact than usual. Please read each statement carefully, and then circle the one number that 
best indicates how often fatigue has affected you in this way during the past 4 weeks. (If you 
need help in marking your responses, tell the interviewer the number of the best response.) 
Please answer every question. If you are not sure which answer to select, please choose the one 
answer that comes closest to describing you. The interviewer can explain any words or phrases 
that you do not understand. 
 
Because of my fatigue during the past 4 weeks.... 
 
 Never Rarely Sometimes Often  Almost 
Always 
1. I have been less alert. 
 
0 1 2 3 4 
2. I have had difficulty paying attention for 
long periods of time. 
0 1 2 3 4 
3. I have been unable to think clearly. 0 1 2 3 4 
4. I have been clumsy and uncoordinated 0 1 2 3 4 
5. I have been forgetful 0 1 2 3 4 
6. I have had to pace myself in my physical 
activities. 
0 1 2 3 4 
7. I have been less motivated to do anything 
that requires physical effort. 
0 1 2 3 4 
8. I have been less motivated to participate 
in social activities. 
0 1 2 3 4 
9. I have been limited in my ability to do 
things away from home. 
     
10. I have had trouble maintaining physical 
effort for long periods. 
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 Never Rarely Sometimes Often  Almost 
Always 
11. I have had difficulty making decisions. 0 1 2 3 4 
12. I have been less motivated to do anything 
that requires thinking. 
0 1 2 3 4 
13. my muscles have felt weak. 0 1 2 3 4 
14. I have been physically uncomfortable. 0 1 2 3 4 
15. I have had trouble finishing tasks that 
require thinking. 
0 1 2 3 4 
16. I have had difficulty organizing my 
thoughts when doing things at home or at 
work. 
0 1 2 3 4 
17. I have been less able to complete tasks 
that require physical effort. 
0 1 2 3 4 
18. my thinking has been slowed down 0 1 2 3 4 
19. I have had trouble concentrating. 0 1 2 3 4 
20. I have limited my physical activities. 0 1 2 3 4 
21. I have needed to rest more often or for 
longer periods. 
0 1 2 3 4 
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Appendix K: 12‐Item MS Walking Scale  
 
 
Date: __________________________ Participant #: _____________________ 
 
12‐Item MS Walking Scale (MSWS‐12) 
Instructions: These questions ask about limitations to your walking due to MS during the past 2 
weeks.  For each statement, please circle the one number that best describes your degree of 
limitation.  Please answer all questions even if some seem rather similar to others, or seem 
irrelevant to you. 
 
In the past two weeks, how 
much has your MS… 
Not at 
all 
A little Moderately  Quite a bit Extremely 
1. Limited your ability to walk? 1 2 3 4 5 
2. Limited your ability to run? 1 2 3 4 5 
3. Limited your ability to climb 
up and down stairs? 
1 2 3 4 5 
4. Made standing when 
doing things more difficult? 
1 2 3 4 5 
5. Limited your balance when 
standing 
or walking? 
1 2 3 4 5 
6. Limit how far you are able to 
walk? 
1 2 3 4 5 
7. Increased the effort 
needed for you to walk? 
1 2 3 4 5 
8. Made it necessary for you to 
use support when walking 
indoors (e.g., holding on to 
furniture, using a stick, etc.)? 
1 2 3 4 5 
9. Made it necessary for you to 
use support when walking 
outdoors (e.g., using a stick, a 
frame, etc.)? 
1 2 3 4 5 
10. Slowed down your 
walking? 
1 2 3 4 5 
11. Affected how smoothly you 
walk? 
1 2 3 4 5 
12.  Made you concentrate on 
your waking? 
1 2 3 4 5 
 
Please check that you have circled ONE number for EACH question 
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Appendix L: Activities-specific Balance Confidence Scale 
 
 
 Date: ____________________  Participant #: _____________________________ 
 
The Activities-specific Balance Confidence (ABC) Scale 
 
Instructions to Participants: 
 
For each of the following, please indicate your level of confidence in doing the activity without 
losing your balance or becoming unsteady from choosing one of the percentage points on the 
scale from 0% to 100%. If you do not currently do the activity in question, try and imagine how 
confident you would be if you had to do the activity. If you normally use a walking aid to do 
the activity or hold onto someone, rate your confidence as it you were using these supports. If 
you have any questions about answering any of these items, please ask the administrator. 
 
For each of the following activities, please indicate your level of self- 
confidence by choosing a corresponding number from the following 
rating scale:  
 
0%     10    20    30    40    50    60    70    80    90    100% 
no confidence        completely confident 
 
“How confident are you that you will not lose your balance or become 
unsteady when you… 
1.…walk around the house? ____% 
2.…walk up or down stairs? ____% 
3.…bend over and pick up a slipper from the front of a closet floor ____% 
4.…reach for a small can off a shelf at eye level? ____% 
5.…stand on your tiptoes and reach for something above your head? ____% 
6.…stand on a chair and reach for something? ____% 
7.…sweep the floor? ____% 
8.…walk outside the house to a car parked in the driveway? ____% 
9.…get into or out of a car? ____% 
10.…walk across a parking lot to the mall? ____% 
11.…walk up or down a ramp? ____% 
12.…walk in a crowded mall where people rapidly walk past you? ____% 
13.…are bumped into by people as you walk through the mall?____% 
14.… step onto or off an escalator while you are holding onto a railing? 
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____% 
15.… step onto or off an escalator while holding onto parcels such that you 
cannot hold onto the railing? ____% 
16.…walk outside on icy sidewalks? ____% 
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Appendix M: Rage of Perceived Exertion Scale 
 
Rate of Perceived Exertion Scale 
 
0 - Nothing at all 
0.5 - Just noticeable 
1 - Very light 
2 - Light 
3 - Moderate 
4 - Somewhat heavy 
5 - Heavy 
6  
7 -Very heavy 
8  
9 
10 -Very, Very heavy 
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Appendix N: Submaximal Clinical Exercise Tolerance 
Test 
 
 
 
Date: __________________  Participant #: ______________________ 
 
Submaximal Clinical Exercise Tolerance Test 
Target Speed: 40 rpm 
Interval Duration 
(minutes) 
Workload Nm  
(Watts) 
RPE HR Pulse Ox BP 
Unloaded 
Pedaling 
2  0 Nm     
1 2 3 Nm (12.6)     
2 2 6 Nm (25.1)     
3 2 9 Nm (37.7)     
4 2 12 Nm (50.3)     
5 2 15 Nm (62.8)     
6 2 18 Nm (75.4)     
7 2 21 Nm (88)     
8 2 24 Nm (100.5)     
9 2 27 Nm (113.1)     
*2-minute passive cool-down (cycling below 40 rpm) will be instituted once a participant 
reaches their threshold. 
 
Conversion of Watts into Nm 
Nm = kW x 9549/rpm 
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Appendix O: TUG Within group differences from BTS G-
Walk based on the mixed-effect model 
 
Table 0-1 TUG Within group differences on phase durations based on the mixed-
effect model 
TUG- Sit to Stand Phase Duration (s) FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS 0.05 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS 0.01 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS 0.001 
TUG- Stand to Sit Phase Duration (s) FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS 0.04 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
TUG- Mid-turning Phase Duration (s) FES Cycling Cycling Only 
Baseline to Mid-point NS 0.05 
Baseline to Post-intervention 0.02 NS 
Baseline to Follow-up 0.001 NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
TUG- End-turning Phase Duration (s) FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
Abbreviations: TUG = Timed Up and Go, s = seconds, FES = Functional Electrical Stimulation, NS = Not 
Significant 
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Appendix P: 6MWT Within group differences on 
spatiotemporal gait parameters based on the mixed-
effect model 
 
Table 0-2 6MWT Within group differences on spatiotemporal parameters based on 
the mixed-effect model 
6MWT- Stride Length-Left (m) FES Cycling Cycling Only 
Baseline to Mid-point NS 0.04 
Baseline to Post-intervention NS 0.01 
Baseline to Follow-up NS 0.001 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
6MWT- Stride Length-Right (m) FES Cycling Cycling Only 
Baseline to Mid-point NS 0.03 
Baseline to Post-intervention NS 0.01 
Baseline to Follow-up NS 0.001 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
6MWT- Step Symmetryd FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
6MWT- Double-Support- Lefte FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS 0.05 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up 0.04 NS 
Post-intervention to Follow-up NS NS 
6MWT- Double-Support- Righte FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up 0.05 NS 
Post-intervention to Follow-up NS NS 
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Appendix Q: Table 0-2 T25FW Within group differences 
on spatiotemporal parameters based on the mixed-
effect model 
Table 0-3 T25FW Within group differences on spatiotemporal parameters based on 
the mixed-effect model 
T25FW- Stride Length-Left (m) FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
T25FW - Stride Length-Right (m) FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
T25FW - Step Symmetryd FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up 0.04 NS 
T25FW - Double-Support- Lefte FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up 0.05 NS 
T25FW - Double-Support- Righte FES Cycling Cycling Only 
Baseline to Mid-point NS NS 
Baseline to Post-intervention NS NS 
Baseline to Follow-up NS NS 
Mid-point to Post-intervention NS NS 
Mid-point to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
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Appendix R: Quality of Life within group differences 
based on the mixed effect Model 
 
Table 0-4 MSQOL-54, MFIS, MSWS-12, and ABC Within group differences based on 
the mixed-effect model 
MSQOL-54 Physical Composite FES Cycling Cycling Only 
Baseline to Post-Intervention 0.01 NS 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
MSQOL-54 Mental Composite FES Cycling Cycling Only 
Baseline to Post-Intervention NS 0.05 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
MSQOL-54 Overall Quality of Life FES Cycling Cycling Only 
Baseline to Post-Intervention 0.005 NS 
Baseline to Follow-up 0.004 NS 
Post-intervention to Follow-up NS NS 
MFIS-Total FES Cycling Cycling Only 
Baseline to Post-Intervention 0.03 NS 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
MFIS-Cognitive FES Cycling Cycling Only 
Baseline to Post-Intervention NS 0.04 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
MFIS-Physical FES Cycling Cycling Only 
Baseline to Post-Intervention NS NS 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
MFIS-Psychosocial FES Cycling Cycling Only 
Baseline to Post-Intervention NS NS 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
MSWS-12 FES Cycling Cycling Only 
Baseline to Post-Intervention NS NS 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
ABC FES Cycling Cycling Only 
Baseline to Post-Intervention NS NS 
Baseline to Follow-up NS NS 
Post-intervention to Follow-up NS NS 
 
